
<html lang="en"     class="pb-page"  data-request-id="b068164b-26b3-4ed3-bbe2-3ece2b2f0b43"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2015.58.issue-22;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.5b01363;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311)" /></meta><meta name="dc.Creator" content="Jennifer X.  Qiao" /></meta><meta name="dc.Creator" content="Tammy C.  Wang" /></meta><meta name="dc.Creator" content="Leonard P.  Adam" /></meta><meta name="dc.Creator" content="Alice Ye A.  Chen" /></meta><meta name="dc.Creator" content="David S.  Taylor" /></meta><meta name="dc.Creator" content="Richard Z.  Yang" /></meta><meta name="dc.Creator" content="Shaobin  Zhuang" /></meta><meta name="dc.Creator" content="Paul G.  Sleph" /></meta><meta name="dc.Creator" content="Julia P.  Li" /></meta><meta name="dc.Creator" content="Danshi  Li" /></meta><meta name="dc.Creator" content="Xiaohong  Yin" /></meta><meta name="dc.Creator" content="Ming  Chang" /></meta><meta name="dc.Creator" content="Xue-Qing  Chen" /></meta><meta name="dc.Creator" content="Hong  Shen" /></meta><meta name="dc.Creator" content="Jianqing  Li" /></meta><meta name="dc.Creator" content="Daniel  Smith" /></meta><meta name="dc.Creator" content="Dauh-Rurng  Wu" /></meta><meta name="dc.Creator" content="Leslie  Leith" /></meta><meta name="dc.Creator" content="Lalgudi S.  Harikrishnan" /></meta><meta name="dc.Creator" content="Muthoni G.  Kamau" /></meta><meta name="dc.Creator" content="Michael M.  Miller" /></meta><meta name="dc.Creator" content="Donna  Bilder" /></meta><meta name="dc.Creator" content="Richard  Rampulla" /></meta><meta name="dc.Creator" content="Yi-Xin  Li" /></meta><meta name="dc.Creator" content="Carrie  Xu" /></meta><meta name="dc.Creator" content="R. Michael  Lawrence" /></meta><meta name="dc.Creator" content="Michael A.  Poss" /></meta><meta name="dc.Creator" content="Paul  Levesque" /></meta><meta name="dc.Creator" content="David A.  Gordon" /></meta><meta name="dc.Creator" content="Christine S.  Huang" /></meta><meta name="dc.Creator" content="Heather J.  Finlay" /></meta><meta name="dc.Creator" content="Ruth R.  Wexler" /></meta><meta name="dc.Creator" content="Mark E.  Salvati" /></meta><meta name="dc.Description" content="Cholesteryl ester transfer protein (CETP) inhibitors raise HDL-C in animals and humans and may be antiatherosclerotic by enhancing reverse cholesterol transport (RCT). In this article, we describe ..." /></meta><meta name="Description" content="Cholesteryl ester transfer protein (CETP) inhibitors raise HDL-C in animals and humans and may be antiatherosclerotic by enhancing reverse cholesterol transport (RCT). In this article, we describe ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 17, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01363" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01363" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01363" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01363" /></link>
        
    
    

<title>Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01363" /></meta><meta property="og:title" content="Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0021.jpeg" /></meta><meta property="og:description" content="Cholesteryl ester transfer protein (CETP) inhibitors raise HDL-C in animals and humans and may be antiatherosclerotic by enhancing reverse cholesterol transport (RCT). In this article, we describe the lead optimization efforts resulting in the discovery of a series of triphenylethanamine (TPE) ureas and amides as potent and orally available CETP inhibitors. Compound 10g is a potent CETP inhibitor that maximally inhibited cholesteryl ester (CE) transfer activity at an oral dose of 1 mg/kg in human CETP/apoB-100 dual transgenic mice and increased HDL cholesterol content and size comparable to torcetrapib (1) in moderately-fat fed hamsters. In contrast to the off-target liabilities with 1, no blood pressure increase was observed with 10g in rat telemetry studies and no increase of aldosterone synthase (CYP11B2) was detected in H295R cells. On the basis of its preclinical profile, compound 10g was advanced into preclinical safety studies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01363"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01363">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01363&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01363&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01363&amp;href=/doi/10.1021/acs.jmedchem.5b01363" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 9010-9026</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01343" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01371" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of <i>N</i>-[(1<i>R</i>)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311)</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer+X.++Qiao">Jennifer X. Qiao</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tammy+C.++Wang">Tammy C. Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Leonard+P.++Adam">Leonard P. Adam</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alice+Ye+A.++Chen">Alice Ye A. Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+S.++Taylor">David S. Taylor</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard+Z.++Yang">Richard Z. Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shaobin++Zhuang">Shaobin Zhuang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+G.++Sleph">Paul G. Sleph</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julia+P.++Li">Julia P. Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Danshi++Li">Danshi Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaohong++Yin">Xiaohong Yin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ming++Chang">Ming Chang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xue-Qing++Chen">Xue-Qing Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Shen">Hong Shen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jianqing++Li">Jianqing Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Smith">Daniel Smith</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dauh-Rurng++Wu">Dauh-Rurng Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Leslie++Leith">Leslie Leith</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lalgudi+S.++Harikrishnan">Lalgudi S. Harikrishnan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Muthoni+G.++Kamau">Muthoni G. Kamau</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+M.++Miller">Michael M. Miller</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Donna++Bilder">Donna Bilder</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Rampulla">Richard Rampulla</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yi-Xin++Li">Yi-Xin Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carrie++Xu">Carrie Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=R.+Michael++Lawrence">R. Michael Lawrence</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+A.++Poss">Michael A. Poss</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Levesque">Paul Levesque</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+A.++Gordon">David A. Gordon</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christine+S.++Huang">Christine S. Huang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Heather+J.++Finlay">Heather J. Finlay</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ruth+R.++Wexler">Ruth R. Wexler</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+E.++Salvati">Mark E. Salvati</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Departments of <sup>â </sup>Discovery Chemistry, <sup>â¡</sup>Discovery Biology, <sup>Â§</sup>Discovery Toxicology, <sup>â¥</sup>Preclinical Candidate Optimization, and <sup>â¥</sup>Pharmaceutics, Bristol-Myers Squibb Company, Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#315b545f5f585754431f4058505e71535c421f525e5c"><span class="__cf_email__" data-cfemail="ed87888383848b889fc39c848c82ad8f809ec38e8280">[emailÂ protected]</span></a>. Phone: (609) 252-7554.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01363&amp;href=/doi/10.1021%2Facs.jmedchem.5b01363" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 9010â9026</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 2, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 September 2015</li><li><span class="item_label"><b>Published</b> online</span>17 November 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 November 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01363" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01363</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9010%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJennifer%2BX.%2BQiao%252C%2BTammy%2BC.%2BWang%252C%2BLeonard%2BP.%2BAdam%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D22%26contentID%3Dacs.jmedchem.5b01363%26title%3DTriphenylethanamine%2BDerivatives%2Bas%2BCholesteryl%2BEster%2BTransfer%2BProtein%2BInhibitors%253A%2BDiscovery%2Bof%2BN-%255B%25281R%2529-1-%25283-Cyclopropoxy-4-fluorophenyl%2529-1-%255B3-fluoro-5-%25281%252C1%252C2%252C2-tetrafluoroethoxy%2529phenyl%255D-2-phenylethyl%255D-4-fluoro-3-%2528trifluoromethyl%2529benzamide%2B%2528BMS-795311%2529%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9026%26publicationDate%3DNovember%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01363"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1874</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01363" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;X. Qiao&quot;},{&quot;first_name&quot;:&quot;Tammy&quot;,&quot;last_name&quot;:&quot;C. Wang&quot;},{&quot;first_name&quot;:&quot;Leonard&quot;,&quot;last_name&quot;:&quot;P. Adam&quot;},{&quot;first_name&quot;:&quot;Alice&quot;,&quot;last_name&quot;:&quot;Ye A. Chen&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;S. Taylor&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Z. Yang&quot;},{&quot;first_name&quot;:&quot;Shaobin&quot;,&quot;last_name&quot;:&quot;Zhuang&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;G. Sleph&quot;},{&quot;first_name&quot;:&quot;Julia&quot;,&quot;last_name&quot;:&quot;P. Li&quot;},{&quot;first_name&quot;:&quot;Danshi&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Xiaohong&quot;,&quot;last_name&quot;:&quot;Yin&quot;},{&quot;first_name&quot;:&quot;Ming&quot;,&quot;last_name&quot;:&quot;Chang&quot;},{&quot;first_name&quot;:&quot;Xue-Qing&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Jianqing&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Smith&quot;},{&quot;first_name&quot;:&quot;Dauh-Rurng&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Leslie&quot;,&quot;last_name&quot;:&quot;Leith&quot;},{&quot;first_name&quot;:&quot;Lalgudi&quot;,&quot;last_name&quot;:&quot;S. Harikrishnan&quot;},{&quot;first_name&quot;:&quot;Muthoni&quot;,&quot;last_name&quot;:&quot;G. Kamau&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;M. Miller&quot;},{&quot;first_name&quot;:&quot;Donna&quot;,&quot;last_name&quot;:&quot;Bilder&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Rampulla&quot;},{&quot;first_name&quot;:&quot;Yi-Xin&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Carrie&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;R.&quot;,&quot;last_name&quot;:&quot;Michael Lawrence&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;A. Poss&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Levesque&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;A. Gordon&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;S. Huang&quot;},{&quot;first_name&quot;:&quot;Heather&quot;,&quot;last_name&quot;:&quot;J. Finlay&quot;},{&quot;first_name&quot;:&quot;Ruth&quot;,&quot;last_name&quot;:&quot;R. Wexler&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;E. Salvati&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;9010-9026&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01363&quot;},&quot;abstract&quot;:&quot;Cholesteryl ester transfer protein (CETP) inhibitors raise HDL-C in animals and humans and may be antiatherosclerotic by enhancing reverse cholesterol transport (RCT). In this article, we describe the lead optimization efforts resulting in the discovery of a series of triphenylethanamine (TPE) ureas and amides as potent and orally available CETP inhibitors. Compound 10g is a potent CETP inhibitor that maximally inhibited cholesteryl ester (CE) transfer activity at an oral dose of 1 mg/kg in human CETP/apoB-100 dual transgenic mice and increased HDL cholesterol content and size comparable to torcetrapib (1) in moderately-fat fed hamsters. In contrast to the off-target liabilities with 1, no blood pressure increase was observed with 10g in rat telemetry studies and no increase of aldosterone synthase (CYP11B2) was detected in H295R cells. On the basis of its preclinical profile, compound 10g was advanced into preclinical safety studies.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01363&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01363" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01363&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01363" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01363&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01363" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01363&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01363&amp;href=/doi/10.1021/acs.jmedchem.5b01363" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01363" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01363" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01363%26sid%3Dliteratum%253Aachs%26pmid%3D26524347%26genre%3Darticle%26aulast%3DQiao%26date%3D2015%26atitle%3DTriphenylethanamine%2BDerivatives%2Bas%2BCholesteryl%2BEster%2BTransfer%2BProtein%2BInhibitors%253A%2BDiscovery%2Bof%2BN-%255B%25281R%2529-1-%25283-Cyclopropoxy-4-fluorophenyl%2529-1-%255B3-fluoro-5-%25281%252C1%252C2%252C2-tetrafluoroethoxy%2529phenyl%255D-2-phenylethyl%255D-4-fluoro-3-%2528trifluoromethyl%2529benzamide%2B%2528BMS-795311%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D22%26spage%3D9010%26epage%3D9026%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291774" title="Nuclear magnetic resonance spectroscopy">Nuclear magnetic resonance spectroscopy</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/jmcmar.2015.58.issue-22/20151125/jmcmar.2015.58.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Cholesteryl ester transfer protein (CETP) inhibitors raise HDL-C in animals and humans and may be antiatherosclerotic by enhancing reverse cholesterol transport (RCT). In this article, we describe the lead optimization efforts resulting in the discovery of a series of triphenylethanamine (TPE) ureas and amides as potent and orally available CETP inhibitors. Compound <b>10g</b> is a potent CETP inhibitor that maximally inhibited cholesteryl ester (CE) transfer activity at an oral dose of 1 mg/kg in human CETP/apoB-100 dual transgenic mice and increased HDL cholesterol content and size comparable to torcetrapib (<b>1</b>) in moderately-fat fed hamsters. In contrast to the off-target liabilities with <b>1</b>, no blood pressure increase was observed with <b>10g</b> in rat telemetry studies and no increase of aldosterone synthase (CYP11B2) was detected in H295R cells. On the basis of its preclinical profile, compound <b>10g</b> was advanced into preclinical safety studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23842" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23842" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cardiovascular (CV) disease remains the leading cause of morbidity and mortality worldwide. In addition to high levels of low density lipoprotein-cholesterol (LDL-C), low levels of high density lipoprotein-cholesterol (HDL-C) are known to be an independent risk factor for coronary heart disease (CHD) based on epidemiological studies.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that is responsible for transporting neutral lipids such as cholesteryl esters (CEs) and triglycerides (TGs) among various classes of lipoproteins including HDL, LDL, and very low density lipoprotein (VLDL).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Physiologically, CETP facilitates the transfer of CE from HDL to LDL and VLDL in exchange for TG, leading to decreased HDL-C levels and increased LDL-C levels. Preclinical animal models and clinical data with four CETP inhibitors (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A), torcetrapib (<b>1</b>), dalcetrapib (<b>2</b>), anacetrapib (<b>3</b>), and evacetrapib (<b>4</b>), demonstrate an elevation of plasma HDL-C and a reduction of plasma LDL-C levels associated with CETP inhibition.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> An increased level of HDL-C by CETP inhibition is potentially beneficial for patients with CHD due to an increase in reverse cholesterol transport (RCT), i.e., the transport of cholesterol from peripheral tissues (e.g., the atherosclerotic plaque) to the liver for disposal from the body.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In addition to invoking a significant increase in HDL-C, CETP inhibitors such as compounds <b>3</b> and <b>4</b> have also been shown to lower LDL and lipoprotein(a) (Lp(a)) levels that could potentially contribute to a reduction of atherosclerosis.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Although the known effects of CETP inhibition on plasma lipoproteins, i.e., profound elevation of HDL-C levels as well as lowering LDL-C levels, are considered positive, the effects on morbidity and mortality in CHD patients are still being evaluated in late-stage clinical trials with compounds <b>3</b> and <b>4</b>. Compound <b>1</b>, on the other hand, was abruptly terminated in the ILLUMINATE phase III trial in 2006 after a little more than a year of treatment due to an unacceptable mortality increase in the <b>1</b> plus atorvastatin group versus the atorvastatin group alone.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The increased mortality is now widely believed to be due to adverse off-target effects including a significant increase of blood pressure (BP)<a onclick="showRef(event, 'cit6b cit6c'); return false;" href="javascript:void(0);" class="ref cit6b cit6c">(6b, 6c)</a> and aldosterone levels.<a onclick="showRef(event, 'cit6d cit6e'); return false;" href="javascript:void(0);" class="ref cit6d cit6e">(6d, 6e)</a> Clinical studies with compound <b>2</b>, a weak and covalent inhibitor of CETP, were terminated in 2011 due to the lack of clinical efficacy in the reduction of CV events.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) CETP inhibitors <b>1</b>â<b>4</b> that have entered phase III clinical trials. (B) Diphenylpyridylethanamine (DPPE) lead <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We previously disclosed a series of diphenylpyridylethanamine (DPPE) derivatives that resulted in the optimized lead <b>5</b> bearing a 4-chloro-2-pyridyl A-ring (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>B) as a potent CETP inhibitor.<a onclick="showRef(event, 'cit8a'); return false;" href="javascript:void(0);" class="ref cit8a">(8a)</a> The in vitro CETP inhibitory activity of <b>5</b> was 36 nM in an enzyme-based scintillation proximity assay (SPA).<a onclick="showRef(event, 'cit8a ref9'); return false;" href="javascript:void(0);" class="ref cit8a ref9">(8a, 9)</a> In a human whole plasma assay (hWPA),<a onclick="showRef(event, 'cit8a'); return false;" href="javascript:void(0);" class="ref cit8a">(8a)</a> an assay that measures the transfer of [<sup>3</sup>H]CE from HDL to LDL in about 95% human plasma, <b>5</b> had an IC<sub>50</sub> of 3.6 Î¼M, 100-fold right-shifted from the SPA IC<sub>50</sub>. The hWPA is thought to be more predictive of in vivo activity than the SPA because it takes into consideration plasma protein binding. At the time of optimization of the DPPE series, compound <b>1</b> was in a phase IIb clinical trial and was selected as the benchmark compound for our studies, while structures and activity profiles of <b>3</b> and <b>4</b> have been disclosed only at later time points. Compound <b>1</b> was more potent than <b>5</b> in both the SPA and the hWPA assays (SPA IC<sub>50</sub> = 2.7 nM, hWPA IC<sub>50</sub> = 0.10 Î¼M). Nevertheless, sufficient plasma exposures of <b>5</b> could be achieved which resulted in inhibition of CETP-mediated CE transfer in human CETP/apoB-100 (hCETP/apoB-100) dual transgenic (Tg) mice<a onclick="showRef(event, 'cit8a ref10'); return false;" href="javascript:void(0);" class="ref cit8a ref10">(8a, 10)</a> and an elevation of plasma HDL-C levels in moderately fat fed hamsters.<a onclick="showRef(event, 'cit8a ref11'); return false;" href="javascript:void(0);" class="ref cit8a ref11">(8a, 11)</a> The goal of this work was to identify a more potent compound than <b>5</b> that had excellent plasma exposures upon oral dosing, improved pharmacodynamic effects (similar to <b>1</b>) and did not possess known off-target effects (e.g., BP increase in animals). Initially, with the identification of <b>5</b>, various A-ring analogs were surveyed in an effort to identify compounds with improved hWPA CETP inhibitory potency with the hope that this would translate into enhanced reduction of CE transfer activity in vivo and elevation of HDL-C at lower doses.</div><div class="NLM_p">It was previously believed that the pyridine nitrogen in the A-ring of <b>5</b> was critical for potency.<a onclick="showRef(event, 'cit8a'); return false;" href="javascript:void(0);" class="ref cit8a">(8a)</a> This was based on the early ester series obtained from virtual screening, in which the phenyl A-ring analog <b>6b</b> was much less potent in the hWPA than the corresponding 2-pyridyl analog <b>6a</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). In search of diverse monocyclic A-rings other than the 2-pyridyl group, we found that hWPA potency was sensitive to the polarity of the heterocyclic A-ring. Polar heteroaryls such as pyridinones, imidazoles, and pyrazines were not tolerated, while relatively nonpolar heteroaryls such as thiazoles and furans exhibited potency similar to the 2-pyridyl A-ring analogs.<a onclick="showRef(event, 'cit8a ref12'); return false;" href="javascript:void(0);" class="ref cit8a ref12">(8a, 12)</a> We also found that the meta substituted CF<sub>3</sub> group in <b>7b</b> improved hWPA activity similar to that previously observed for the para-chloropyridyl A-ring in <b>5</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). However, the isomeric pyridine <b>7a</b> was much less potent. Although the trifluoromethyl group in <b>7a</b> might be making favorable interactions with the protein, its adjacent pyridyl nitrogen atom (X = N) may be buried in an energy penalizing hydrophobic environment. Conversely, the pyridyl nitrogen atom (Y = N) in <b>7b</b> may be more solvent exposed; thus N and CH at this position may be interchangeable. Compound <b>7c</b> bearing a more polar pyrimidine A-ring (X = Y = N) exhibited a decrease in hWPA activity. The observed A-ring SAR prompted us to investigate nonpolar phenyl A-ring analogs. We were gratified that the first phenyl A-ring analog <b>8a</b>, a triphenylethanamine (TPE) derivative containing a meta CF<sub>3</sub> group, was equipotent to the corresponding aza analog <b>7b</b> in both the SPA and the hWPA. At the time of the research, there was no CETP structural information available. Structure-based design was therefore not used in the lead optimization process.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Evolution of the First Triphenylethanamine (TPE) Derivative: Phenyl A-Ring Analog <b>8a</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0014.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">CETP SPA IC<sub>50</sub>Â (nM)</th><th class="colsep0 rowsep0" align="center">CETP hWPA IC<sub>50</sub>Â (Î¼M)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">1300Â Â±Â 800 (<i>n</i>Â =Â 3)</td><td class="colsep0 rowsep0" align="left">9.4Â Â±Â 1.8 (<i>n</i>Â =Â 2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">4200Â Â±Â 2700 (<i>n</i>Â =Â 3)</td><td class="colsep0 rowsep0" align="left">53, >100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7a</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">760Â Â±Â 200 (<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="left">29Â Â±Â 0.2 (<i>n</i>Â =Â 2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7b</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">24Â Â±Â 12 (<i>n</i>Â =Â 3)</td><td class="colsep0 rowsep0" align="left">2.2Â Â±Â 0.9 (<i>n</i>Â =Â 5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7c</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8a</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">1.5Â Â±Â 0.5 (<i>n</i>Â =Â 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">36Â Â±Â 15 (<i>n</i>Â =Â 7)</td><td class="colsep0 rowsep0" align="left">3.6Â Â±Â 2.8 (<i>n</i>Â =Â 7)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">2.7Â Â±Â 0.9 (<i>n</i>Â =Â 183)</td><td class="colsep0 rowsep0" align="left">0.10Â Â±Â 0.05 (<i>n</i>Â =Â 248)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Compound inhibition in the SPA and hWPA was measured in duplicate at six concentrations, and the mean values were used to calculate the IC<sub>50</sub>. IC<sub>50</sub> values are reported as the mean Â± SD for <i>n</i> â¥ 2. See ref <a onclick="showRef(event, 'cit8a'); return false;" href="javascript:void(0);" class="ref cit8a">8a</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_001.pdf" class="ext-link">Supporting Information</a> for details.</p></div></div></div><div class="NLM_p last">In this paper, we shall discuss optimization efforts on the phenyl A-ring of <b>8a</b>, which resulted in the identification of a series of potent and orally bioavailable TPE amides and ureas with improved hWPA activity. These compounds showed improved pharmacodynamic effects in terms of both CE transfer inhibition and HDL elevation as compared with <b>5</b>. Furthermore, we demonstrate with a large set of TPE analogs that there are strong correlations between the in vitro hWPA potency and metabolic stability and in vivo inhibition of CE transfer in Tg mice. Throughout our studies, the in vitro hWPA potency and stability profile were used to guide compound selection for Tg mouse studies. After achieving a compound-<b>1</b>-like PD response, we investigated the effect on BP of the lead compounds in telemeterized rats, which guided our efforts to focus on further modifications on the 4-fluoro-3-substituted phenyl A-rings in the N-terminus arylamide series. This ultimately led to the discovery of our first preclinical candidate BMS-795311 (compound <b>10g</b>). The in vitro and in vivo activity and liability profile of <b>10g</b> will be described.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68853" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68853" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p"><a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>â<a class="ref internalNav" href="#sch6" aria-label="6">6</a> illustrate the synthesis of compounds described herein. To construct the requisite tertiary carbinamines of TPE analogs, we adapted two general synthetic strategies that had previously been disclosed for the DPPE series.<a onclick="showRef(event, 'cit8a ref13'); return false;" href="javascript:void(0);" class="ref cit8a ref13">(8a, 13)</a> In the first method, racemic tertiary amines were obtained by the addition of benzyl Grignard to the TMSCl-activated imines derived from the corresponding arylnitriles and the aryllithium species, followed by removal of the labile TMS group in a one-pot three-component reaction. <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> illustrates the initial synthesis of TPE ureas <b>8a</b>â<b>e</b> from 3-fluoro-5-trifluoromethylphenyl bromide (<b>11</b>) and the corresponding A-ring nitriles <b>12</b>. Unlike the formation of DPPE carbinamines, an additional equivalent of benzylmagnesium bromide, a higher temperature, and a longer reaction time (stirring the mixture at room temperature overnight) were necessary in order to obtain the TPE carbinamines in good yields at the Grignard addition step. The racemic mixture of ureas <b>14</b> was separated via chiral HPLC. The desired enantiomers <b>8a</b>, <b>8b</b>, and <b>8e</b> eluted much slower than the corresponding undesired enantiomer (e.g., <b>8c</b>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>n-</i>BuLi (2.5 M in hexanes, 1.1 equiv), Et<sub>2</sub>O, â78 Â°C, 30 min, 4-fluoro-3-(trifluoromethyl)benzonitrile (1.0 equiv), â78 Â°C, 2 h, TMSCl, THF, â78 Â°C to rt, 2 h; BnMgBr (2.0 M in THF, 2 equiv), â78 Â°C to rt, 16 h, 1 N HCl, 19â87%; (b) NCO-cyclopentyl, 1,4-dioxane, 16 h, 55â67%; (c) chiral preparative HPLC, AD column (10% isopropanol/heptane/0.1% DEA, isocratic); <b>8c</b>, fast eluting, 44%; <b>8b</b>, slow eluting, 42%.</p></p></figure><div class="NLM_p">Since the in vitro potency of the TPE derivatives resided in only one enantiomer, we then used Ellmanâs <i>tert-</i>butanesulfinamide chemistry to generate the desired TPE tertiary carbinamines via the addition of benzyl Grignard to the <i>N</i>-<i>tert</i>-butanesulfinyl ketimines derived from the corresponding diaryl ketones followed by the separation of the diastereomers using silica gel chromatography and removal of the <i>tert</i>-butanesulfinyl group (second general method).<a onclick="showRef(event, 'cit8a ref13'); return false;" href="javascript:void(0);" class="ref cit8a ref13">(8a, 13)</a> In large-scale syntheses, the diastereomeric mixtures were separated by supercritical fluid chromatography (SFC). <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> illustrates the synthesis of <b>9b</b>, <b>9c</b>, <b>9f</b>, and <b>9i</b> bearing the 4-fluorophenyl A-ring and the 3-fluoro-5-tetrafluoroethyl ether phenyl B-ring. The benzylic protons (CH<sub>a</sub>H<sub>b</sub>Ph) of the two diastereomers (<i>R</i>,<i>R</i>s)-<b>17</b> and (<i>S</i>,<i>R</i>s)-<b>17</b> showed a distinctive AAâ²BBâ² pattern in the 1D proton NMR. The chemical shifts of CH<sub>a</sub>H<sub>b</sub> of the desired diastereomer (<i>R</i>,<i>R</i>s)-<b>17</b> were more separated than the other isomer (<i>S</i>,<i>R</i>s)-<b>17</b>. Therefore, we used the integration of the CH<sub>a</sub>H<sub>b</sub>Ph protons of the crude reaction mixture to determine the diastereomeric ratio (dr) of the Grignard reaction (step c in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The temperature, solvent, concentration, and additive effects on the dr of the Grignard addition step were investigated. The noncoordinating solvents such as CH<sub>2</sub>Cl<sub>2</sub> gave better dr, suggesting a favorable chelated six-membered cyclic TS<sup>â§§</sup>.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Single crystal X-ray crystallography confirmed the absolute stereochemistry of the major diastereomer as (<i>R</i>,<i>R</i>s)-<b>17</b>.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Due to the absence of hetero ring atoms on the A- or B-rings, Lewis acid additives, such as BF<sub>3</sub>Â·Et<sub>2</sub>O did not improve dr; however, the reaction generally proceeded faster with Et<sub>2</sub>OÂ·BF<sub>3</sub> than without Et<sub>2</sub>OÂ·BF<sub>3</sub>. The best conditions utilized 2 equiv of BF<sub>3</sub>Â·Et<sub>2</sub>O in CH<sub>2</sub>Cl<sub>2</sub> at â78 Â°C with 2.1â3.5 equiv of BnMgCl and gave an 84% isolated yield of the desired isomer (<i>R</i>,<i>R</i>s)-<b>17</b> after column chromatography separation. Urea or amide formation from <b>18</b> then provided the desired compounds <b>9b</b>, <b>9c</b>, <b>9f</b>, and <b>9i</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>n</i>-BuLi, 4-fluorobenzonitrile, Et<sub>2</sub>O, â78 Â°C, then 1 N HCl, 87%; (b) (<i>R</i>)-(+)-2-methylpropane-2-sulfinamide, Ti(OEt)<sub>4</sub>, THF, reflux, 81%; (c) BnMgBr (1.0 M in Et<sub>2</sub>O, 2 equiv), BF<sub>3</sub>Â·Et<sub>2</sub>O (2 equiv), â78 Â°C, 1.5 h, CH<sub>2</sub>Cl<sub>2</sub>, dr (<i>R</i>,<i>R</i>s)-<b>17</b>/(<i>S</i>,<i>R</i>s)-<b>17</b> = 5.3:1, isolated yield for (<i>R</i>,<i>R</i>s)-<b>17</b>, 81%; (d) 4 N HCl in dioxane, MeOH, 82%; (e) NCO-cyclopentyl, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 70%; (f) 4-fluoro-3-(trifluoromethyl)benzoyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 5 h, 95%; (g) <i>p</i>-nitrophenyl chloroformate, K<sub>2</sub>CO<sub>3</sub>, THF, rt; then (1<i>S</i>)-3,3-difluorocyclopentan-1-amine,<a onclick="showRef(event, 'cit8b'); return false;" href="javascript:void(0);" class="ref cit8b">(8b)</a> DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, SFC separation, 35%; (h) 4,4,4-trifluorobutanoic acid, PyBOP, <i>N</i>-methylmorpholine, CH<sub>2</sub>Cl<sub>2</sub>, rt, 8 h, 66%.</p></p></figure><div class="NLM_p">The dr of the Grignard adducts (i.e., (<i>R</i>,<i>R</i>s):(<i>S</i>,<i>R</i>s)) bearing different A-ring and B-ring substituents ranged from 1:1 to 9:1. When the A-ring was 3-trifluoromethyl-4-fluorophenyl and the B-ring was 3-fluoro-5-tetrafluoroethyl ether phenyl, the route in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> only offered a 1:1 mixture of diastereomers, which were difficult to separate by column chromatography. Because <b>9d</b> was one of the most advanced compounds in the program, we optimized the tertiary carbinamine synthesis by changing the tetrafluoroethyl ether substituent on the B-ring to a <i>tert</i>-butyldiphenylsilyl ether (OTBDPS) group and switching the (<i>R</i>)-sulfamine reagent to the (<i>S</i>)-sulfamine (compound <b>22</b>). Grignard addition of benzylmagnesium chloride to <b>22</b> provided an improved dr (5:1) in favor of the desired isomer (<i>R</i>,<i>S</i>s)-<b>23</b>, which was the fast eluant by column chromatography (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Deprotection of <b>23</b> and urea formation by reaction of the intermediate isopropenyl carbamate with trifluoroethylamine gave urea <b>24</b>. Removal of the TBDPS group in <b>24</b> followed by alkylation of the resulting phenol with tetrafluoroiodoethane afforded <b>9d</b>.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0010.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>tert</i>-butyldiphenylsilyl chloride, imidazole, 0 Â°C to rt, 18 h, 58%; (b) <i>n</i>-BuLi (2.5 M in hexanes, 1.1 equiv), Et<sub>2</sub>O, â78 Â°C, 30 min; 4-fluoro-3-trifluoromethylbenzonitrile, â78 Â°C, 1.5 h; 1 N HCl, 79%; (c) (<i>S</i>)-(â)-2-methylpropane-2-sulfinamide, Ti(OEt)<sub>4</sub>, THF, reflux, 83%; (d) BF<sub>3</sub>Â·Et<sub>2</sub>O (2 equiv), BnMgCl in Et<sub>2</sub>O (2.8 equiv), CH<sub>2</sub>Cl<sub>2</sub>, â78 Â°C, dr, (<i>R</i>,<i>S</i>s)-<b>23</b>/(<i>S</i>,<i>S</i>s)-<b>23</b> = 5:1, yield for (<i>R</i>,<i>S</i>s)-<b>23</b>, 62%; (e) 4 N HCl dioxane/MeOH; (f) isopropenyl chloroformate, K<sub>2</sub>CO<sub>3</sub>, THF/H<sub>2</sub>O, rt, 4 h; (g) NH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>, <i>N</i>-methylpyrrolidine (cat.), THF/DMSO, microwave irradiation, 180 Â°C, 20 min, 82% for 3 steps; (h) TBAF, THF, 0 Â°C, 45 min, 77%; (i) ICF<sub>2</sub>CF<sub>2</sub>H, K<sub>2</sub>CO<sub>3</sub>, DMSO, 70 Â°C, 16 h, 58%.</p></p></figure><div class="NLM_p">To access kilogram quantities of the optimal B-ring bromide <b>15</b>, we developed a practical synthesis of 3-bromo-5-fluorophenol (<b>21</b>) that involved nucleophilic substitution of the readily available 3,5-difluorobromobenzene (<b>25</b>) with potassium trimethylsilanoate (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Nucleophilic substitution of 1,2-dibromotetrafluoroethane with phenol <b>21</b> gave a mixture of <b>26</b> and <b>15</b> (<b>26</b>/<b>15</b> = 95:5), which was subsequently reduced with zinc dust to provide the B-ring intermediate <b>15</b>.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0011.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) KOSiMe<sub>3</sub> (3.5 equiv), diglyme, 120 Â°C, 5 h, 92%; (b) BrCF<sub>2</sub>CF<sub>2</sub>Br, DMSO, Cs<sub>2</sub>CO<sub>3</sub> (1.5 equiv), 50 Â°C, 5 h, 94%; (c) Zn, HOAc, 50 Â°C, 1 h, 87%.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> illustrates the synthesis of 3-alkyl ether-4-fluorophenyl analogs <b>10a</b>â<b>11g</b> starting from the methoxy ether <b>10b</b>. Compound <b>10b</b> was synthesized following the procedures described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Removal of the methyl group in <b>10b</b> followed by alkylation with either ethyl iodide or isopropyl iodide provided <b>10c</b> and <b>10d</b>, respectively. The <i>tert</i>-butyl ether <b>10e</b> was obtained by heating <b>10a</b> in the presence of 1,1-di-<i>tert</i>-butoxy-<i>N</i>,<i>N</i>-dimethylmethanamine in DMF. Initially, the cyclopropyl ether <b>10g</b> was synthesized via formation of the vinyl ether <b>27</b> using either Cu(OAc)<sub>2</sub>-mediated CâO coupling of phenol <b>10a</b> with trivinylcyclotriboroxaneâpyridine complex<a onclick="showRef(event, 'cit18a'); return false;" href="javascript:void(0);" class="ref cit18a">(18a)</a> or iridium-catalyst transfer vinylation of phenol <b>10a</b> with vinyl acetate,<a onclick="showRef(event, 'cit18b'); return false;" href="javascript:void(0);" class="ref cit18b">(18b)</a> followed by SimmonsâSmith cyclopropanation of <b>27</b> with diiodomethane and diethylzinc in the presence of trifluoroacetic acid. In large-scale syntheses, to avoid heavy metal usage close to the end of the synthetic route, the vinyl ether <b>27</b> was prepared in a two-step nucleophilic addition and then elimination process using Cs<sub>2</sub>CO<sub>3</sub> as the base for the addition step and <i>t</i>-BuOK as the base for the elimination step.</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0012.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 Â°C to rt, 2 h, 100%; (b) ethyl iodide, K<sub>2</sub>CO<sub>3</sub>, 50 Â°C, DMF, 90%; (c) isopropyl iodide, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 Â°C, 16 h, 86%; (d) 1,1-di-<i>tert</i>-butoxy-<i>N</i>,<i>N</i>-dimethylmethanamine, DMF, 110 Â°C, 5 h, 81%; (e) ethyl 2-bromopropanoate, K<sub>2</sub>CO<sub>3</sub>, rt, 16 h, then NaBH<sub>4</sub>, THF, 0 Â°C to rt, 16 h, 27% for 2 steps; (f) 2,4,6-trivinylcyclotriboroxaneâpyridine complex, Cu(OAc)<sub>2</sub>, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 days, 93%; (g) ethenyl acetate, [Ir(COD)Cl]<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, toluene, 100 Â°C, 77%; (h) 2-chloroethyl 4-methylbenzene-1-sulfonate (1.75 equiv), Cs<sub>2</sub>CO<sub>3</sub> (1.1 equiv), Triton X-405 (5% w/w), THF; KO-<i>t</i>-Bu (5 equiv), 0â7 Â°C, 76â80% for 2 steps; (i) Et<sub>2</sub>Zn, TFA, CH<sub>2</sub>I<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, â10 Â°C to rt, 78â83%.</p></p></figure><div class="NLM_p">3-Isobutyl-4-fluorophenyl A ring analog <b>10h</b> and 3-cyclopropyl-4-fluorophenyl A ring analog <b>10i</b> were obtained from the corresponding bromide intermediate <b>28</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>). Negishi coupling of <b>28</b> with isobutylzinc bromide using PEPPSI-IPr as the catalyst followed by amide formation gave <b>10h</b>. Amide formation of <b>28</b> followed by Suzuki coupling with cyclopropylboronic acid afforded <b>10i</b>. The synthesis of the methyldimethylamine analog <b>10j</b> started with the bromobenzophenone intermediate <b>29</b>. Nitrile formation followed by double reduction of the cyano group and ketone group, protection of the amine, and then DessâMartin oxidation provided the ketone intermediate <b>30</b>. Following similar procedures as shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, the Boc-protected arylamide <b>31</b> was obtained. Removal of the Boc group and subsequent reductive amination afforded <b>10j</b>.</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0013.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PEPPSI-IPr (0.2 equiv), isobutylzinc(II) bromide (6 equiv), NMP, THF, 75 Â°C, 2 h, rt, 3 days, 36%; (b) 4-fluoro-3-(trifluoromethyl)benzoyl chloride, Na<sub>2</sub>CO<sub>3</sub>, THF, rt, 2 h, 48%; (b) cyclopropylboronic acid, palladium(II) acetate (5 mol %), tricyclohexylphosphine (10 mol %), K<sub>3</sub>PO<sub>4</sub>, toluene, 100 Â°C, microwave irradiation, 15 min, 30%; (d) 1,1-di-<i>tert</i>-butoxy-<i>N</i>,<i>N</i>-dimethylmethanamine; (e) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 175 Â°C, 90%; (f) NaBH<sub>4</sub>, NiCl<sub>2</sub>, Boc<sub>2</sub>O, MeOH, 0 Â°C to rt, 6 h, 85%; (g) DessâMartin periodinane, CH<sub>2</sub>Cl<sub>2</sub>/H<sub>2</sub>O, rt, 3 h, 33%; (h) (<i>R</i>)-(+)-2-methylpropane-2-sulfinamide, Ti(OEt)<sub>4</sub>, THF, 75 Â°C, 16 h, 58%; (i) BF<sub>3</sub>.OEt<sub>2</sub> (2 equiv), BnMgCl (3 equiv), CH<sub>2</sub>Cl<sub>2</sub>, â78 Â°C to rt, 3 h; (j) 4 N HCl, dioxane/MeOH; (k) (Boc)<sub>2</sub>O, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 Â°C, 1.5 h, 72% for 3 steps; (l) 4-fluoro-3-(trifluoromethyl)benzoyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 Â°C to rt, 16 h, 91%; (m) 1 N HCl/Et<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h; (n) formaldehyde, NaCNBH<sub>3</sub>, AcOH, MeOH, rt, 1 h, 33% for two steps.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Medicinal Chemistry Lead Optimization of TPE Series: Discovery of Compound <b>10g</b></h3><div class="NLM_p">The aforementioned TPE urea <b>8a</b> bearing the 3-trifluoromethylphenyl A-ring in combination with the 3-trifluoromethyl-5-fluorophenyl B-ring exhibited an IC<sub>50</sub> of 12 nM in the SPA and 1.5 Î¼M in the hWPA. Continued SAR studies on phenyl A-ring substitution generated many TPE analogs, some of which are exemplified in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. The <i>R</i> enantiomers were generally more potent than the corresponding <i>S</i> enantiomers (e.g., <b>8b</b> vs <b>8c</b>). Compounds with 3,4-disubstituted phenyl A-rings, such as <b>8b</b> and <b>8f</b>, showed good potency in the SPA and hWPA assays. The 4-fluorophenyl substituted analog <b>8e</b> was also potent having submicromolar hWPA potency. However, the 3-fluoro-5-trifluoromethylphenyl analog <b>8d</b> was much less potent; this was also true for other 3,5-disubstituted phenyl A-ring analogs (data not shown). After optimizing the substitution pattern of the phenyl A-ring, we replaced the 3-fluoro-5-trifluoromethylphenyl B-ring with the more optimal 3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl present in the DPPE lead <b>5</b>. The resulting compounds <b>9a</b> and <b>9b</b> were an order of magnitude more potent than <b>5</b>, having IC<sub>50</sub> values that were similar to <b>1</b>. Compound <b>9c</b> bearing the same aryl amide N-terminus as that of <b>5</b> also demonstrated improved potency (hWPA = 0.62 Î¼M) relative to <b>5</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro CETP Inhibitory Activity of Phenyl A-Ring Analogs<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0015.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0016.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Compound inhibition in the SPA and hWPA was measured in duplicate at six concentrations, and the mean values were used to calculate the IC<sub>50</sub>. IC<sub>50</sub> values are reported as the mean Â± SD for <i>n</i> â¥ 2; see ref <a onclick="showRef(event, 'cit8a'); return false;" href="javascript:void(0);" class="ref cit8a">8a</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_001.pdf" class="ext-link">Supporting Information</a> for details.</p></div></div><div></div></div><div class="NLM_p">The selectivity of the TPE derivatives <b>8f</b>, <b>9b</b>, and <b>9c</b> was tested against phospholipid transfer protein (PLTP),<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> the closest family member of four to CETP, and none of them inhibited PL transfer activity up to 100 Î¼M. In addition, these compounds did not disrupt HDL particle integrity (altered [<sup>3</sup>H]HDL mobility) in a lipoprotein disruption assay.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">With the hWPA activity of several compounds approaching <b>1</b>, we next measured in vivo CETP inhibition in the primary screening model, i.e., a dual transgenic (Tg) mouse PK/PD model, in which mice expressed both human CETP and human apoB-100 (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Because mice utilize non-CETP mechanisms to transfer CE, the maximal inhibition of CE transfer in the Tg mouse model due to CETP inhibition was 50â70% (i.e., 30â50% of predosing activity). The lowest dose required to maximally inhibit plasma CETP activity for 8 h was defined as the minimal efficacious dose (MED). For compound <b>1</b>, the MED was 3 mg/kg, and for compound <b>5</b>, the MED was 30 mg/kg, as determined in separate dose escalation studies.</div><div class="NLM_p">As shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, the cyclopentylurea analogs <b>9a</b> and <b>9b</b> offered good hWPA and TgWPA activity, but the cyclopentyl functionality resulted in poor metabolic stability<a onclick="showRef(event, 'cit8a'); return false;" href="javascript:void(0);" class="ref cit8a">(8a)</a> (MLM rate: â¼0.3 nmol min<sup>â1</sup> mg<sup>â1</sup>); thus, neither showed significant CETP inhibition at the 8 h time point in the Tg PK/PD studies (98% and 78% of predosing activity for <b>9a</b> and <b>9b</b>, respectively). On the other hand, despite its somewhat lower hWPA and TgWPA activity compared with <b>9a</b> and <b>9b</b>, the arylamide <b>9c</b> exhibited very good metabolic stability and demonstrated complete CETP inhibition during the 8 h assay period with a plasma concentration of 7 Î¼M at the 8 h time point, 5-fold higher than the TgWPA IC<sub>50</sub> of 1.3 Î¼M. In addition to the phenylamide analog <b>9c</b>, we incorporated fluorinated (cyclo)alkylureas, such as trifluoroethyl, trifluoropropyl, and <i>S</i>-difluorocyclopentyl substituents which had previously demonstrated improved metabolic stability in the DPPE series,<a onclick="showRef(event, 'cit8b'); return false;" href="javascript:void(0);" class="ref cit8b">(8b)</a> into the TPE series with the hope of improving metabolic stability and maintaining or improving in vitro potency. From this approach, we identified several advanced lead compounds such as <b>9d</b>â<b>g</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). TPE fluorinated ureas <b>9d</b>â<b>g</b> were potent having hWPA and TgWPA IC<sub>50</sub> values comparable to <b>1</b>. In addition, these compounds showed improved metabolic stability (except for <b>9f</b>) compared with the cyclopentyl analogs <b>9a</b> and <b>9b</b>. In Tg mouse efficacy studies, compounds <b>9d</b>, <b>9e</b>, and <b>9g</b> exhibited complete inhibition of CETP at 10 mg/kg. Furthermore, <b>9d</b> demonstrated efficacy equivalent to that of <b>1</b> at 3 mg/kg in a separate dose escalation study (AUC<sub>0â8h</sub> for <b>9d</b> was 4.8 Î¼MÂ·h; AUC<sub>0â8h</sub> for <b>1</b> was 2.4 Î¼MÂ·h); the MED for both was 3 mg/kg. Compound <b>9f</b>, on the other hand, showed a near complete inhibition of CE transfer at the 2 and 4 h time points but lost considerable activity at the 8 h time point. The reduced efficacy of <b>9f</b> over time was likely due to an increased rate of metabolism (MLM = 0.126 nmol min<sup>â1</sup> mg<sup>â1</sup>) resulting in lower plasma concentrations (<i>C</i><sub>8h</sub> = 0.054 Î¼M) in Tg mice.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vivo Efficacy of TPE Derivatives in Inhibition of CE Transfer in Tg Mice<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0017.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="3" align="center">CETP activity in Tg mice (% of predosing activity)</th><th class="rowsep1 colsep0" colspan="3" align="center">plasma concentration in Tg mice (Î¼M)</th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">hWPA IC<sub>50</sub>Â (Î¼M)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">TgWPA IC<sub>50</sub>Â (Î¼M)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">2Â h</th><th class="colsep0 rowsep0" align="center">4Â h</th><th class="colsep0 rowsep0" align="center">8Â h</th><th class="colsep0 rowsep0" align="center">2Â h</th><th class="colsep0 rowsep0" align="center">4Â h</th><th class="colsep0 rowsep0" align="center">8Â h</th><th class="colsep0 rowsep0" align="center">AUC<sub>0â8h</sub> (Î¼MÂ·h)</th><th class="colsep0 rowsep0" align="center">HLM/MLM rate (nmolÂ min<sup>â1</sup>Â mg<sup>â1</sup>)<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9a</b></td><td class="colsep0 rowsep0" align="left">0.17Â Â±Â 0.02 (<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">98</td><td class="colsep0 rowsep0" align="left">0.48</td><td class="colsep0 rowsep0" align="left">0.08</td><td class="colsep0 rowsep0" align="left">0.03</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">0.273/0.275</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9b</b></td><td class="colsep0 rowsep0" align="left">0.23Â Â±Â 0.08 (<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="left">0.21Â Â±Â 0.08 (<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">53</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="left">5.9</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">0.55</td><td class="colsep0 rowsep0" align="left">17.5</td><td class="colsep0 rowsep0" align="left">0.295/0.298</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9c</b></td><td class="colsep0 rowsep0" align="left">0.62Â Â±Â 0.30 (<i>n</i>Â =Â 3)</td><td class="colsep0 rowsep0" align="left">1.3Â Â±Â 0.1 (<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="left">35</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">14.5</td><td class="colsep0 rowsep0" align="left">11.6</td><td class="colsep0 rowsep0" align="left">7.0</td><td class="colsep0 rowsep0" align="left">77.0</td><td class="colsep0 rowsep0" align="left">0.000/0.000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9d</b></td><td class="colsep0 rowsep0" align="left">0.18Â Â±Â 0.07 (<i>n</i>Â =Â 11)</td><td class="colsep0 rowsep0" align="left">0.072</td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">35</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">0.84</td><td class="colsep0 rowsep0" align="left">15.8</td><td class="colsep0 rowsep0" align="left">0.007/0.000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9e</b></td><td class="colsep0 rowsep0" align="left">0.19Â Â±Â 0.07 (<i>n</i>Â =Â 5)</td><td class="colsep0 rowsep0" align="left">0.19</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">0.92</td><td class="colsep0 rowsep0" align="left">19.1</td><td class="colsep0 rowsep0" align="left">0.006/0.040</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9f</b></td><td class="colsep0 rowsep0" align="left">0.21Â Â±Â 0.10 (<i>n</i>Â =Â 9)</td><td class="colsep0 rowsep0" align="left">0.11</td><td class="colsep0 rowsep0" align="left">42</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">63</td><td class="colsep0 rowsep0" align="left">0.89</td><td class="colsep0 rowsep0" align="left">0.19</td><td class="colsep0 rowsep0" align="left">0.054</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">0.062/0.126</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9g</b></td><td class="colsep0 rowsep0" align="left">0.30Â Â±Â 0.12 (<i>n</i>Â =Â 6)</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">35</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">0.55</td><td class="colsep0 rowsep0" align="left">0.14</td><td class="colsep0 rowsep0" align="left">4.9</td><td class="colsep0 rowsep0" align="left">0.038/0.048</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">0.10Â Â±Â 0.05 (<i>n</i>Â =Â 248)</td><td class="colsep0 rowsep0" align="left">0.16</td><td class="colsep0 rowsep0" align="left">38</td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">0.68</td><td class="colsep0 rowsep0" align="left">0.15</td><td class="colsep0 rowsep0" align="left">6.0</td><td class="colsep0 rowsep0" align="left">0.092/0.092</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b><a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">3.6Â Â±Â 2.8 (<i>n</i>Â =Â 7)</td><td class="colsep0 rowsep0" align="left">9.0</td><td class="colsep0 rowsep0" align="left">55<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">48<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">40<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">14.5<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">15.2<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">9.8<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">93<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">0.000/0.003</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">hCETP/apoB-100 dual Tg mice were divided into groups of <i>n</i> = 4 or 5. Animals were fasted for 2 h, bled, and vehicle (EtOH/Cremophor/water, 10/10/80) or test compound was orally dosed at 10 mg/kg. Mice were bled at 2, 4, and 8 h post dosing. Plasma was analyzed for CETP activity and drug exposure. Compound effects on plasma CE transfer activities at the 2, 4, and 8 h time points were determined by analysis of the activity difference between samples obtained after dosing and that of the same animal before dosing.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Inhibition in the hWPA was measured in duplicate at six concentrations, and the mean values were used to calculate IC<sub>50</sub> values, which are reported as the mean Â± SD (see ref <a onclick="showRef(event, 'cit8a'); return false;" href="javascript:void(0);" class="ref cit8a">8a</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_001.pdf" class="ext-link">Supporting Information</a> for details).</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">For TgWPA, see ref <a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">21</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_001.pdf" class="ext-link">Supporting Information</a> for details.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">Microsomal metabolic rate during 10 min incubation at 0.5 Î¼M concentration. HLM: human liver microsomes. MLM: mouse liver microsomes.</p></div><div class="footnote" id="t3fn5"><sup>e</sup><p class="last">Dose: 30 mg/kg (po).</p></div></div></div><div class="NLM_p">Compounds in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> are representative of a large set of TPE analogs, many of which demonstrated robust in vivo efficacy with complete inhibition of CE transfer activity at a 10 mg/kg oral dose in the Tg mouse studies, similar to that of compound <b>1</b>. The data in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> demonstrate a strong correlation between the in vitro metabolic stability and WPA activity of a compound with its in vivo PD effects in the Tg mice (very good PK/PD correlation). Because hWPA and TgWPA data were similar across all the compounds tested and because of the excellent PK/PD relationship, we used the in vitro metabolic stability profile and hWPA potency data to guide compound selection for the Tg mouse studies.</div><div class="NLM_p">Since a large number of CETP polymorphisms are present in the human population, some occurring at a relatively high frequency, it is important for CETP inhibitors to be comparably potent against these mutants. In the literature, compound <b>1</b> behaved similarly against a set of nine relatively common CETP variants, with no significant differences in inhibition.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> We therefore studied the effect of compound <b>9d</b> on CETP mutants. The studies of <b>9d</b> and <b>1</b> were carried out using the same set of nine published mutants. IC<sub>50</sub> inhibition values for both <b>9d</b> and <b>1</b> varied less than 3-fold across all CETP mutants tested, suggesting that the TPE derivatives as a class of CETP inhibitors were equally potent against common human CETP variants.</div><div class="NLM_p">The moderately high-fat-, high-cholesterol-fed hamster model was our primary animal model to assess compound ability to elevate HDL-C through CETP inhibition, as the HDL/LDL profiles in this hamster model are similar to humans. The effects of compounds <b>9d</b>, <b>9e</b>, <b>1</b>, and <b>5</b> on plasma HDL-C were obtained in a 3-day study in this model. As shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, HDL-C was increased by all compounds. Compound <b>9d</b>, therefore, showed equivalent CETP inhibition in Tg mice and elevation of HDL-C in hamsters when compared with <b>1</b>.</div><figure id="fig2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Elevation in HDL-C for compounds <b>9d</b>, <b>9e</b>, <b>1</b>, and <b>5</b> in moderately fat-fed hamsters. (A) Plasma HDL-C and (B) percent changes in HDL-C after dosing compounds (po, q.d.) for 3 days. Vehicle: EtOH/Cremophor/water, 1/1/8. Plasma was obtained before dosing and 2 h after the last dose (48 h after the initiation of dosing) to determine the effects of drug treatment on HDL-C levels. HDL-C levels were measured using an automated lipid analyzer (Lipi+plus from Polymedco on a COBAS MIRA chemistry analyzer): (âââ) <i>p</i> < 0.001, (ââ) <i>p</i> < 0.01, (â) <i>p</i> < 0.05 vs vehicle (<i>n</i> = 6/group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>1</b> produced a mild increase in BP in patients<a onclick="showRef(event, 'cit6a cit6b cit6c'); return false;" href="javascript:void(0);" class="ref cit6a cit6b cit6c">(6a-6c)</a> and in conscious telemeterized rats.<a onclick="showRef(event, 'cit6d cit8a ref23'); return false;" href="javascript:void(0);" class="ref cit6d cit8a ref23">(6d, 8a, 23)</a> Therefore, the potential for compound <b>9d</b> to alter BP and heart rate (HR) was also assessed in conscious, telemeterized rats. A mild increase in mean arterial pressure (MAP) (â¼10â15 mmHg) lasting approximately 12 h was observed in rats treated with <b>9d</b> at 30 and 60 mg/kg single dose, po (<i>C</i><sub>max</sub> of 14.6 and 16.3 Î¼M, respectively), while MAP was not increased in the vehicle-treated rats. The increase in MAP for <b>9d</b> was due to an elevation of both systolic and diastolic BP (SBP and DBP). Previously, TPE phenylamide <b>9c</b>, a close analog to DPPE lead <b>5</b>, was tested side-by-side with <b>5</b>, and neither effected BP in rats (<b>9c</b>, <i>C</i><sub>max</sub> = 9.5 Î¼M at 30 mg/kg, po; <b>5</b>, <i>C</i><sub>max</sub> = 25.5 Î¼M at 60 mg/kg, po), suggesting the N-terminus amides may be less at risk for BP effects than ureas.</div><div class="NLM_p">Because of the BP increase observed with <b>9d</b>, we selected a set of compounds for BP studies that showed complete CE inhibition in Tg mice at 10 mg/kg, po. <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> summarizes rat telemetry data for representative TPE compounds with different N-terminus groups (E) in comparison with <b>1</b> and <b>5</b>. <i>C</i><sub>max</sub> values and time point sampled as well as plasma exposure over 24 h, determined in a satellite set of rats, are shown for each compound tested. Among linear ureas (e.g., <b>9d</b> and <b>9h</b>), cyclic ureas (e.g., <b>9f</b>), linear amides (e.g., <b>9i</b> and <b>9j</b>), and arylamide N-terminus groups (e.g., <b>9c</b> and <b>5</b>), only arylamides consistently demonstrated no BP increase despite high and sustained exposure (AUC<sub>0â24h</sub> of 270 and 562 Î¼MÂ·h for <b>9c</b> (30 mg/kg, po) and <b>5</b> (60 mg/kg, po), respectively). No effects on HR or locomotion were observed for any of the compounds tested. Thus, we turned our focus on further optimization of the arylamide series.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. BP Effects for TPE Ureas and Amides in Telemeterized Rats<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0018.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0019.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Compound or vehicle (ethanol/cremophor/water, 1/1/8) was dosed orally to designated groups of telemeterized rats (male SpragueâDawley, â¼450 g, 17 weeks), and BP, HR, and locomotor activities were monitored for 24 h. BP, HR, and locomotor activities were recorded from 24 h prior to vehicle dosing through 24 h after dosing. Plasma exposures were assessed in two nontelemeterized satellite rats dosed with the same dosing solution. Plasma was sampled at 1, 2, 6, and 24 h after dosing in satellite rats.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">Inhibition in the hWPA was measured in duplicate at six concentrations, and the mean values were used to calculate the IC<sub>50</sub>. IC<sub>50</sub> values are reported as the mean Â± SD for <i>n</i> â¥ 2 (see ref <a onclick="showRef(event, 'cit8a'); return false;" href="javascript:void(0);" class="ref cit8a">8a</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_001.pdf" class="ext-link">Supporting Information</a> for details).</p></div></div><div></div></div><div class="NLM_p">The phenylamides were historically less potent in the hWPA when compared with the fluorinated ureas. A breakthrough came when further modifications to the phenyl A-ring substituent were carried out. The 4-fluoro-3-methoxyphenyl A-ring in urea <b>9j</b> exhibited no BP increase. In addition, its corresponding phenylamide analog <b>10b</b> demonstrated hWPA activity similar to the 4-fluorophenyl A-ring analog <b>9c</b> (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). These findings prompted a further exploration around the substitution of the hydroxyl at the 3 position of the phenyl A-ring. As shown in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>, the methyl ether <b>10b</b> exhibited more than a 100-fold increase in hWPA potency compared with the 3-hydroxy analog <b>10a</b>. Increasing steric bulk at the 3-ether position led to an improvement in hWPA potency (methyl <b>10b</b> to ethyl <b>10c</b> to isopropyl <b>10d</b> and <i>tert</i>-butyl <b>10e</b>) with isopropyl ether analogs <b>10d</b> and <b>10e</b> being the most potent compounds in the series. Adding polar groups generally decreased hWPA potency; <b>10f</b> having an isopropyl alcohol was the most potent when polar substitution was present on the A-ring. The cyclopropyl ether analog <b>10g</b> was equipotent with <b>10d</b> and <b>10e</b> in the hWPA. The carbon linked 3-substituents, such as isopropyl <b>10h</b> or cyclopropyl <b>10i</b>, were also potent, as was <i>N</i>,<i>N</i>-dimethylmethylamine <b>10j</b>.</div><div class="NLM_p">It is expected that high plasma exposures and a low peak-to-trough ratio are determining factors for achieving good CETP inhibitory efficacy in vivo. In PK bridging studies, a series of compounds with high, medium, and low exposure in the Tg mouse model were tested in wild-type Balb/C mice via oral dosing. The exposures in both Tg mice and Balb/C mice were similar. Therefore, oral PK screening was performed using more cost-effective Balb/C mice with compounds having good hWPA potency and liver microsomal stability (see both AUC<sub>0â8h</sub> and <i>C</i><sub>8h</sub> in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). The cyclopropyl ether analog <b>10g</b> stood out as having the best combination of hWPA potency and PK profile and was therefore advanced to extensive in vitro, in vivo, and liability profiling.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. SAR of 4-Fluoro-3-substituted Phenyl A-Ring Analogs with N-Terminus Arylamides</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0020.gif" alt="" id="fx7" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">CETP SPA IC<sub>50</sub>Â (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">CETP WPA IC<sub>50</sub>Â (Î¼M)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">human LM %Â remaining<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">mouse LM %Â remaining<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">po AUC<sub>0â8h</sub> (Î¼MÂ·h)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">po <i>C</i><sub>8h</sub> (Î¼M)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9c</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">0.62Â Â±Â 0.30 (<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">50.8</td><td class="colsep0 rowsep0" align="left">3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10a</b></td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">860Â Â±Â 22 (<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="left">73</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">7.2</td><td class="colsep0 rowsep0" align="left">0.66Â Â±Â 0.41 (<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="left">21.5</td><td class="colsep0 rowsep0" align="left">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10c</b></td><td class="colsep0 rowsep0" align="left">OCH<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">0.34Â Â±Â 0.01 (<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="left">17.9</td><td class="colsep0 rowsep0" align="left">0.51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10d</b></td><td class="colsep0 rowsep0" align="left">OCH(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">4.6Â Â±Â 1.8 (<i>n</i>Â =Â 8)</td><td class="colsep0 rowsep0" align="left">0.17Â Â±Â 0.07 (<i>n</i>Â =Â 23)</td><td class="colsep0 rowsep0" align="left">82</td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="left">9.9, 14.5<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">0.29, 0.5<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10e</b></td><td class="colsep0 rowsep0" align="left">OC(CH<sub>3</sub>)<sub>3</sub></td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">0.18Â Â±Â 0.05 (<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">0.45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10f</b></td><td class="colsep0 rowsep0" align="left">OCH(CH<sub>3</sub>)CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">0.51</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10g</b></td><td class="colsep0 rowsep0" align="left">O-cyclopropyl</td><td class="colsep0 rowsep0" align="left">3.8Â Â±Â 2.6 (<i>n</i>Â =Â 9)</td><td class="colsep0 rowsep0" align="left">0.22Â Â±Â 0.06 (<i>n</i>Â =Â 14)</td><td class="colsep0 rowsep0" align="left">97</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">20.4<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">1.5<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10h</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">19Â Â±Â 7 (<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="left">0.92Â Â±Â 0.29 (<i>n</i>Â =Â 3)</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">76</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10i</b></td><td class="colsep0 rowsep0" align="left">cyclopropyl</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">0.29Â Â±Â 0.05 (<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">99</td><td class="colsep0 rowsep0" align="left">2.9</td><td class="colsep0 rowsep0" align="left">0.40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10j</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">0.39Â Â±Â 0.03 (<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="left">null<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">null<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">0.043</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Inhibition in the SPA and WPA was measured in duplicate at six concentrations, and the mean values were used to calculate the IC<sub>50</sub>. IC<sub>50</sub> values are reported as the mean Â± SD, for <i>n</i> â¥ 2 (see ref <a onclick="showRef(event, 'cit8a'); return false;" href="javascript:void(0);" class="ref cit8a">8a</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_001.pdf" class="ext-link">Supporting Information</a> for details).</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Microsomal metabolic rate during 10 min incubation at 0.5 Î¼M concentration. HLM: human liver microsomes. MLM: mouse liver microsomes.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Oral PK in Balb/c mice at 10 mg/kg, po. Vehicle: ethanol/Cremophor/water, 1/1/8.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Null: not detected. NT: not tested.</p></div><div class="footnote" id="t5fn5"><sup>e</sup><p class="last">AUC<sub>0â8</sub> and <i>C</i><sub>8h</sub> in Tg mouse studies (10 mg/kg, po).</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> In Vitro, in Vivo, and Preclinical Liability Profile of Compound <b>10g</b></h3><div class="NLM_p">Compound <b>10g</b> is a potent CETP inhibitor having a SPA IC<sub>50</sub> of 4 nM, and in the hWPA it inhibited CE transfer with an IC<sub>50</sub> of 0.22 Î¼M, slightly less potent than compound <b>1</b> (IC<sub>50</sub> = 0.11 Î¼M). In contrast, <b>10g</b> exhibited superior potency as measured by in vivo inhibition of CE transfer when dosed orally in hCETP/apoB-100 dual Tg mice (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Compound <b>10g</b> maximally inhibited CETP activity at a dose of 1 mg/kg at the 8 h time point (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A, MED = 1 mg/kg), while in a separate study the MED for <b>1</b> was 3 mg/kg. The reason for the greater efficacy of <b>10g</b> at a lower dose is its improved plasma exposure and peak-to-trough ratio as compared with <b>1</b> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B).</div><figure id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Inhibition of plasma CE transfer activity by compound <b>10g</b> (1 and 3 mg/kg) and compound <b>1</b> (10 mg/kg) in Tg mice. (B) Exposure levels of <b>10g</b> (dose, 3 mg/kg <b>10g</b> in blue, 1 mg/kg of <b>10g</b> in red) and <b>1</b> (dose, 10 mg/kg in black), respectively, in Tg mice studies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>10g</b> increased plasma HDL-C content by 45% when dosed orally at 10 mg/kg for 3 days in moderately fat-fed hamsters (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). The extent of HDL-C elevation was equivalent to the increase observed with <b>1</b> (51% increase in HDL-C). The plasma concentration of compound <b>10g</b> at 2 h after dosing on the third day was 4.2 Î¼M, while the plasma concentration of compound <b>1</b> at the same time point was 1.2 Î¼M. Plasma samples from hamsters treated with 10 mg/kg <b>10g</b> were assayed for cholesterol content after fractionation by FPLC to determine the effects of the compound on the various plasma lipoprotein classes. After each individual plasma sample was fractionated, the cholesterol content in each FPLC fraction was then averaged. By this analysis, <b>10g</b> was determined to increase HDL-C content by 51% (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B). Plasma samples from hamsters treated with 10 mg/kg <b>1</b> were pooled before FPLC fractionation and the determination of cholesterol content (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>C). The size of HDL particles was increased with <b>10g</b> to an extent similar to that observed for <b>1</b>; i.e., there was a similar leftward shift of the HDL peak in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B and <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>C.</div><figure id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0005.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Effect of compound <b>10g</b> (3 and 10 mg/kg, po) and compound <b>1</b> (10 mg/kg, po) on HDL-C in moderately high-fat fed hamsters dosed for 3 days (q.d.). One-way ANOVA (Dunnettâs) test: (ââ) <i>p</i> < 0.01, <i>n</i> = 6. (B) Cholesterol profiles of plasma from hamsters before and after dosing for 3 days with <b>10g</b> (10 mg/kg, po) after FPLC fractionation. (C) Cholesterol profiles of plasma from hamsters before and after dosing for 3 days with <b>1</b> (10 mg/kg, po) after FPLC fractionation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The physicochemical, pharmaceutical, and pharmacokinetic properties of <b>10g</b> were analyzed to enable optimization of additional in vivo studies. Compound <b>10g</b> is an amorphous solid, and no crystalline forms were identified in a high-throughput crystallization screen. It is highly lipophilic with a calculated ACD logÂ <i>P</i> of 10.4, similar to <b>1</b> and <b>3</b>. The solubility of <b>10g</b> is less than 1 Î¼g/mL in aqueous buffer (pH 6.5) but more than 300 mg/mL in various pharmaceutically accepted nonaqueous lipids and oils. The mouse PK profile of <b>10g</b> using Cremophor/ethanol/water (10/10/80) as the vehicle for intravenous (iv) (5 mg/kg) and po (10 mg/kg) administrations showed low oral bioavailability (<i>F</i> = 7%). The low oral exposure is likely due to compound precipitation after oral administration (solubility-limited absorption). On the basis of formulation studies using the structurally similar compound <b>10d</b>, several lipid-based and spray-dried dispersion (SDD) formulations were selected and evaluated to assess the oral exposure of <b>10g</b>. Gelucire- and miglyol-based lipid formulations provided the best exposures, and compound <b>10g</b> had reasonable oral bioavailability with <i>F</i> values of 37%, 37%, 20%, and 5% in mice, rats, monkeys, and dogs, respectively (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Compound <b>10g</b> was not extensively distributed outside the vascular compartment in mice, rats, dogs, and monkeys. Compound <b>10g</b> was highly bound to human serum proteins (>99.6%) and serum proteins of all animal species tested (â¥99.8% for rat and >99.7% for cyno). Following iv dosing, plasma concentrations of <b>10g</b> exhibited a multiexponential decline. The total plasma clearance (CL) of <b>10g</b> after iv administration was low in mice (2.0 mL min<sup>â1</sup> kg<sup>â1</sup>), rats (0.9 mL min<sup>â1</sup> kg<sup>â1</sup>), dogs (1.4 mL min<sup>â1</sup> kg<sup>â1</sup>), and monkeys (0.9 mL min<sup>â1</sup> kg<sup>â1</sup>). This is consistent with the long half-life (<i>t</i><sub>1/2</sub>) in NADPH-fortified human liver microsomes (>86 min) and in animal liver microsomes (>94 min in mice, rats, and monkeys; 39 min in dogs). The elimination half-life (<i>t</i><sub>1/2</sub>) of <b>10g</b> after iv administration was 6, 7, >18, and 10 h in mice, rats, monkeys, and dogs, respectively. These studies supported further work with <b>10g</b> in animal studies using lipid formulations.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Discrete PK Parameters of Compound <b>10g</b> across Species</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">cyno</th><th class="colsep0 rowsep0" align="center">dog</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">doseÂ (mg/kg) (route)</td><td class="colsep0 rowsep0" align="left">5 (iv)</td><td class="colsep0 rowsep0" align="left">1 (iv)</td><td class="colsep0 rowsep0" align="left">4 (iv)</td><td class="colsep0 rowsep0" align="left">1 (iv)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">10 (po)</td><td class="colsep0 rowsep0" align="left">10 (po)</td><td class="colsep0 rowsep0" align="left">5 (po)</td><td class="colsep0 rowsep0" align="left">5 (po)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">formulation</td><td class="colsep0 rowsep0" align="left">Cremophor (iv)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">Cremophor (iv)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">Cremo/EtOH (iv)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">PEG/EtOH/H<sub>2</sub>O (iv)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Miglyol (po)<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">Gelucire (po)<a class="ref internalNav" href="#t6fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">Gelucire (po)<a class="ref internalNav" href="#t6fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">Miglyol (po)<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mLÂ min<sup>â1</sup>Â kg<sup>â1</sup>)</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>dss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iv <i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">>18</td><td class="colsep0 rowsep0" align="left">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iv AUC<sub>0â24h</sub> (Î¼MÂ·h)</td><td class="colsep0 rowsep0" align="left">44<a class="ref internalNav" href="#t6fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">82</td><td class="colsep0 rowsep0" align="left">17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po <i>C</i><sub>max</sub> (Î¼M)</td><td class="colsep0 rowsep0" align="left">5.3</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">0.43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po <i>t</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po AUC<sub>0â24h</sub> (Î¼MÂ·h)</td><td class="colsep0 rowsep0" align="left">85</td><td class="colsep0 rowsep0" align="left">99</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i>Â (%)</td><td class="colsep0 rowsep0" align="left">37</td><td class="colsep0 rowsep0" align="left">37</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Cremophor = Cremophor/EtOH/water (10/10/80).</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Cremo/EtOH = EtOH/Cremophor/water (12.5/2.5/85).</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">PEG/EtOH/water (70/10/20).</p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">Miglyol = Miglyol 812/Capmul MCM/Triacetin/Cremophor RH40 (15/30/15/40).</p></div><div class="footnote" id="t6fn5"><sup>e</sup><p class="last">Gelucire = Gelucire/Labrosol/Tween 80 (70/29/1).</p></div><div class="footnote" id="t6fn6"><sup>f</sup><p class="last">AUC<sub>0â8h</sub>.</p></div></div></div><div class="NLM_p">In telemeterized rats, compound <b>10g</b> had no effect on mean, systolic, or diastolic BP (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A), HR, or locomotor activity as compared with vehicle following iv infusion (8 mg/kg), achieving a <i>C</i><sub>max</sub> of 33 Î¼M, which is a significant multiple (â¼30-fold) of the estimated efficacious concentration (â¼1 Î¼M). In comparison, an increase in BP was seen at efficacious concentrations in rats following oral administration (<i>C</i><sub>max</sub> of 3.0 Î¼M) of compound <b>1</b> (10 mg/kg) (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B).</div><figure id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0006.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Effect of compound <b>10g</b> on BP (8 mg/kg, iv infusion) in telemeterized rats. (B) Effect of compound <b>1</b> on BP (10 mg/kg, po, and 30 mg/kg, po, respectively) in telemeterized rats. Compound <b>1</b> increased mean arterial pressure (MAP) by 8 and 15 mmHg at 10 and 30 mg/kg (<i>C</i><sub>max</sub> of 3.0 and 6.5 Î¼M), respectively. Compound or vehicle (ethanol/Cremophor/water at 1/1/8) was dosed orally to designated groups of telemeterized rats (male SpragueâDawley, â¼450 g, 17 weeks), and BP was averaged over either a 10 min or 1 h time frame. Each data point is expressed as the mean Â± SEM. Data were compared between compound and vehicle group using repeated ANOVA with Dunnettâs post hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">After the termination of the ILLUMINATE trial of compound <b>1</b>, it was found that the observed increase in BP and serum electrolyte changes in humans were consistent with increasing levels of circulating aldosterone.<a onclick="showRef(event, 'cit6d cit6e'); return false;" href="javascript:void(0);" class="ref cit6d cit6e">(6d, 6e)</a> In addition, <b>1</b> increased aldosterone in rats as well as aldosterone synthase in cells. The increase in aldosterone levels could be modeled in adrenocarcinoma cells (H295R) by an increase in the enzyme responsible for synthesizing aldosterone, CYP11B2 (aldosterone synthase). In studies using these cells, <b>1</b> increased CYP11B2 mRNA at a concentration as low as 3 nM and by up to 90-fold at 300 nM. In contrast, compound <b>10g</b> did not increase CYP11B2 mRNA at 10 Î¼M (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>).</div><figure id="fig6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0007.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of compound <b>1</b> and <b>10g</b> on CYP11B2 expression in H295R cells. Compounds were incubated with the cells at the indicated concentrations for 24 h, and CYP11B2 mRNA levels were measured and compared to the levels in vehicle (DMSO)-treated cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Overall, compound <b>10g</b>, being structurally different from the four clinical compounds <b>1</b>â<b>4</b>, demonstrated favorable in vitro and in vivo properties and a lack of off-target effects on BP and aldosterone levels in cells compared to <b>1</b>. Therefore, <b>10g</b> was selected for preclinical safety studies.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18886" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18886" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Lead optimization efforts on the DPPE pyridyl A-ring led to the discovery of a series of TPE ureas and amides with improved in vitro hWPA potency and in vivo inhibition of CE transfer in Tg mice as compared with the DPPE lead <b>5</b>. Subsequent screening of compound effects on BP in telemeterized rats allowed us to focus on the modification of the 3,4-disubstituted phenyl A-rings in the amide series, resulting in the discovery of TPE amide <b>10g</b>. Compound <b>10g</b> is a potent CETP inhibitor having a preclinical liability profile superior to the benchmark CETP inhibitor, compound <b>1</b>. Compound <b>10g</b> demonstrated dose-dependent CETP inhibition in Tg mice with a MED of 1 mg/kg and a comparable increase in HDL-C content and size in hamsters as compared with <b>1</b>. In contrast to the off-target BP and aldosterone synthase (CYP11B2) increases observed with <b>1</b>, compound <b>10g</b> did not increase BP in rat telemetry studies and did not increase aldosterone synthase (CYP11B2) in vitro. As a result, compound <b>10g</b> was selected for preclinical safety studies.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21277" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21277" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> General Information</h3><div class="NLM_p last">All reagents and solvents used, including anhydrous solvents, were of commercial quality. All reactions were carried out under a static atmosphere of argon or nitrogen and stirred magnetically unless otherwise stated. All flash chromatographic separations were performed using either an ISCO RediSep disposable silica gel column or a biotage column, eluting with hexanes/ethyl acetate or methylene chloride/methanol. For large amount of diastereomeric mixtures, the desired compound was obtained via SFC on the Thar 350 system. The SFC conditions were 20% isopropanol in CO<sub>2</sub> at 240 mL/min on Chiralpak AD-H (5 cm Ã 25 cm); wavelength, 254 nm; back pressure, 100 bar; sample concentration, 110 mg/mL; injection volume, 10 mL; cycle time, 6.5 min; temperature, 35 Â°C. Final compounds were also purified by reverse phase HPLC on a Sunfire C18 preparative column using appropriate gradients of acetonitrile/water/0.1% trifluoroacetic acid or methanol/water/0.1% trifluoroacetic acid as the eluent. Reactions were monitored either by analytical LCMS or by TLC using 0.25 mm E. Merck silica gel plates (60 F<sub>254</sub>) and were visualized with UV light or by staining with various of staining agents. LCMS data were recorded on a Shimadzu LC-10AT equipped with a SIL-10A injector, a SPD-10AV detector, running DISCOVERY VP software, and coupled with a Waters ZQ mass spectrometer running MassLynx, version 3.5, software using the following methods: Phenomenex Luna C-18 4.6 mm Ã 50 mm column eluted with a 4 min linear gradient from 0% to 100% of B and then 1 min at 100% of B wherein A = 10% methanol/90% water/0.1% TFA and B = 90% methanol/10% water/0.1% TFA (method A). Phenomenex Luna C-18 2.0 mm Ã 30 mm column eluted with a 2 min linear gradient from 0% to 100% of B and then 1 min at 100% of B wherein A = 10% methanol/90% water/0.1% TFA and B = 90% methanol/10% water/0.1% TFA (method B). Phenomenex Luna C-18 2.0 mm Ã 30 mm column eluted with a 2 min linear gradient from 0% to 100% of B and then 1 min at 100% of B wherein A = 2% methanol/98% water/0.1% formic acid and B = 100% methanol/0.1% formic acid (method C). Phenomenex Luna C-18 4.6 mm Ã 50 mm column eluted with a 4 min linear gradient from 10% to 100% of B and then 1 min at 100% of B wherein A = 10% methanol/90% water/0.1% NH<sub>4</sub>OAc and B = 90% methanol/10% water/0.1% NH<sub>4</sub>OAc (method D). Purity of all final compounds tested was determined to be at or above 95% by using the following orthogonal HPLC conditions: Sunfire C18 3.5 Î¼m (3.0 mm Ã 150 mm), flow rate 1.0 mL/min, gradient 10â100% 95:5 AcCN in H<sub>2</sub>O (0.05% TFA) in 5:95 AcCN in H<sub>2</sub>O (0.05% TFA) over 10 min and then 100% of 95:5 AcCN in H<sub>2</sub>O (0.05% TFA) over 5 min (HPLC method A) and Xbridge phenyl 3.5 Î¼m (3.0 mm Ã 150 mm), flow rate 1.0 mL/min, gradient 10â100% 95:5 AcCN in H<sub>2</sub>O (0.05% TFA) in 5:95 AcCN in H<sub>2</sub>O (0.05% TFA) over 10 min and then 100% of 95:5 AcCN in H<sub>2</sub>O (0.05% TFA) over 5 min (HPLC method B) or Sunfire, 150 mm Ã 4.6 mm, 3 mm, flow rate 1.0 mL/min, gradient 65â95% gradient AcCN in H<sub>2</sub>O (0.05% TFA) over 30 min and then 95% of AcCN in H<sub>2</sub>O (0.05% TFA) over 5 min (HPLC method C) or Zorbax SB-C8 3.5 Î¼m, 150 mm (<i>L</i>) Ã 4.6 mm, flow rate 1.0 mL/min, gradient 55â95% AcCN in H<sub>2</sub>O (0.05% TFA) over 30 min and then 95% of AcCN in H<sub>2</sub>O (0.05% TFA) over 5 min (HPLC method D) and/or elemental analyses. <sup>1</sup>H NMR, <sup>13</sup>C NMR, or <sup>19</sup>F NMR spectra were recorded on either Bruker or JEOL Fourier transform spectrometers operating at frequencies as follows: <sup>1</sup>H NMR, 400 MHz (Bruker or JEOL) or 500 MHz (JEOL); <sup>13</sup>C NMR, 101 MHz (Bruker or JEOL) or 125 MHz (JEOL); and <sup>19</sup>F NMR, 471 MHz (Bruker or JEOL). Spectra data are reported in the format chemical shift (multiplicity, coupling constants, and number of hydrogens). Chemical shifts are specified in ppm referenced to deuterated solvent peaks. All <sup>13</sup>C NMR and <sup>19</sup>F NMR spectra were proton decoupled. Most of the final compounds were confirmed for molecular weight using accurate mass LCMS (HRMS). A Thermo Fisher LTQ Orbitrap mass spectrometer in line with a Waters Acquity UPLC allowed collection of molecular ion data with accuracy of <5 ppm.</div></div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> 3-Cyclopentyl-1-[(1<i>R</i>)-1-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[3-fluoro-5-(trifluoromethyl)phenyl]-2-phenylethyl]urea (<b>8b</b>) and 3-Cyclopentyl-1-[(1<i>S</i>)-1-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[3-fluoro-5-(trifluoromethyl)phenyl]-2-phenylethyl]urea (<b>8c</b>)</h3><div class="NLM_p last">An ether solution (40 mL) of 1-bromo-3-fluoro-5-(trifluoromethyl)benzene (2.00 g, 8.23 mmol) was stirred in an oven-dried round-bottom flask at â78 Â°C under Ar. <i>n</i>-BuLi (2.5 M in hexanes, 3.6 mL, 9.1 mmol, 1.1 equiv) was added dropwise. The resulting solution was stirred at â78 Â°C for 30 min. A solution of 4-fluoro-3-(trifluoromethyl)benzonitrile (1.55 g, 8.23 mmol, 1.0 equiv) in Et<sub>2</sub>O (5 mL) was added dropwise. The resulting reddish mixture was stirred at â78 Â°C for 2 h. TMSCl (pretreated with Et<sub>3</sub>N, TMSCl/Et<sub>3</sub>N = 10:1 (v:v), 1.1 mL, 1.2 equiv) was added dropwise. The dry ice bath was removed, and the resulting slurry was stirred at room temperature for 2 h. The reaction was cooled to â78 Â°C, and a solution of benzylmagnesium chloride in THF (2.0 M, 8.4 mL, 2.0 equiv) was added dropwise. The resulting mixture was slowly warmed up to room temperature and stirred at room temperature for 16 h. The reaction flask was cooled in an ice bath, and 1 N HCl (100 mL) was added. The mixture was stirred at room temperature for 30 min, extracted with Et<sub>2</sub>O (2Ã), washed with 1 N NaOH, H<sub>2</sub>O, and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash column chromatography (silica gel, hexanes:ethyl acetate) to give 1-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[3-fluoro-5-(trifluoromethyl)phenyl]-2-phenylethan-1-amine (<b>13b</b>) (1.6 g, 44%). LCMS ESI 429.2 [M â NH<sub>3</sub> + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.42 min (method A). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 7.66 (dd, <i>J</i> = 6.7, 2.3 Hz, 1H), 7.49â7.59 (m, 1H), 7.45 (s, 1H), 7.18â7.30 (m, 6H), 6.74 (d, <i>J</i> = 6.9 Hz, 2H), 3.57 (m, 2H). <sup>13</sup>C NMR (101 MHz, MeOD) Î´ ppm 163.74 (d, <i>J</i> = 249.0 Hz), 159.94 (dq, <i>J</i> = 255.7, 3.0 Hz), 153.24 (d,<i>J</i> = 6.8 Hz), 144.91 (d, <i>J</i> = 3.8 Hz), 136.68, 134.53 (d, <i>J</i> = 9.1 Hz), 133.35 (qd, <i>J</i> = 33.1, 8.2 Hz), 132.01, 129.07, 128.05, 126.92 (q, <i>J</i> = 4.5 Hz), 124.84 (qd, <i>J</i> = 272.5, 3.2 Hz), 124.16 (q, <i>J</i> = 271.6 Hz), 121.01 (m), 119.31 (d, <i>J</i> = 23.0 Hz), 118.73 (qd, <i>J</i> = 32.7, 12.7 Hz), 117.85 (d, <i>J</i> = 20.6 Hz), 112.16 (dq, <i>J</i> = 24.7, 3.5 Hz), 62.54, 48.87. <sup>19</sup>F NMR (471 MHz, MeOD) Î´ ppm â62.61 (d, <i>J</i> = 16.2 Hz), â64.05, â111.96, â119.13 (q, <i>J</i> = 12.8 Hz). Compound <b>13b</b> (300 mg, 0.67 mmol) and cyclopentyl isocyanate (0.4 mL, 3.9 mmol, 5.8 equiv) were stirred in 1,4-dioxane (2 mL) at room temperature for 16 h. The reaction mixture was concentrated and purified by flash chromatography (silica gel, hexanes/EtOAc) to give <b>14b</b> (250 mg, 67%). The racemate <b>14b</b> (250 mg) was dissolved in 10% isopropanol in heptane and was resolved by chiral prep HPLC using an AD column (10% isopropanol/heptane/0.1% DEA, isocratic) to give the fast eluting enantiomer corresponding to <b>8c</b> (110 mg, 44%); analytical chiral HPLC (AD column, 10% isopropanol/heptane/0.1% DEA, isocratic), 99%, <i>t</i><sub>R</sub> = 4.85 min; and the slow eluting enantiomer corresponding to <b>8b</b> (105 mg, 42%): analytical chiral HPLC (AD, 10% isopropanol/heptane/0.1% DEA, isocratic), 99%, <i>t</i><sub>R</sub> = 14.11 min. LCMS (ESI), 557.32 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.33 min (method A). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 7.36â7.44 (m, 2H), 7.23â7.29 (m, 3H), 7.13â7.21 (m, 4H), 6.68â6.74 (m, 2H), 4.84 (s, 1H), 4.40 (s, br, 1H), 3.84â3.95 (m, 3H), 1.88â1.98 (m, 2H), 1.56â1.68 (m, 4H), 1.34 (d, <i>J</i> = 6.36 Hz, 2H). <sup>13</sup>C NMR (101 MHz, MeOD) Î´ 163.86 (d, <i>J</i> = 247.5 Hz), 160.37 (dd, <i>J</i> = 255.8, 2.0 Hz), 159.36 (d, <i>J</i> = 2.1 Hz), 151.71 (d, <i>J</i> = 6.8 Hz), 143.15 (m), 137.26, 134.58 (d, <i>J</i> = 9.0 Hz), 133.21 (qd, <i>J</i> = 33.1, 8.3 Hz), 132.10, 128.80, 127.91, 126.72 (q, <i>J</i> = 4.6 Hz), 124.84 (dq, <i>J</i> = 271.6, 2.9 Hz), 124.10 (q, <i>J</i> = 271.2 Hz), 120.83 (m), 119.31 (d, <i>J</i> = 23.4 Hz), 118.46 (qd, <i>J</i> = 32.4, 12.8 Hz), 117.82 (d, <i>J</i> = 21.2 Hz), 112.18 (dq, <i>J</i> = 25.3, 3.7 Hz), 63.39, 63.32, 52.73, 44.96, 34.35, 24.48. <sup>19</sup>F NMR (471 MHz, MeOD) Î´ â62.85 (d, <i>J</i> = 12.7 Hz), â64.22, â112.35, â119.42 (q, <i>J</i> = 12.9 Hz). Orthogonal HPLC purity: 96.5%, <i>t</i><sub>R</sub> = 14.25 min (HPLC method A); 95.6%, <i>t</i><sub>R</sub> = 10.91 min (HPLC method B).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> 4-Fluoro-<i>N</i>-[(1<i>R</i>)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-1-(4-fluorophenyl)-2-phenylethyl]-3-(trifluoromethyl)benzamide (<b>9c</b>)</h3><div class="NLM_p last">To a solution of <b>18</b> (30 mg, 0.079 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (0.2 mL) was added 4-fluoro-3-(trifluoromethyl)benzoyl chloride (0.048 mL, 0.16 mmol), followed by Et<sub>3</sub>N (0.040 mL, 0.16 mmol). The resulting mixture was stirred at room temperature for 5 h. The crude product was purified on a preparative C18 HPLC column using 30â100% CH<sub>3</sub>CN in H<sub>2</sub>O with 0.1% TFA as the mobile phase. The solvent was removed under reduced pressure to afford <b>9c</b> (43 mg, 95%) as a white powder. LCMS (ESI) <i>m</i>/<i>z</i> 568.30 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.27 min (method A). <sup>1</sup>H NMR (400 MHz, MeOD) Î´ ppm 8.10â7.78 (m, 2H), 7.44 (t, <i>J</i> = 9.4 Hz, 1H), 7.28â6.87 (m, 10H), 6.71 (d, <i>J</i> = 7.0 Hz, 2H), 6.28 (tt, <i>J</i> = 52.7, 3.0 Hz, 1H), 4.10 and 3.92 (ABq, <i>J</i> = 12.7 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ ppm 164.35, 162.58 (d, <i>J</i> = 249.5 Hz), 162.02 (d, <i>J</i> = 248.8 Hz), 161.78 (d, <i>J</i> = 262.5 Hz), 149.35 (d, <i>J</i> = 11.5 Hz), 148.32 (d, <i>J</i> = 8.1 Hz), 138.37 (d, <i>J</i> = 3.0 Hz), 134.98, 132.54 (d, <i>J</i> = 9.6 Hz), 131.20 (d, <i>J</i> = 4.1 Hz), 130.66, 128.71 (d, <i>J</i> = 8.0 Hz), 128.28, 127.52, 126.49 (m), 122.00 (q, <i>J</i> = 272.4 Hz), 119.12 (m), 117.60 (d, <i>J</i> = 21.8 Hz), 116.44 (tt, <i>J</i> = 273.5, 29.1 Hz), 116.36 (d, <i>J</i> = 3.3 Hz), 115.43 (d, <i>J</i> = 21.1 Hz), 112.85 (d, <i>J</i> = 23.6 Hz), 108.50 (d, <i>J</i> = 24.6 Hz), 107.48 (tt, <i>J</i> = 252.9 41.0 Hz), 64.92, 44.86. <sup>19</sup>F NMR (471 MHz, MeOD) Î´ ppm â61.71 (d, <i>J</i> = 12.7 Hz), â88.40 (m), â108.70 (m), â109.09 (t, <i>J</i> = 9.5 Hz), â114.05 (m), â137.81 (m). Orthogonal HPLC purity: 100%, <i>t</i><sub>R</sub> = 14.30 min (HPLC method A); 97.7%, <i>t</i><sub>R</sub> = 11.34 min (HPLC method B). HRMS (M + H)<sup>+</sup> ESI calcd for C<sub>30</sub>H<sub>20</sub>F<sub>10</sub>NO<sub>2</sub> 616.13283, found 616.13338.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 1-[(1<i>R</i>)-1-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-3-(2,2,2-trifluoroethyl)urea (<b>9d</b>)</h3><div class="NLM_p last">To a solution of <b>24</b> (85 mg, 0.11 mmol) in THF (1.5 mL) was added TBAF (1.0 M in THF, 0.12 mL, 0.12 mmol) at 0 Â°C. The mixture was stirred at 0 Â°C to room temperature for 50 min. The reaction was diluted with CH<sub>2</sub>Cl<sub>2</sub>, washed with saturated NH<sub>4</sub>Cl, H<sub>2</sub>O, and then saturated NaCl, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by flash chromatography (silica gel, hexanes/EtOAc) to give 1-[(1<i>R</i>)-1-[4-fluoro-3-(trifluoromethyl)phenyl]-1-(3-fluoro-5-hydroxyphenyl)-2-phenylethyl]-3-(2,2,2-trifluoroethyl)urea (45 mg, 77%). LCMS (ESI) <i>m</i>/<i>z</i> 519.10 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 2.0 min (method B). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 7.20â7.27 (m, 3H), 7.09â7.18 (m, 3H), 6.72 (d, <i>J</i> = 9.60 Hz, 1H), 6.66 (m, 3H), 6.57 (s, 1H), 3.73â3.78 (m, 1H), 3.65â3.71 (m, 1H), 3.63 (d, <i>J</i> = 8.59 Hz, 1H), 3.47â3.58 (m, 1H). To a solution of the above phenol (15 mg, 0.03 mmol) in DMSO (0.1 mL) were added ICF<sub>2</sub>CF<sub>2</sub>H (11 mg, 0.05 mmol) and K<sub>2</sub>CO<sub>3</sub> (20 mg, 0.14 mmol). The reaction mixture was heated in a capped vial at 70 Â°C for 16 h. After cooling to rt, it was purified by flash chromatography (silica gel, hexanes/EtOAc) to give compound <b>9d</b> as a white solid (18 mg, 58%). LCMS (ESI) <i>m</i>/<i>z</i> 619.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.09 min (method A). <sup>1</sup>H NMR (400 MHz, MeOD) Î´ ppm 7.52â7.43 (m, 1H), 7.39 (dd, <i>J</i> = 6.0, 2.2 Hz, 1H), 7.26 (t, <i>J</i> = 9.6 Hz, 1H), 7.21â7.07 (m, 3H), 7.05â6.91 (m, 3H), 6.72 (d, <i>J</i> = 7.1 Hz, 2H), 6.28 (tt, <i>J</i> = 52.2, 3.0 Hz, 1H), 3.95 and 3.83 (ABq, <i>J</i> = 12.8 Hz, 2H), 3.88â3.71 (m, 1H). <sup>13</sup>C NMR (101 MHz, MeOD) Î´ ppm 162.63 (d, <i>J</i> = 249.0 Hz), 158.74 (d, <i>J</i> = 259.6 Hz), 155.48, 149.43 (d, <i>J</i> = 11.7 Hz), 148.13 (d, <i>J</i> = 9.0 Hz), 140.39 (d, <i>J</i> = 3.7 Hz), 134.77, 132.48 (d, <i>J</i> = 8.3 Hz), 130.71, 128.17, 127.37, 125.35 (m), 124.24 (q, <i>J</i> = 279.4 Hz), 122.36 (q, <i>J</i> = 275.5 Hz), 118.12 (qd, <i>J</i> = 33.0, 12.8 Hz), 116.99 (d, <i>J</i> = 20.8 Hz), 116.40 (tt, <i>J</i> = 273.5, 29.0 Hz), 115.96 (d, <i>J</i> = 2.6 Hz), 112.46 (d, <i>J</i> = 23.3 Hz), 108.66 (d, <i>J</i> = 24.5 Hz), 107.44 (tt, <i>J</i> = 252.0, 41.8 Hz), 64.13, 44.49, 41.39 (q, <i>J</i> = 34.4 Hz). <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub> + MeOD) Î´ ppm â61.57 (d, <i>J</i> = 13.9 Hz), â73.63, â88.58, â109.43, â117.71 (q, <i>J</i> = 13.5 Hz), â137.05 (t, <i>J</i> = 6.0 Hz). Orthogonal HPLC purity: 99.5%, <i>t</i><sub>R</sub> = 13.34 min (HPLC method A); 97.6%, <i>t</i><sub>R</sub> = 10.58 min (HPLC method B). Chriral analytical HPLC (AD, 20% heptane/IPA/0.1% DEA), <i>t</i><sub>R</sub> = 8.91 min, chiral purity >99%. HRMS (M + H)<sup>+</sup> ESI calcd for C<sub>26</sub>H<sub>19</sub>F<sub>12</sub>N<sub>2</sub>O<sub>2</sub> 619.12495; found, 619.12517.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> 4-Fluoro-<i>N</i>-[(1<i>R</i>)-1-(4-fluoro-3-hydroxyphenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-3-(trifluoromethyl)benzamide (<b>10a</b>)</h3><div class="NLM_p last">To a solution of <b>10b</b> (2.8 g, 4.43 mmol), prepared according to procedures described for the synthesis of compound <b>9c</b>, in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) was added BBr<sub>3</sub> (12 mL, 12 mmol). The resulting mixture was stirred at room temperature for 2 h and quenched by addition of ice. The reaction mixture was diluted with EtOAc and washed with saturated NaHCO<sub>3</sub>, saturated NaCl, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford <b>10a</b> as a slightly yellow solid (2.9 g, 100%). LCMS (ESI) <i>m</i>/<i>z</i> 632.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.23 min (method A). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) Î´ ppm 7.90â7.76 (m, 2H). 7.23â7.11 (m, 4H), 7.04â6.88 (m, 4H), 6.81â6.56 (m, 5H), 5.84 (tt, <i>J</i> = 52.7, 2.9 Hz, 1H), 5.27 (s, 1H), 3.95 (d, <i>J</i> = 13.2 Hz, 1H), 3.79 (d, <i>J</i> = 13.2 Hz, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ ppm 164.86, 162.48(d, <i>J</i> = 249.5 Hz), 161.74 (d, <i>J</i> = 261.9 Hz), 150.28 (d, <i>J</i> = 241.5 Hz), 149.24 (d, <i>J</i> = 12.7 Hz), 148.08 (d, <i>J</i> = 7.5 Hz), 143.61 (d, <i>J</i> = 15.3 Hz), 139.42 (d, <i>J</i> = 5.3 Hz), 134.96, 132.53 (d, <i>J</i> = 10.2 Hz), 131.01, 130.58, 128.18, 127.45, 126.48, 122.95 (q, <i>J</i> = 272.4 Hz), 119.17 (m), 118.83 (d, <i>J</i> = 7.2 Hz), 117.55 (d, <i>J</i> = 20.5 Hz), 116.37 (tt, <i>J</i> = 272.0, 29.0 Hz), 116.27 (d, <i>J</i> = 34.3 Hz), 115.45 (d, <i>J</i> = 20.4 Hz), 112.64 (d, <i>J</i> = 22.9 Hz), 108.35 (d, <i>J</i> = 25.5 Hz), 107.41 (tt, <i>J</i> = 251.1, 41.2 Hz), 64.91, 44.11. <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) Î´ ppm â61.62 (d, <i>J</i> = 11.5 Hz), â88.34, â108.45, â108.99 (m), â136.68 (d, <i>J</i> = 52.5 Hz), â140.04. HRMS (M + H)<sup>+</sup> ESI calcd for C<sub>30</sub>H<sub>20</sub>F<sub>10</sub>NO<sub>3</sub> 632.12776, found 632.12876. Orthogonal HPLC purity: 99.7%, <i>t</i><sub>R</sub> = 12.27 min (HPLC method A); 99.3%, <i>t</i><sub>R</sub> = 10.63 min (HPLC method B).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 4-Fluoro-<i>N</i>-[(1<i>R</i>)-1-[4-fluoro-3-(propan-2-yloxy)phenyl]-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-3-(trifluoromethyl)benzamide (<b>10d</b>)</h3><div class="NLM_p last">To a solution of <b>10a</b> (2.70 g, 4.27 mmol) in DMF (6 mL) was added K<sub>2</sub>CO<sub>3</sub> (1.47 g, 10.69 mmol), followed by isopropyl iodide (0.64 mL, 6.40 mmol). The reaction mixture was stirred at 60 Â°C for 16 h. The reaction mixture was filtered, and the solid was washed with EtOAc. The filtrate was washed with H<sub>2</sub>O, saturated NaCl, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by ISCO silica gel column using 0â50% EtOAc in hexane as eluting solvents to yield <b>10d</b> as an off-white solid (2.4 g, 83% yield). LCMS (ESI) <i>m</i>/<i>z</i> 674.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.05 min (method A). <sup>1</sup>H NMR (500 MHz, MeOD) Î´ ppm 8.01â7.95 (m, 2H), 7.44 (dd, <i>J = </i>10.2, 8.5 Hz, 1H), 7.21â7.16 (m, 1H), 7.15â7.09 (m, 3H), 7.06 (s, 1H), 7.03 (dd, <i>J = </i>8.2 Hz, 1H), 6.99 (dt, <i>J = </i>8.8, 2.2 Hz, 1H), 6.80 (dd, <i>J = </i>8.0 Hz, 1H), 6.78â6.74 (m, 1H), 6.73 (d, <i>J = </i>7.1 Hz, 2H), 6.27 (tt, <i>J = </i>52.5, 3.0 Hz, 1H), 4.29 (q, <i>J = </i>6.0 Hz, 1H), 4.12 and 3.85 (ABq, <i>J = </i>13.2 Hz, 2H), 1.23 (d, <i>J = </i>6.0 Hz, 3H), 1.17 (d, <i>J = </i>6.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, MeOD) Î´ ppm 168.45. 163.78 (d, <i>J = </i>246.4 Hz), 162.84 (dq, <i>J = </i>259.9, 2.3 Hz), 154.00 (d, <i>J = </i>245.7 Hz), 150.85 (d, <i>J = </i>8.4 Hz), 150.51 (d, <i>J = </i>11.4 Hz), 146.33 (d, <i>J = </i>11.4 Hz), 140.97 (d, <i>J = </i>3.1 Hz), 137.40, 135.29 (d, <i>J = </i>9.2 Hz), 133.58 (d, <i>J = </i>3.8 Hz), 132.03, 128.83, 128.08 (qd, <i>J = </i>4.6, 2.3 Hz), 127.98, 123.74 (q, <i>J = </i>271.6 Hz), 121.37 (d, <i>J = </i>6.9 Hz), 119.26 (qd, <i>J = </i>33.6, 13.4 Hz), 118.53 (d, <i>J = </i>1.5 Hz), 118.52 (d, <i>J = </i>21.4 Hz), 118.16 (d, <i>J = </i>2.3 Hz), 117.98 (tt, <i>J = </i>271.6, 29.0 Hz), 116.51 (d, <i>J = </i>19.1 Hz), 114.23 (d, <i>J = </i>23.7 Hz), 109.32 (tt, <i>J = </i>249.5, 40.4 Hz), 109.09 (d, <i>J = </i>25.9 Hz), 73.37, 66.79 (d, <i>J = </i>1.5 Hz), 44.08, 22.28, 22.19. <sup>19</sup>F NMR (376 MHz, MeOD) Î´ ppm â139.79 (dd, <i>J</i> = 6.8, 4.6 Hz, 2F), â137.20 (s, 1F), â112.74 to â112.55 (m, 2F), â90.65 to â90.51 (m, 2F), â63.57 (d, <i>J</i> = 11.4 Hz, 3F). HRMS (M â H)<sup>â</sup> ESI calcd for C<sub>33</sub>H<sub>24</sub>F<sub>10</sub>NO<sub>3</sub> 672.1602, found 672.1595. Purity by HPLC/UV with detection at 220 nm: >99.9%, <i>t</i><sub>R</sub> = 19.23 min (HPLC method C). Analytical chiral HPLC (Chiralpak AD-H, 150 mm Ã 4.6 mm, 5 Î¼m, 5% isopropanol/heptane/0.1% DEA, isocratic, 20 min), >99.9%, <i>t</i><sub>R</sub> = 10.39 min. Anal. Calcd for C<sub>33</sub>H<sub>25</sub>F<sub>10</sub>NO<sub>3</sub>: C, 58.84; H, 3.74; N, 2.08; F: 28.20. Found: 58.88; H, 3.71; N, 2.02; F: 28.16. Specific rotation at 589 nm: [Î±]<sub>D</sub><sup>25</sup> +9.549 (<i>c</i> 1.03, MeOH).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> (<i>N</i>-[(1<i>R</i>)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (<b>10g</b>)</h3><div class="NLM_p last">To a 3 L, flame-dried, four-necked round-bottom flask equipped with a thermometer, a mechanical stirrer, an additional funnel, and a N<sub>2</sub> inlet were charged 1 N Et<sub>2</sub>Zn in hexane (422.1 mL, 422.1 mmol), and dry CH<sub>2</sub>Cl<sub>2</sub> (500 mL) under N<sub>2</sub>. The solution was cooled to â10 <i>Â°</i>C. Trifluoroacetic acid (32.5 mL, 422.1 mmol) was added dropwise over a period of 1 h at below 0 <i>Â°</i>C. After 10 min, diiodomethane (34.1 mL, 422.1 mmol) was added at 0 <i>Â°</i>C. After the mixture was stirred for 15 min at 0 <i>Â°</i>C, a solution of <b>27</b> (92.5 g, 141 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (600 mL) was added portionwise. The reaction mixture was then allowed to warm to rt over a period of 21 h. 1 N HCl (1 L) was added, and the mixture was stirred for 15 min. The organic phase was separated, and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (1 L). The combined organic phases were washed with brine (1.5 L) and then concentrated in vacuo. The residue yellow oil (120 g) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (150 mL). The solution was subjected to a flash column packed with 1.5 kg of silica gel in hexane. The column was then eluted with CH<sub>2</sub>Cl<sub>2</sub> in hexane (20â50%) to give BMS-795311 (<b>10g</b>) (91.0 g, 96%) as a white solid, after high vacuum drying for 20 h. <sup>1</sup>H NMR (400 MHz, MeOD) Î´ ppm 8.02â7.95 (m, 2H). 7.44 (t, <i>J</i> = 9.8 Hz, 1H), 7.23â7.16 (m, 2H), 7.16â7.10 (m, 3H), 7.07 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 7.04â6.96 (m, 1 H), 6.99 (d, <i>J = </i>11.0 Hz, 1H), 6.73 (d, <i>J</i> = 7.1 Hz, 2H), 6.69 (ddd, <i>J</i> = 8.7, 3.8, 2.6 Hz, 1H), 6.27 (tt, <i>J</i> = 52.5, 3.1, 2.9 Hz, 1H), 4.22 and 3.77 (ABq, <i>J</i> = 13.0 Hz, 2H), 3.59â3.51 (m, 1H), 0.73â0.49 (m, 4H). <sup>13</sup>C NMR (101 MHz, MeOD) Î´ ppm 168.44, 163.83 (d, <i>J = </i>246.4 Hz), 162.86 (dd, <i>J = </i>260.2, 1.5 Hz), 152.60 (d, <i>J = </i>245.7 Hz), 150.97 (d, <i>J = </i>7.6 Hz), 150.56 (d, <i>J = </i>11.4 Hz), 147.34 (d, <i>J = </i>10.7 Hz), 140.74 (d, <i>J = </i>3.8 Hz), 137.43, 135.30 (d, <i>J = </i>9.9 Hz), 133.61 (d, <i>J = </i>3.8 Hz), 132.12, 128.83, 128.03â128.15 (m), 128.01, 123.74 (q, <i>J = </i>271.6 Hz), 119.26 (m), 118.56 (d, <i>J = </i>21.4 Hz), 118.21 (d, <i>J = </i>3.1 Hz), 116.46 (d, <i>J = </i>1.5 Hz), 116.23 (d, <i>J = </i>18.3 Hz), 118.00 (tt, <i>J</i> = 272.0, 29.0 Hz), 114.29 (d, <i>J = </i>23.7 Hz), 109.11 (d, <i>J = </i>25.2 Hz), 109.33 (tt, <i>J = </i>249.9, 40.4 Hz), 66.85 (m), 52.39, 44.15, 6.49. <sup>19</sup>F NMR (471 MHz, MeOD) Î´ ppm â139.20 (d, <i>J = </i> 51.8 Hz, 2F), â 138.45 (br s, 1F), â112.04 (m, 2F), â90.01 (br s, 2F), â62.98 (m, 3F). HRMS (M â H)<sup>â</sup> ESI calcd for C<sub>33</sub>H<sub>22</sub>F<sub>10</sub>NO<sub>3</sub> 670.14455, found 670.14335. Purity by HPLC/UV with detection at 220 nm: >99.9%, <i>t</i><sub>R</sub> = 10.59 min (HPLC method D). Analytical chiral HPLC (RR-Whelk-01, 250 mm Ã 4.6 mm, 10 Î¼m, 20% isopropanol/heptane/0.1% DEA, isocratic, 20 min), >99.9%, <i>t</i><sub>R</sub> = 11.29 min. Anal. Calcd for C<sub>33</sub>H<sub>23</sub>F<sub>10</sub>NO<sub>3</sub>: C, 59.02; H, 3.45; N, 2..09; F, 28.72. Found: 58.95; H, 3.38; N, 1.96; F, 26.71. Specific rotation at 589 nm: [Î±]<sub>D</sub><sup>25</sup> +18.02 (<i>c</i> 0.93, MeOH).</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> (<i>R</i>)-<i>N</i>-[(1<i>Z</i>/<i>E</i>)-[3-Fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl](4-fluorophenyl)methylidene]-2-methylpropane-2-sulfinamide (<b>16</b>)</h3><div class="NLM_p last">To an oven-dried round-bottomed flask cooled at â78 Â°C was added 1-bromo-3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)benzene (7.20 g, 24.8 mmol) in anhydrous ether (300 mL) under argon, and the mixture was stirred at â78 Â°C for 10 min. <i>n</i>-BuLi (2.5 M in hexanes, 11.5 mL, 28.8 mmol, 1.16 equiv) was added dropwise at â78 Â°C. The reaction mixture was stirred at â78 Â°C for 45 min. An Et<sub>2</sub>O solution (20 mL) of 4-fluorobenzonitrile (3.06 g, 25.3 mmol, 1.02 equiv) was added dropwise. The resulting reddish solution was stirred at â78 Â°C for 2 h. The reaction mixture was quenched by adding 1 N HCl (200 mL), and the dry iceâacetone bath was removed. The resulting slurry was stirred at room temperature for 1 h followed by the addition of Et<sub>2</sub>O (100 mL). The organic layer was separated and then washed with saturated NaHCO<sub>3</sub>, H<sub>2</sub>O, brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash chromatography (EtOAc/hexanes = 0â30%) to give (3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)(4-fluorophenyl)methanone as a slightly tan oil (7.2 g, 87%). LCMS (ESI) <i>m</i>/<i>z</i> 335.31 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.81 min (method A). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ ppm 7.91â7.72 (m, 2H), 7.55â7.35 (m, 2H), 7.25â7.09 (m, 3H), 5.92 (tt, <i>J</i> = 52, 2.8 Hz, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ ppm 192.20 (d, <i>J</i> = 2.7 Hz), 165.82 (d, <i>J</i> = 257.2 Hz), 162.47 (d, <i>J</i> = 251.9 Hz), 149.43 (d, <i>J</i> = 10.2 Hz), 140.33 (d, <i>J</i> = 7.5 Hz), 132.70, 132.61 (m), 118.58 (d, <i>J</i> = 3.8 Hz), 116.49 (tt, <i>J</i> = 273.8, 29.0 Hz), 115.83 (d, <i>J</i> = 21.8 Hz), 114.87 (d, <i>J</i> = 22.7 Hz), 113.18 (d, <i>J</i> = 24.7 Hz), 107.46 (tt, <i>J</i> = 252.2, 40.9 Hz). <sup>19</sup>F NMR (470 MHz, CDCl<sub>3</sub>) Î´ ppm â88.56, â104.50, â108.38, â136.89. (3-Fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)(4-fluorophenyl)methanone (3.3 g, 9.9 mmol) was stirred in anhydrous THF (20 mL) at rt under N<sub>2</sub>. <i>(R</i>)-(+)-2-Methylpropane-2-sulfinamide (1.20 g, 10.0 mmol, 1.01 equiv) was added as one single portion, followed by addition of Ti(OEt)<sub>4</sub> (3.09 mL, 14.9 mmol, 1.51 equiv). The resulting solution was heated at reflux for 48 h. The cooled mixture was evaporated. H<sub>2</sub>O (100 mL) was added, followed by the addition of EtOAc (100 mL). The mixture was filtered through Celite and washed with EtOAc (200 mL). The filtrate was washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by silica gel flash chromatography (0â30% EtOAc in hexanes) to give <b>16</b> as yellowish viscous oil which solidified after drying under vacuum as a light yellow solid (3.50 g, yield 81.0%). LCMS (ESI) <i>m</i>/<i>z</i> 437.88 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.83 min (method A). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 7.82â6.99 (br, m, 7H), 5.90 (tt, <i>J</i> = 52, 4 Hz, 1H), 1.31 (s, 9H).</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (<i>R</i>)-<i>N</i>-[(1<i>R</i>)-1-[3-Fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-1-(4-fluorophenyl)-2-phenylethyl]-2-methylpropane-2-sulfinamide ((<i>R</i>,<i>R</i>s)-<b>17</b>)</h3><div class="NLM_p last">Compound <b>16</b> (150 mg, 0.34 mmol) was stirred in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (7 mL) at â78 Â°C for 5 min under argon. BF<sub>3</sub>Â·Et<sub>2</sub>O (0.10 mL, 2.0 equiv) was added dropwise. The mixture was stirred at â78 Â°C for 10 min. Benzylmagnesium chloride (1.0 M in Et<sub>2</sub>O, 1.4 mL, 3.0 equiv) was added slowly at â78 Â°C, and the resulting mixture was stirred at â78 Â°C for 1.5 h. The reaction mixture was quenched with saturated NH<sub>4</sub>Cl and then extracted with Et<sub>2</sub>O (2Ã). The combined organic portion was washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified by flash chromatography (silica gel, EtOAc/hexanes = 0â30%) to give the fast eluting fraction corresponding to (<i>S</i>,<i>R</i>s)-<b>17</b> (29 mg); LCMS (ESI) <i>m</i>/<i>z</i> 530.36 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.11 min (method A); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 7.31â7.39 (m, 2H), 7.16â7.20 (m, 4H), 6.94â7.09 (m, 4H), 6.90 (m, 1H), 5.90 (m, 1H), 4.21 (s, 1H), 3.94 and 3.63 (ABq, <i>J</i> = 12.4 Hz, 2H), 1.23 (s, 9H); and the slow eluting fraction corresponding to (<i>R</i>,<i>R</i>s)-<b>17</b> (146 mg, 81%): LCMS (ESI) <i>m</i>/<i>z</i> 530.36 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.11 min (method A). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 7.35â7.43 (m, 2H), 7.13â7.20 (m, 3H), 7.07 (t, <i>J</i> = 8.7 Hz, 2H), 6.93 (dd, <i>J</i> = 7.6, 1.8 Hz, 2H), 6.84 (d, <i>J</i> = 8.6 Hz, 1H), 6.70 (m, 2H), 5.85 (tt, <i>J</i> = 52.0, 4.0 Hz, 1H), 4.25 (s, 1H), 4.02 and 3.58 (ABq, <i>J</i> = 12.6 Hz, 2H), 1.20 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ ppm 162.43 (d, <i>J</i> = 249.0 Hz), 150.50 (d, <i>J</i> = 7.4 Hz), 149.17 (d, <i>J</i> = 11.4 Hz), 137.52 (d, <i>J</i> = 3.2 Hz), 134.36, 132.07, 130.96 (d, <i>J</i> = 8.3 Hz), 128.12, 127.20, 116.43 (tt, <i>J</i> = 273.2, 28.3 Hz), 116.13 (d, <i>J</i> = 2.9 Hz), 115.44 (d, <i>J</i> = 21.7 Hz), 112.44 (d, <i>J</i> = 23.0 Hz), 108.03 (d, <i>J</i> = 25.3 Hz), 107.49 (tt, <i>J</i> = 251.9, 41.0 Hz), 65.74, 56.51, 46.97, 22.98. <sup>19</sup>F NMR (471 MHz, MeOD) Î´ ppm â88.43 (m), â109.37, â113.21, â136.80 (m). The material of the slow eluting product was crystallized from CDCl<sub>3</sub>, and the single crystal X-ray structure confirmed its stereochemistry.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (1<i>R</i>)-1-[3-Fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-1-(4-fluorophenyl)-2-phenylethan-1-amine (<b>18</b>)</h3><div class="NLM_p last">Compound (<i>R</i>,<i>R</i>s)-<b>17</b> (234 mg, 0.442 mmol) was stirred in 4 N HCl in a mixture of dioxane (1.5 mL) and MeOH (1.5 mL) at room temperature under Ar for 10 min. The reaction mixture was concentrated and then purified by flash chromatography (silica gel, hexanes/EtOAc) to give <b>18</b> (169 mg, 90%). LCMS (ESI) <i>m</i>/<i>z</i> 409.16 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.26 min (method A). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) Î´ ppm 7.29â7.50 (m, 2H), 6.87â7.22 (m, 8H), 6.77 (d, <i>J</i> = 6.15 Hz, 2H), 6.04â6.48 (m, 1 H), 3.57 (s, 2 H).</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>N</i>-[(1<i>R</i>)-1-[3-(Ethenyloxy)-4-fluorophenyl]-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (<b>27</b>)</h3><div class="NLM_p last">To a flame-dried, 5 L four-necked round-bottom flask equipped with a temperature controller, a mechanical stirrer, a condenser, and a N<sub>2</sub> inlet were charged Cs<sub>2</sub>CO<sub>3</sub> (56.4 g, 173 mmol), 2-chloroethyl 4-methylbenzenesulfonate (64.6 g, 275 mmol), Triton X-405 (5 g), and a solution of <b>10a</b> in dry THF (1.5 L). The reaction mixture was heated to 65 <i>Â°</i>C and stirred 16 h. After cooling to 0 <i>Â°</i>C, a solution of 1 M KO-<i>t</i>-Bu in THF (787 mL) was added slowly below 7 Â°C over a period of 40 min. The reaction mixture was stirred below 7 Â°C for 6 h. Water (2 L) was added. After stirring for 10 min, the reaction mixture concentrated in vacuo to remove most of THF. It was then extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 Ã 1 L). The combined organic extracts were washed with brine (1 L) and then concentrated in vacuo to give a yellow oil, which was subjected to column chromatography using 30â50% CH<sub>2</sub>Cl<sub>2</sub> in hexane to give <b>27</b> (93 g, 90%). LCMS (ESI) <i>m</i>/<i>z</i> 658.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.31 min (method A). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) Î´ ppm 7.89â7.79 (m, 2H). 7.28â7.05 (m, 5H), 6.93â6.85 (m, 5H), 6.76 (d, <i>J</i> = 5.5 Hz, 2H), 6.55 (s, 1H), 6.44 (dd, <i>J</i> = 13.9, 6.2 Hz, 1H), 5.84 (tt, <i>J</i> = 53.0, 3.0 Hz, 1H), 4.62 (dd, <i>J</i> = 13.9, 2.2 Hz, 1H), 4.39 (dd, <i>J</i> = 6.2, 2.2 Hz, 1H), 3.95 (d, <i>J</i> = 13.2, 1H), 3.77 (d, <i>J</i> = 13.2, 1H). <sup>19</sup>F NMR (471 MHz, CDCl<sub>3</sub>) Î´ ppm â61.61 (d, <i>J</i> = 11.5 Hz), â88.25, â108.34, â108.67 (m), â132.24, â136.62 (d, <i>J</i> = 52.4 Hz). HRMS (M + H)<sup>+</sup> ESI calcd for C<sub>32</sub>H<sub>22</sub>F<sub>10</sub>NO<sub>3</sub> 658.14345, found 658.14411. Orthogonal HPLC purity: 99.6%, <i>t</i><sub>R</sub> = 12.35 min (HPLC method A); 99.5%, <i>t</i><sub>R</sub> = 11.66 min (HPLC method B).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> PK/PD</h3><div class="NLM_p last">All animal studies were performed under the approval of the Bristol-Myers Squibb (BMS) Animal Care and Use Committee and in accordance with the American Association for Accreditation of Laboratory Animal Care (AAALAC).</div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> In Vivo Moderate Fat-Fed Hamster Model for Assessing HDL Modulation by <b>10g</b></h3><div class="NLM_p last">Male Golden Syrian hamsters (mesocricetus auratus) had been on a moderate-fat diet containing 2.5% coconut oil and 0.25% cholesterol (research diet no. 11975) for 3 weeks. Source of the animals: Charles River; VSTRACK ID 96695, ATM number 2002H009. Age and weight of the animals: upon receipt, 8 weeks old and weight is approximately 110â120 g. Upon first day of dosing, 12 weeks old and weight was approximately 160â170 g. Animals were block randomized and bled to determine baseline HDL-C. Compound <b>10g</b> (50.19 mg) was dissolved in 6.01 mL of the mixture solution composed of 100% EtOH and Cremophor (1:1). This solution was diluted 5-fold with 24.04 mL of H<sub>2</sub>O to prepare a 6 mL/kg (10 mpk) dosing solution of <b>10g</b>. A dosing solution for administration of <b>1</b> was similarly prepared. Animals were dosed once a day for 3 days according to the groups (<i>n</i> = 3 for each group). Two hours after final dose, blood specimens from all hamsters were retrieved (retro-orbital puncture) and collected in 500 Î¼L Vacutainer tubes containing K<sub>2</sub> EDTA. Animals were fasted 16 h prior to bleeding. The plasma lipid values (TG, total cholesterol, direct-HDL-C analysis) were determined using a COBAS MIRA chemistry analyzer. Plasma aliquots were also used to determine CE transfer activity and compound plasma exposures. Plasma (100 Î¼L) from animals dosed with <b>10g</b> was fractionated using a Superose 6HR 10/30 column (GE Healthcare) attached to an AKTA purifier FPLC (GE Healthcare). Lipoproteins were eluted (0.5 mL/min) with PBS, and 300 Î¼L fractions were collected. To determine cholesterol content, 200 Î¼L of the cholesterol reagent and 50 Î¼L of the fraction were mixed, and the absorbance at 500 nm was read in a spectrophotometer after 20 min incubation at 37 Â°C. For hamsters dosed with <b>1</b>, equal volumes of plasma from each animal were combined and the pooled plasma sample was then fractionated by FPLC and subsequently analyzed for cholesterol content.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Rat Telemetry Studies of Compound <b>10g</b> on BP Effect</h3><div class="NLM_p last">The study was conducted in 15 adult male SpragueâDawley (SD) rats (â¼450 g, â¼7 weeks old, fed with normal diet). These rats were implanted with a TA11PA-C40 telemetry transmitter (DSI) capable of monitoring BP, HR, and locomotor activity. The telemeterized rats (<i>n</i> = 6/group) were randomized to a vehicle group or treatment group that was dosed with compound <b>10g</b>. Three age-matched nontelemeterized satellite rats were dosed in a similar fashion as the telemetry rats to determine plasma exposures. The dose was selected to achieve â¥30 times the <i>C</i><sub>max</sub> observed in efficacy studies. Compound <b>10g</b> was dosed as an iv infusion in solution using 33% EtOH and 67% PEG400 as the vehicle. The dosing volume was 1 mL/kg, and the dose regimen was iv infusion of 2.5 mg/kg in the first 5 min followed by iv infusion of 5.5 mg/kg in 55 min. Arterial BP, heart rate, and gross locomotor activity were recorded continuously throughout the study period via the DSI telemetry system. Data were averaged every 10 min from continuous 36 h data recordings (12 h before and 24 h after drug) and were expressed as the mean Â± SEM. Statistical comparisons were made among different treatment groups using two-factor ANOVA with Studentâs <i>t</i> test. Blood samples were taken at 5, 15, 30, 60, 70, and 90 min after the initiation of iv infusion from nontelemeterized satellite rats.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01363">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70703" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70703" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01363" class="ext-link">10.1021/acs.jmedchem.5b01363</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Analytical and spectral characterization data and/or experimental procedures of all the key intermediates and final compounds <b>7a</b>â<b>c</b>, <b>8a</b>,<b>d</b>,<b>e</b>, <b>9a</b>,<b>b</b>,<b>e</b>â<b>j</b>, <b>10a</b>,<b>c</b>,<b>e</b>,<b>f</b>,<b>h</b>â<b>j</b>; table of solvent and addictive effects on Grignard addition of (<i>R</i>s)-<b>16</b>, and in vitro assays (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_001.pdf">jm5b01363_si_001.pdf (348.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_002.csv">jm5b01363_si_002.csv (2.63 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01363" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27856" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27856" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer X. Qiao</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#38525d5656515e5d4a1649515957785a554b165b5755"><span class="__cf_email__" data-cfemail="650f000b0b0c0300174b140c040a250708164b060a08">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tammy C. Wang</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leonard P. Adam</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alice Ye A. Chen</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David S. Taylor</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Z. Yang</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shaobin Zhuang</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul G. Sleph</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julia P. Li</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Danshi Li</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaohong Yin</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ming Chang</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xue-Qing Chen</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Shen</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianqing Li</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Smith</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dauh-Rurng Wu</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leslie Leith</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lalgudi S. Harikrishnan</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Muthoni G. Kamau</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael M. Miller</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donna Bilder</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Rampulla</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi-Xin Li</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carrie Xu</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">R. Michael Lawrence</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael A. Poss</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Levesque</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David A. Gordon</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine S. Huang</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Heather J. Finlay</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ruth R. Wexler</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark E. Salvati</span> - <span class="hlFld-Affiliation affiliation">Departments
of â Discovery Chemistry, â¡Discovery Biology, Â§Discovery Toxicology, â¥Preclinical Candidate
Optimization, and â¥Pharmaceutics, Bristol-Myers Squibb Company,
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1971e6003-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85461" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85461" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. Mary Malley and Michael Galella for single crystal analysis of (<i>R</i>,<i>R</i>s)-<b>17</b>, Robert Langish for HRMS, Qiu Feng and the Analytical group for key compound characterizations of <b>10g</b>, and Dr. Arvind Mathur and members of Discovery Chemical Synthesis group, CETP chemistry group, and Chemical Synthesis group at the Bristol-Biocon Research Center for the scale-up of several key intermediates.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i30" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i30"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i31" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i31"> Abbreviations Used</h2><tr><td class="NLM_term">BP</td><td class="NLM_def"><p class="first last">blood pressure</p></td></tr><tr><td class="NLM_term">CETP</td><td class="NLM_def"><p class="first last">cholesteryl ester transfer protein</p></td></tr><tr><td class="NLM_term">CHD</td><td class="NLM_def"><p class="first last">coronary heart disease</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">DPB</td><td class="NLM_def"><p class="first last">diastolic blood pressure</p></td></tr><tr><td class="NLM_term">DPPE</td><td class="NLM_def"><p class="first last">diphenylpyridinylethanamine</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">hWPA</td><td class="NLM_def"><p class="first last">human whole plasma assay</p></td></tr><tr><td class="NLM_term">Lp(a), iv</td><td class="NLM_def"><p class="first last">intravenous lipoprotein(a)</p></td></tr><tr><td class="NLM_term">MAP</td><td class="NLM_def"><p class="first last">mean arterial pressure</p></td></tr><tr><td class="NLM_term">MED</td><td class="NLM_def"><p class="first last">minimal efficacious dose</p></td></tr><tr><td class="NLM_term">MEE</td><td class="NLM_def"><p class="first last">minimal efficacious exposure</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsome</p></td></tr><tr><td class="NLM_term">PL</td><td class="NLM_def"><p class="first last">phospholipid</p></td></tr><tr><td class="NLM_term">PLTP</td><td class="NLM_def"><p class="first last">phospholipid transfer protein</p></td></tr><tr><td class="NLM_term">RCT</td><td class="NLM_def"><p class="first last">reverse cholesterol transport</p></td></tr><tr><td class="NLM_term">SBP</td><td class="NLM_def"><p class="first last">systolic blood pressure</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">SPA</td><td class="NLM_def"><p class="first last">scintillation proximity assay</p></td></tr><tr><td class="NLM_term">Tg</td><td class="NLM_def"><p class="first last">transgenic</p></td></tr><tr><td class="NLM_term">TPE</td><td class="NLM_def"><p class="first last">triphenylethanamine</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>dss</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44450" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44450" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 23 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gordon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelli, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjortland, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kannel, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawber, T. R.</span><span> </span><span class="NLM_article-title">High density lipoprotein as a protective factor against coronary heart disease. The Framingham study</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">707</span><span class="NLM_x">â</span> <span class="NLM_lpage">714</span><span class="refDoi">Â DOI: 10.1016/0002-9343(77)90874-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1016%2F0002-9343%2877%2990874-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=193398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADyaE2sXhvVOhtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1977&pages=707-714&author=T.+Gordonauthor=W.+P.+Castelliauthor=M.+C.+Hjortlandauthor=W.+B.+Kannelauthor=T.+R.+Dawber&title=High+density+lipoprotein+as+a+protective+factor+against+coronary+heart+disease.+The+Framingham+study&doi=10.1016%2F0002-9343%2877%2990874-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">High density lipoprotein as a protective factor against coronary heart disease.  The framingham study</span></div><div class="casAuthors">Gordon, Tavia; Castelli, William P.; Hjortland, Marthana C.; Kannel, William B.; Dawber, Thomas R.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medicine</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">707-14</span>CODEN:
                <span class="NLM_cas:coden">AJMEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    </div><div class="casAbstract">Lipid and lipoprotein values, including fasting triglycerides and high d. lipoproteins (HDL), low d. lipoproteins (LDL), and total cholesterol levels, were obtained on 2815 men and women aged 49-82 years chiefly between 1969 and 1971 at Framingham.  In the â¼4 years following the characterization of lipids, coronary heart disease developed in 79 of the 1025 men and 63 of the 1445 women free of coronary heart diseases.  At these older ages the major potent lipid risk factor was HDL cholesterol.  This lipid was assocd. with each major manifestation of coronary heart disease.  Triglycerides were assocd. with the incidence of coronary heart disease only in women and then only when the level of other lipids was not taken into account.  At these ages total cholesterol was not assocd. with the risk of coronary heart disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd43DXOPo8vrVg90H21EOLACvtfcHk0ljDKiagROXjAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXhvVOhtbg%253D&md5=4627db810c609ea43992d8f508b7ec08</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1016%2F0002-9343%2877%2990874-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9343%252877%252990874-9%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DT.%26aulast%3DCastelli%26aufirst%3DW.%2BP.%26aulast%3DHjortland%26aufirst%3DM.%2BC.%26aulast%3DKannel%26aufirst%3DW.%2BB.%26aulast%3DDawber%26aufirst%3DT.%2BR.%26atitle%3DHigh%2520density%2520lipoprotein%2520as%2520a%2520protective%2520factor%2520against%2520coronary%2520heart%2520disease.%2520The%2520Framingham%2520study%26jtitle%3DAm.%2520J.%2520Med.%26date%3D1977%26volume%3D62%26spage%3D707%26epage%3D714%26doi%3D10.1016%2F0002-9343%2877%2990874-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Drexel, H.</span><span> </span><span class="NLM_article-title">Reducing risk by raising HDL-cholesterol: the evidence</span> <span class="citation_source-journal">Eur. Heart J. Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">F23</span><span class="NLM_x">â</span> <span class="NLM_lpage">F29</span><span class="refDoi">Â DOI: 10.1093/eurheartj/sul037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1093%2Feurheartj%2Fsul037" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=F23-F29&author=H.+Drexel&title=Reducing+risk+by+raising+HDL-cholesterol%3A+the+evidence&doi=10.1093%2Feurheartj%2Fsul037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fsul037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fsul037%26sid%3Dliteratum%253Aachs%26aulast%3DDrexel%26aufirst%3DH.%26atitle%3DReducing%2520risk%2520by%2520raising%2520HDL-cholesterol%253A%2520the%2520evidence%26jtitle%3DEur.%2520Heart%2520J.%2520Suppl.%26date%3D2006%26volume%3D8%26spage%3DF23%26epage%3DF29%26doi%3D10.1093%2Feurheartj%2Fsul037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Di Angelantonio, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarwar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptoge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewington, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sattar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packard, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danesh, J.</span><span> </span><span class="NLM_article-title">Major lipids, apolipoproteins, and risk of vascular disease</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">1993</span><span class="NLM_x">â</span> <span class="NLM_lpage">2000</span><span class="refDoi">Â DOI: 10.1001/jama.2009.1619</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1001%2Fjama.2009.1619" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=19903920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSktLjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2009&pages=1993-2000&author=E.+Di+Angelantonioauthor=N.+Sarwarauthor=P.+Perryauthor=S.+Kaptogeauthor=K.+K.+Rayauthor=A.+Thompsonauthor=A.+M.+Woodauthor=S.+Lewingtonauthor=N.+Sattarauthor=C.+J.+Packardauthor=R.+Collinsauthor=S.+G.+Thompsonauthor=J.+Danesh&title=Major+lipids%2C+apolipoproteins%2C+and+risk+of+vascular+disease&doi=10.1001%2Fjama.2009.1619"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Major lipids, apolipoproteins, and risk of vascular disease</span></div><div class="casAuthors">Di Angelantonio, Emanuele; Sarwar, Nadeem; Perry, Philip; Kaptoge, Stephen; Ray, Kausik K.; Thompson, Alexander; Wood, Angela M.; Lewington, Sarah; Sattar, Naveed; Packard, Chris J.; Collins, Rory; Thompson, Simon G.; Danesh, John; Tipping, R. W.; Ford, C. E.; Pressel, S. L.; Walldius, G.; Jungner, I.; Folsom, A. R.; Chambless, L. E.; Panagiotakos, D. B.; Pitsavos, C.; Chrysohoou, C.; Stefanadis, C.; Knuiman, M.; Goldbourt, U.; Benderly, M.; Tanne, D.; Whincup, P. H.; Wannamethee, S. G.; Morris, R. W.; Kiechl, S.; Willeit, J.; Santer, P.; Mayr, A.; Wald, N.; Ebrahim, S.; Lawlor, D. A.; Yarnell, J. W. G.; Gallacher, J.; Casiglia, E.; Tikhonoff, V.; Nietert, P. J.; Sutherland, S. E.; Bachman, D. L.; Keil, J. E.; Cushman, M.; Psaty, B. M.; Tracy, R. P.; Tybjaerg-Hansen, A.; Nordestgaard, B. G.; Benn, M.; Frikke-Schmidt, R.; Giampaoli, S.; Palmieri, L.; Panico, S.; Vanuzzo, D.; Pilotto, L.; Gomez de la Camara, A.; Gomez-Gerique, J. A.; Simons, L.; McCallum, J.; Friedlander, Y.; Fowkes, F. G. R.; Lee, A. J.; Smith, F. B.; Taylor, J.; Guralnik, J. M.; Phillips, C. L.; Wallace, R.; Guralnik, J.; Phillips, C. L.; Blazer, D. G.; Guralnik, J. M.; Khaw, K.-T.; Brenner, H.; Raum, E.; Muller, H.; Rothenbacher, D.; Jansson, J. H.; Wennberg, P.; Nissinen, A.; Donfrancesco, C.; Giampaoli, S.; Salomaa, V.; Harald, K.; Jousilahti, P.; Vartiainen, E.; Woodward, M.; D'Agostino, R. B.; Wolf, P. A.; Vasan, R. S.; Pencina, M. J.; Bladbjerg, E. M.; Jorgensen, T.; Moller, L.; Jespersen, J.; Dankner, R.; Chetrit, A.; Lubin, F.; Rosengren, A.; Wilhelmsen, L.; Lappas, G.; Eriksson, H.; Bjorkelund, C.; Lissner, L.; Bengtsson, C.; Cremer, P.; Nagel, Dd; Tilvis, R. S.; Strandberg, T. E.; Rodriguez, B.; Dekker, J. M.; Nijpels, G.; Stehouwer, C. D. A.; Rimm, E.; Pai, J. K.; Sato, S.; Iso, H.; Kitamura, A.; Noda, H.; Salonen, J. T.; Nyyssonen, K.; Tuomainen, T.-P.; Deeg, J. H.; Poppelaars, J. L.; Meade, T. W.; Cooper, J. A.; Hedblad, B.; Berglund, G.; Engstrom, G.; Verschuren, W. M. M.; Blokstra, A.; Doring, A.; Koenig, W.; Meisinger, C.; Mraz, W.; Verschuren, W. M. M.; Blokstra, A.; Bueno-de-Mesquita, H. Bas; Wilhelmsen, L.; Rosengren, A.; Lappas, G.; Kuller, L. H.; Grandits, G.; Selmer, R.; Tverdal, A.; Nystad, W.; Gillum, R.; Mussolino, M.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1993-2000</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context Assocns. of major lipids and apolipoproteins with the risk of vascular disease have not been reliably quantified.  Objective To assess major lipids and apolipoproteins in vascular risk.  Design, Setting, and Participants Individual records were supplied on 302 430 people without initial vascular disease from 68 long-term prospective studies, mostly in Europe and North America.  During 2.79 million person-years of follow-up, there were 8857 nonfatal myocardial infarctions, 3928 coronary heart disease [CHD] deaths, 2534 ischemic strokes, 513 hemorrhagic strokes, and 2536 unclassified strokes.  Main Outcome Measures Hazard ratios (HRs), adjusted for several conventional factors, were calcd. for 1-SD higher values: 0.52 loge triglyceride, 15 mg/dL high-d. lipoprotein cholesterol (HDL-C), 43 mg/dL non-HDL-C, 29 mg/dL apolipoprotein Al, 29 mg/dL apolipoprotein B, and 33 mg/dL directly measured low-d. lipoprotein cholesterol (LDL-C).  Within-study regression analyses were adjusted for within-person variation and combined using meta-anal.  Results The rates of CHD per 1000 person-years in the bottom and top thirds of baseline lipid distributions, resp., were 2.6 and 6.2 with triglyceride, 6.4 and 2.4 with HDL-C, and 2.3 and 6.7 with non-HDL-C.  Adjusted HRs for CHD were 0.99 (95% CI, 0.94-1.05) with triglyceride, 0.78 (95% CI, 0.74-0.82) with HDL-C, and 1.50 (95% CI, 1.39-1.61) with non-HDL-C.  Hazard ratios were at least as strong in participants who did not fast as in those who did.  The HR for CHD was 0.35 (95% CI, 0.30-0.42) with a combination of 80 mg/dL lower non-HDL-C and 15 mg/dL higher HDL-C.  For the subset with apolipoproteins or directly measured LDL-C, HRs were 1.50 (95% CI, 1.38-1.62) with the ratio non-HDL-C/HDL-C, 1.49 (95% CI, 1.39-1.60) with the ratio apo B/apo Al, 1.42 (95% CI, 1.06-1.91) with non-HDL-C, and 1.38 (95% CI, 1.09-1.73) with directly measured LDL-C.  Hazard ratios for ischemic stroke were 1.02 (95% CI, 0.94-1.11) with triglyceride, 0.93 (95% CI, 0.84-1.02) with HDL-C, and 1.12 (95% CI, 1.04-1.20) with non-HDL-C.  Conclusion Lipid assessment in vascular disease can be simplified by measurement of either total and HDL cholesterol levels or apolipoproteins without the need to fast and without regard to triglyceride.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK5NOuPaBMcrVg90H21EOLACvtfcHk0lhTFFVGb7C20g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSktLjN&md5=97d12d893f26b4de09cdfb71cf294d51</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1001%2Fjama.2009.1619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2009.1619%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BAngelantonio%26aufirst%3DE.%26aulast%3DSarwar%26aufirst%3DN.%26aulast%3DPerry%26aufirst%3DP.%26aulast%3DKaptoge%26aufirst%3DS.%26aulast%3DRay%26aufirst%3DK.%2BK.%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DWood%26aufirst%3DA.%2BM.%26aulast%3DLewington%26aufirst%3DS.%26aulast%3DSattar%26aufirst%3DN.%26aulast%3DPackard%26aufirst%3DC.%2BJ.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DThompson%26aufirst%3DS.%2BG.%26aulast%3DDanesh%26aufirst%3DJ.%26atitle%3DMajor%2520lipids%252C%2520apolipoproteins%252C%2520and%2520risk%2520of%2520vascular%2520disease%26jtitle%3DJAMA%26date%3D2009%26volume%3D302%26spage%3D1993%26epage%3D2000%26doi%3D10.1001%2Fjama.2009.1619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1aa"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Rhoads, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulbrandsen, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagan, A.</span><span> </span><span class="NLM_article-title">Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">294</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">â</span> <span class="NLM_lpage">298</span><span class="refDoi">Â DOI: 10.1056/NEJM197602052940601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1aa&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1056%2FNEJM197602052940601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1aa&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=173994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1aa&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A280%3ADyaE287gtVKgsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=1976&pages=293-298&author=G.+G.+Rhoadsauthor=C.+L.+Gulbrandsenauthor=A.+Kagan&title=Serum+lipoproteins+and+coronary+heart+disease+in+a+population+study+of+Hawaii+Japanese+men&doi=10.1056%2FNEJM197602052940601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aaR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men</span></div><div class="casAuthors">Rhoads G G; Gulbrandsen C L; Kagan A</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">293-8</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">To ascertain the frequency of defined hyperlipoproteinemia and to investigate the relation between lipoprotein fractions and coronary heart disease, we measured serum lipoprotein cholesterol levels in a population-based sample of Hawaii Japanese men 50 to 72 years old.  Type II hyperlipoproteinemia was present in 3 per cent of 1859 men, and Type IV in 26 per cent.  Relative risks for coronary heart disease, based on 264 prevalence cases, were found to be 1.8, 1.8 and 0.46, between the upper and lower quartiles of total, beta, and alpha cholesterol, respectively.  We found no significant relation between triglyceride and coronary heart disease.  The inverse relation of alpha cholesterol of prevalence of coronary heart disease was independent of beta cholesterol, obesity, and other factors.  The data suggest the need for further evaluation of the protective effect of the alpha lipoprotein fraction on the development of coronary heart disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0SY02znK7rJPlX7E30qdzfW6udTcc2eZJ_fD56qQx5rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE287gtVKgsw%253D%253D&md5=4a9f19dd74b088b5b1b9df214a2bb91d</span></div><a href="/servlet/linkout?suffix=cit1aa&amp;dbid=16384&amp;doi=10.1056%2FNEJM197602052940601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM197602052940601%26sid%3Dliteratum%253Aachs%26aulast%3DRhoads%26aufirst%3DG.%2BG.%26aulast%3DGulbrandsen%26aufirst%3DC.%2BL.%26aulast%3DKagan%26aufirst%3DA.%26atitle%3DSerum%2520lipoproteins%2520and%2520coronary%2520heart%2520disease%2520in%2520a%2520population%2520study%2520of%2520Hawaii%2520Japanese%2520men%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1976%26volume%3D294%26spage%3D293%26epage%3D298%26doi%3D10.1056%2FNEJM197602052940601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1bb"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Castelli, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrison, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbott, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalousdian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kannel, W. B.</span><span> </span><span class="NLM_article-title">Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">256</span><span class="NLM_x">, </span> <span class="NLM_fpage">2835</span><span class="NLM_x">â</span> <span class="NLM_lpage">2838</span><span class="refDoi">Â DOI: 10.1001/jama.1986.03380200073024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1bb&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1001%2Fjama.1986.03380200073024" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1986&pages=2835-2838&author=W.+P.+Castelliauthor=R.+J.+Garrisonauthor=P.+W.+Wilsonauthor=R.+D.+Abbottauthor=S.+Kalousdianauthor=W.+B.+Kannel&title=Incidence+of+coronary+heart+disease+and+lipoprotein+cholesterol+levels.+The+Framingham+Study&doi=10.1001%2Fjama.1986.03380200073024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1bb&amp;dbid=16384&amp;doi=10.1001%2Fjama.1986.03380200073024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.1986.03380200073024%26sid%3Dliteratum%253Aachs%26aulast%3DCastelli%26aufirst%3DW.%2BP.%26aulast%3DGarrison%26aufirst%3DR.%2BJ.%26aulast%3DWilson%26aufirst%3DP.%2BW.%26aulast%3DAbbott%26aufirst%3DR.%2BD.%26aulast%3DKalousdian%26aufirst%3DS.%26aulast%3DKannel%26aufirst%3DW.%2BB.%26atitle%3DIncidence%2520of%2520coronary%2520heart%2520disease%2520and%2520lipoprotein%2520cholesterol%2520levels.%2520The%2520Framingham%2520Study%26jtitle%3DJAMA%26date%3D1986%26volume%3D256%26spage%3D2835%26epage%3D2838%26doi%3D10.1001%2Fjama.1986.03380200073024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1cc"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Kannel, W. B.</span><span> </span><span class="NLM_article-title">Range of serum cholesterol values in the population developing coronary artery disease</span> <span class="citation_source-journal">Am. J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">69c</span><span class="NLM_x">â</span> <span class="NLM_lpage">77c</span><span class="refDoi">Â DOI: 10.1016/S0002-9149(99)80474-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1cc&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1016%2FS0002-9149%2899%2980474-3" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1995&pages=69c-77c&author=W.+B.+Kannel&title=Range+of+serum+cholesterol+values+in+the+population+developing+coronary+artery+disease&doi=10.1016%2FS0002-9149%2899%2980474-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1cc&amp;dbid=16384&amp;doi=10.1016%2FS0002-9149%2899%2980474-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9149%252899%252980474-3%26sid%3Dliteratum%253Aachs%26aulast%3DKannel%26aufirst%3DW.%2BB.%26atitle%3DRange%2520of%2520serum%2520cholesterol%2520values%2520in%2520the%2520population%2520developing%2520coronary%2520artery%2520disease%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D1995%26volume%3D76%26spage%3D69c%26epage%3D77c%26doi%3D10.1016%2FS0002-9149%2899%2980474-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Barter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennekens, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rader, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tall, A. R.</span><span> </span><span class="NLM_article-title">Cholesteryl ester transfer protein</span> <span class="citation_source-journal">Arterioscler., Thromb., Vasc. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">160</span><span class="NLM_x">â</span> <span class="NLM_lpage">167</span><span class="refDoi">Â DOI: 10.1161/01.ATV.0000054658.91146.64</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1161%2F01.ATV.0000054658.91146.64" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=12588754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptF2jsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=160-167&author=P.+J.+Barterauthor=H.+B.+Brewerauthor=M.+J.+Chapmanauthor=C.+H.+Hennekensauthor=D.+J.+Raderauthor=A.+R.+Tall&title=Cholesteryl+ester+transfer+protein&doi=10.1161%2F01.ATV.0000054658.91146.64"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cholesteryl Ester Transfer Protein</span></div><div class="casAuthors">Barter, Philip J.; Brewer, H. Bryan; Chapman, M. John; Hennekens, Charles H.; Rader, Daniel J.; Tall, Alan R.</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">160-167</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Cholesteryl ester transfer protein (CETP) promotes the transfer of cholesteryl esters from antiatherogenic HDLs to proatherogenic apolipoprotein B (apoB)-contg. lipoproteins, including VLDLs, VLDL remnants, IDLs, and LDLs.  A deficiency of CETP is assocd. with increased HDL levels and decreased LDL levels, a profile that is typically antiatherogenic.  Studies in rabbits, a species with naturally high levels of CETP, support the therapeutic potential of CETP inhibition as an approach to retarding atherogenesis.  Studies in mice, a species that lacks CETP activity, have provided mixed results.  Human subjects with heterozygous CETP deficiency and an HDL cholesterol level >60 mg/dL have a reduced risk of coronary heart disease.  Evidence that atherosclerosis may be increased in CETP-deficient subjects whose HDL levels are not increased is difficult to interpret and may reflect confounding or bias.  Small-mol. inhibitors of CETP have now been tested in human subjects and shown to increase the concn. of HDL cholesterol while decreasing that of LDL cholesterol and apoB.  Thus, it seems important and timely to test the hypothesis in randomized trials of humans that pharmacol. inhibition of CETP retards the development of atherosclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGBGX_CUbamrVg90H21EOLACvtfcHk0lisaUY8hc1Eqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptF2jsw%253D%253D&md5=1cf83327815b82a906915c61e355e891</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1161%2F01.ATV.0000054658.91146.64&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.ATV.0000054658.91146.64%26sid%3Dliteratum%253Aachs%26aulast%3DBarter%26aufirst%3DP.%2BJ.%26aulast%3DBrewer%26aufirst%3DH.%2BB.%26aulast%3DChapman%26aufirst%3DM.%2BJ.%26aulast%3DHennekens%26aufirst%3DC.%2BH.%26aulast%3DRader%26aufirst%3DD.%2BJ.%26aulast%3DTall%26aufirst%3DA.%2BR.%26atitle%3DCholesteryl%2520ester%2520transfer%2520protein%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2003%26volume%3D23%26spage%3D160%26epage%3D167%26doi%3D10.1161%2F01.ATV.0000054658.91146.64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="note"><p class="first last">For recent reviews on CETP inhibitors, see the following:</p></div><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mantlo, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escribano, A.</span><span> </span><span class="NLM_article-title">Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">17</span><div class="note"><p class="first last">and references therein</p></div><span class="refDoi">Â DOI: 10.1021/jm400574e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400574e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OjtbjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1-17&author=N.+B.+Mantloauthor=A.+Escribano&title=Update+on+the+discovery+and+development+of+cholesteryl+ester+transfer+protein+inhibitors+for+reducing+residual+cardiovascular+risk&doi=10.1021%2Fjm400574e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Update on the Discovery and Development of Cholesteryl Ester Transfer Protein Inhibitors for Reducing Residual Cardiovascular Risk</span></div><div class="casAuthors">Mantlo, Nathan B.; Escribano, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-17</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cholesteryl ester transfer protein (CETP) facilitates the transfer of cholesteryl ester and triglycerides between plasma lipoprotein particles HDL and LDL/VLDL, resulting in equilibration between these lipoprotein fractions.  Therapy that modulates HDL metab. to increase HDL-c levels could be an effective strategy to reduce residual cardiovascular risk since it is estd. that for each mg/dL increase in plasma HDL cholesterol, there could be a 2-3% decrease in cardiovascular risk.  Modification of the lipoprotein profile by CETP inhibitors is promising, but the beneficial effect of reducing coronary heart disease risk has not yet been proven.  To date, four CETP inhibitors have advanced to phase 3 cardiovascular outcome clin. trials, and two have been terminated for off-target adverse effects and lack of efficacy.  This perspective will summarize recent events, new research developments, and the discovery of new classes of CETP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHidqL01H0brVg90H21EOLACvtfcHk0lisaUY8hc1Eqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OjtbjL&md5=1b54b68fd41896b2d513161e20c7c432</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1021%2Fjm400574e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400574e%26sid%3Dliteratum%253Aachs%26aulast%3DMantlo%26aufirst%3DN.%2BB.%26aulast%3DEscribano%26aufirst%3DA.%26atitle%3DUpdate%2520on%2520the%2520discovery%2520and%2520development%2520of%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibitors%2520for%2520reducing%2520residual%2520cardiovascular%2520risk%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1%26epage%3D17%26doi%3D10.1021%2Fjm400574e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3aa"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sikorski, J. A.</span><span> </span><span class="NLM_article-title">Oral cholesteryl ester transfer protein (CETP) inhibitors: a potent approach for treating coronary artery disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">22</span><div class="note"><p class="first last">and references therein</p></div><span class="refDoi">Â DOI: 10.1021/jm058224l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058224l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=1-22&author=J.+A.+Sikorski&title=Oral+cholesteryl+ester+transfer+protein+%28CETP%29+inhibitors%3A+a+potent+approach+for+treating+coronary+artery+disease&doi=10.1021%2Fjm058224l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3aa&amp;dbid=16384&amp;doi=10.1021%2Fjm058224l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058224l%26sid%3Dliteratum%253Aachs%26aulast%3DSikorski%26aufirst%3DJ.%2BA.%26atitle%3DOral%2520cholesteryl%2520ester%2520transfer%2520protein%2520%2528CETP%2529%2520inhibitors%253A%2520a%2520potent%2520approach%2520for%2520treating%2520coronary%2520artery%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D1%26epage%3D22%26doi%3D10.1021%2Fjm058224l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chapman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeGoff, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kontush, A.</span><span> </span><span class="NLM_article-title">Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors</span> <span class="citation_source-journal">Eur. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">149</span><span class="NLM_x">â</span> <span class="NLM_lpage">164</span><span class="refDoi">Â DOI: 10.1093/eurheartj/ehp399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1093%2Feurheartj%2Fehp399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=19825813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlKksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=149-164&author=M.+J.+Chapmanauthor=W.+LeGoffauthor=M.+Guerinauthor=A.+Kontush&title=Cholesteryl+ester+transfer+protein%3A+at+the+heart+of+the+action+of+lipid-modulating+therapy+with+statins%2C+fibrates%2C+niacin%2C+and+cholesteryl+ester+transfer+protein+inhibitors&doi=10.1093%2Feurheartj%2Fehp399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors</span></div><div class="casAuthors">Chapman, M. John; Le Goff, Wilfried; Guerin, Maryse; Kontush, Anatol</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">149-164</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Subnormal plasma levels of high-d. lipoprotein cholesterol (HDL-C) constitute a major cardiovascular risk factor; raising low HDL-C levels may therefore reduce the residual cardiovascular risk that frequently presents in dyslipidemic subjects despite statin therapy.  Cholesteryl ester transfer protein (CETP), a key modulator not only of the intravascular metab. of HDL and apolipoprotein (apo) A-I but also of triglyceride (TG)-rich particles and low-d. lipoprotein (LDL), mediates the transfer of cholesteryl esters from HDL to pro-atherogenic apoB-lipoproteins, with heterotransfer of TG mainly from very low-d. lipoprotein to HDL.  Cholesteryl ester transfer protein activity is elevated in the dyslipidemias of metabolic disease involving insulin resistance and moderate to marked hypertriglyceridemia, and is intimately assocd. with premature atherosclerosis and high cardiovascular risk.  Cholesteryl ester transfer protein inhibition therefore presents a preferential target for elevation of HDL-C and redn. in atherosclerosis.  This review appraises recent evidence for a central role of CETP in the action of current lipid-modulating agents with HDL-raising potential, i.e. statins, fibrates, and niacin, and compares their mechanisms of action with those of pharmacol. agents under development which directly inhibit CETP.  New CETP inhibitors, such as dalcetrapib and anacetrapib, are targeted to normalize HDL/apoA-I levels and anti-atherogenic activities of HDL particles.  Further studies of these CETP inhibitors, in particular in long-term, large-scale outcome trials, will provide essential information on their safety and efficacy in reducing residual cardiovascular risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotgbYNLr-Yu7Vg90H21EOLACvtfcHk0lisaUY8hc1Eqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlKksg%253D%253D&md5=1440a28e8f4a63f45c21cf926476ae47</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehp399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehp399%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DM.%2BJ.%26aulast%3DLeGoff%26aufirst%3DW.%26aulast%3DGuerin%26aufirst%3DM.%26aulast%3DKontush%26aufirst%3DA.%26atitle%3DCholesteryl%2520ester%2520transfer%2520protein%253A%2520at%2520the%2520heart%2520of%2520the%2520action%2520of%2520lipid-modulating%2520therapy%2520with%2520statins%252C%2520fibrates%252C%2520niacin%252C%2520and%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibitors%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2010%26volume%3D31%26spage%3D149%26epage%3D164%26doi%3D10.1093%2Feurheartj%2Fehp399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Linsel-Nitschke, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tall, A. R.</span><span> </span><span class="NLM_article-title">HDL as a target in the treatment of atherosclerotic cardiovascular disease</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">â</span> <span class="NLM_lpage">205</span><div class="note"><p class="first last">and references therein</p></div><span class="refDoi">Â DOI: 10.1038/nrd1658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1038%2Fnrd1658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=15738977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslSnsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=193-205&author=P.+Linsel-Nitschkeauthor=A.+R.+Tall&title=HDL+as+a+target+in+the+treatment+of+atherosclerotic+cardiovascular+disease&doi=10.1038%2Fnrd1658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">HDL as a target in the treatment of atherosclerotic cardiovascular disease</span></div><div class="casAuthors">Linsel-Nitschke, Patrick; Tall, Alan R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-205</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Lipid abnormalities are among the key risk factors for cardiovascular disease.  Indeed, lipid-modifying drugs - in particular, the statins, which primarily lower plasma levels of low-d. lipoprotein (LDL) cholesterol - considerably reduce the risk of cardiovascular events, leading to their widespread use.  Nevertheless, it seems that there might be limits to the degree of benefit that can be achieved by lowering LDL-cholesterol levels alone, which has led to increased interest in targeting other lipid-related risk factors for cardiovascular disease, such as low levels of high-d. lipoprotein (HDL) cholesterol.  In this article, we first consider the mechanisms that underlie the protective effect of HDL cholesterol, and then discuss several strategies that have recently emerged to increase levels of HDL cholesterol to treat cardiovascular disease, including nuclear receptor modulation, inhibition of cholesteryl ester transfer protein and infusion of apolipoprotein/phospholipid complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw-z_u0WhLTrVg90H21EOLACvtfcHk0liK0Z_i8VWFJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslSnsrc%253D&md5=57392b9ff6c31d13de45511d7ac993f3</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1038%2Fnrd1658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1658%26sid%3Dliteratum%253Aachs%26aulast%3DLinsel-Nitschke%26aufirst%3DP.%26aulast%3DTall%26aufirst%3DA.%2BR.%26atitle%3DHDL%2520as%2520a%2520target%2520in%2520the%2520treatment%2520of%2520atherosclerotic%2520cardiovascular%2520disease%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D193%26epage%3D205%26doi%3D10.1038%2Fnrd1658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Briand, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieblemont, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzotte, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbain, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulpice, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johns, D. G.</span><span> </span><span class="NLM_article-title">Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">740</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">â</span> <span class="NLM_lpage">143</span><span class="refDoi">Â DOI: 10.1016/j.ejphar.2014.06.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1016%2Fj.ejphar.2014.06.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=25008069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GrtLzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=740&publication_year=2014&pages=135-143&author=F.+Briandauthor=Q.+Thieblemontauthor=E.+Muzotteauthor=N.+Burrauthor=I.+Urbainauthor=T.+Sulpiceauthor=D.+G.+Johns&title=Anacetrapib+and+dalcetrapib+differentially+alters+HDL+metabolism+and+macrophage-to-feces+reverse+cholesterol+transport+at+similar+levels+of+CETP+inhibition+in+hamsters&doi=10.1016%2Fj.ejphar.2014.06.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters</span></div><div class="casAuthors">Briand, Francois; Thieblemont, Quentin; Muzotte, Elodie; Burr, Noemie; Urbain, Isabelle; Sulpice, Thierry; Johns, Douglas G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">740</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">135-143</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cholesteryl ester transfer protein (CETP) inhibitors dalcetrapib and anacetrapib differentially alter LDL- and HDL-cholesterol levels, which might be related to the potency of each drug to inhibit CETP activity.  We evaluated the effects of both drugs at similar levels of CETP inhibition on macrophage-to-feces reverse cholesterol transport (RCT) in hamsters.  In normolipidemic hamsters, both anacetrapib 30 mg/kg QD and dalcetrapib 200 mg/kg BID inhibited CETP activity by â¼60%.  After injection of 3H-cholesteryl oleate labeled HDL, anacetrapib and dalcetrapib reduced HDL-cholesteryl esters fractional catabolic rate (FCR) by 30% and 26% (both P<0.001 vs. vehicle) resp., but only dalcetrapib increased HDL-derived 3H-tracer fecal excretion by 30% (P<0.05 vs. vehicle).  After 3H-cholesterol labeled macrophage i.p. injection, anacetrapib stimulated 3H-tracer appearance in HDL, but both drugs did not promote macrophage-derived 3H-tracer fecal excretion.  In dyslipidemic hamsters, both anacetrapib 1 mg/kg QD and dalcetrapib 200 mg/kg BID inhibited CETP activity by â¼65% and reduced HDL-cholesteryl ester FCR by 36% (both P<0.001 vs. vehicle), but only anacetrapib increased HDL-derived 3H-tracer fecal excretion significantly by 39%.  After 3H-cholesterol labeled macrophage injection, only anacetrapib 1 mg/kg QD stimulated macrophage-derived 3H-tracer appearance in HDL.  These effects remained weaker than those obsd. with anacetrapib 60 mg/kg QD, which induced a maximal inhibition of CETP and stimulation of macrophage-derived 3H-tracer fecal excretion.  In contrast, dalcetrapib 200 mg/kg BID reduced macrophage-derived 3H-tracer fecal excretion by 23% (P<0.05 vs. vehicle).  In conclusion, anacetrapib and dalcetrapib differentially alter HDL metab. and RCT in hamsters.  A stronger inhibition of CETP may be required to promote macrophage-to-feces reverse cholesterol transport in dyslipidemic hamsters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIW5Yxk_tQrbVg90H21EOLACvtfcHk0liK0Z_i8VWFJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GrtLzJ&md5=8d51917b8f01f614f9c320414b2ef0c7</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2014.06.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2014.06.022%26sid%3Dliteratum%253Aachs%26aulast%3DBriand%26aufirst%3DF.%26aulast%3DThieblemont%26aufirst%3DQ.%26aulast%3DMuzotte%26aufirst%3DE.%26aulast%3DBurr%26aufirst%3DN.%26aulast%3DUrbain%26aufirst%3DI.%26aulast%3DSulpice%26aufirst%3DT.%26aulast%3DJohns%26aufirst%3DD.%2BG.%26atitle%3DAnacetrapib%2520and%2520dalcetrapib%2520differentially%2520alters%2520HDL%2520metabolism%2520and%2520macrophage-to-feces%2520reverse%2520cholesterol%2520transport%2520at%2520similar%2520levels%2520of%2520CETP%2520inhibition%2520in%2520hamsters%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D740%26spage%3D135%26epage%3D143%26doi%3D10.1016%2Fj.ejphar.2014.06.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cannon, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansky, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotto, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stepanavage, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashraf, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zafarino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchel, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barter, P. N.</span><span> </span><span class="NLM_article-title">Safety of anacetrapib in patients with or at high risk for coronary heart disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">2406</span><span class="NLM_x">â</span> <span class="NLM_lpage">2415</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1009744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1056%2FNEJMoa1009744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=21082868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2ltLfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=2406-2415&author=C.+P.+Cannonauthor=S.+Shahauthor=H.+M.+Danskyauthor=M.+Davidsonauthor=E.+A.+Brintonauthor=A.+M.+Gottoauthor=M.+Stepanavageauthor=S.+X.+Liuauthor=P.+Gibbonsauthor=T.+B.+Ashrafauthor=J.+Zafarinoauthor=Y.+Mitchelauthor=P.+N.+Barter&title=Safety+of+anacetrapib+in+patients+with+or+at+high+risk+for+coronary+heart+disease&doi=10.1056%2FNEJMoa1009744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of anacetrapib in patients with or at high risk for coronary heart disease</span></div><div class="casAuthors">Cannon, Christopher P.; Shah, Sukrut; Dansky, Hayes M.; Davidson, Michael; Brinton, Eliot A.; Gotto, Antonio M., Jr.; Phil, D.; Stepanavage, Michael; Liu, Sherry Xueyu; Gibbons, Patrice; Ashraf, Tanya B.; Zafarino, Jennifer; Mitchel, Yale; Barter, Philip</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2406-2415</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-d. lipoprotein (HDL) cholesterol and reduces low-d. lipoprotein (LDL) cholesterol.  METHODS: We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety profile of anacetrapib in patients with coronary heart disease or at high risk for coronary heart disease.  Eligible patients who were taking a statin and who had an LDL cholesterol level that was consistent with that recommended in guidelines were assigned to receive 100 mg of anacetrapib or placebo daily for 18 mo.  The primary end points were the percent change from baseline in LDL cholesterol at 24 wk (HDL cholesterol level was a secondary end point) and the safety and side-effect profile of anacetrapib through 76 wk.  Cardiovascular events and deaths were prospectively adjudicated.  RESULTS: A total of 1623 patients underwent randomization.  By 24 wk, the LDL cholesterol level had been reduced from 81 mg per dL (2.1 mmol per L) to 45 mg per dL (1.2 mmol per L) in the anacetrapib group, as compared with a redn. from 82 mg per dL (2.1 mmol per L) to 77 mg per dL (2.0 mmol per L) in the placebo group (P < 0.001) - a 39.8% redn. with anacetrapib beyond that seen with placebo.  In addn., the HDL cholesterol level increased from 41 mg per dL (1.0 mmol per L) to 101 mg per dL (2.6 mmol per L) in the anacetrapib group, as compared with an increase from 40 mg per dL (1.0 mmol per L) to 46 mg per dL (1.2 mmol per L) in the placebo group (P < 0.001) - a 138.1% increase with anacetrapib beyond that seen with placebo.  Through 76 wk, no changes were noted in blood pressure or electrolyte or aldosterone levels with anacetrapib as compared with placebo.  Prespecified adjudicated cardiovascular events occurred in 16 patients treated with anacetrapib (2.0%) and 21 patients receiving placebo (2.6%) (P = 0.40).  The prespecified Bayesian anal. indicated that this event distribution provided a predictive probability (confidence) of 94% that anacetrapib would not be assocd. with a 25% increase in cardiovascular events, as seen with torcetrapib.  CONCLUSIONS Treatment with anacetrapib had robust effects on LDL and HDL cholesterol, had an acceptable side-effect profile, and, within the limits of the power of this study, did not result in the adverse cardiovascular effects obsd. with torcetrapib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3bzMvd54bDLVg90H21EOLACvtfcHk0liK0Z_i8VWFJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2ltLfL&md5=df74ea8dd8273e576fa26dc70805e719</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1009744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1009744%26sid%3Dliteratum%253Aachs%26aulast%3DCannon%26aufirst%3DC.%2BP.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DDansky%26aufirst%3DH.%2BM.%26aulast%3DDavidson%26aufirst%3DM.%26aulast%3DBrinton%26aufirst%3DE.%2BA.%26aulast%3DGotto%26aufirst%3DA.%2BM.%26aulast%3DStepanavage%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%2BX.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DAshraf%26aufirst%3DT.%2BB.%26aulast%3DZafarino%26aufirst%3DJ.%26aulast%3DMitchel%26aufirst%3DY.%26aulast%3DBarter%26aufirst%3DP.%2BN.%26atitle%3DSafety%2520of%2520anacetrapib%2520in%2520patients%2520with%2520or%2520at%2520high%2520risk%2520for%2520coronary%2520heart%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D2406%26epage%3D2415%26doi%3D10.1056%2FNEJMoa1009744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nicholls, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastelein, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McErlean, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nissen, S. E.</span><span> </span><span class="NLM_article-title">Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: A randomized controlled trial</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">306</span><span class="NLM_x">, </span> <span class="NLM_fpage">2099</span><span class="NLM_x">â</span> <span class="NLM_lpage">2109</span><span class="refDoi">Â DOI: 10.1001/jama.2011.1649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1001%2Fjama.2011.1649" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2011&pages=2099-2109&author=S.+J.+Nichollsauthor=H.+B.+Brewerauthor=J.+J.+Kasteleinauthor=K.+A.+Kruegerauthor=M.+D.+Wangauthor=M.+Shaoauthor=B.+Huauthor=E.+McErleanauthor=S.+E.+Nissen&title=Effects+of+the+CETP+inhibitor+evacetrapib+administered+as+monotherapy+or+in+combination+with+statins+on+HDL+and+LDL+cholesterol%3A+A+randomized+controlled+trial&doi=10.1001%2Fjama.2011.1649"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1001%2Fjama.2011.1649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2011.1649%26sid%3Dliteratum%253Aachs%26aulast%3DNicholls%26aufirst%3DS.%2BJ.%26aulast%3DBrewer%26aufirst%3DH.%2BB.%26aulast%3DKastelein%26aufirst%3DJ.%2BJ.%26aulast%3DKrueger%26aufirst%3DK.%2BA.%26aulast%3DWang%26aufirst%3DM.%2BD.%26aulast%3DShao%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DMcErlean%26aufirst%3DE.%26aulast%3DNissen%26aufirst%3DS.%2BE.%26atitle%3DEffects%2520of%2520the%2520CETP%2520inhibitor%2520evacetrapib%2520administered%2520as%2520monotherapy%2520or%2520in%2520combination%2520with%2520statins%2520on%2520HDL%2520and%2520LDL%2520cholesterol%253A%2520A%2520randomized%2520controlled%2520trial%26jtitle%3DJAMA%26date%3D2011%26volume%3D306%26spage%3D2099%26epage%3D2109%26doi%3D10.1001%2Fjama.2011.1649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kathiresan, S.</span><span> </span><span class="NLM_article-title">Will Cholesteryl Ester Transfer Protein Inhibition Succeed Primarily by Lowering Low--Density Lipoprotein Cholesterol?</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2049</span><span class="NLM_x">â</span> <span class="NLM_lpage">2052</span><span class="refDoi">Â DOI: 10.1016/j.jacc.2012.08.967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1016%2Fj.jacc.2012.08.967" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=23083775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1OlurnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2012&pages=2049-2052&author=S.+Kathiresan&title=Will+Cholesteryl+Ester+Transfer+Protein+Inhibition+Succeed+Primarily+by+Lowering+Low%2D%2DDensity+Lipoprotein+Cholesterol%3F&doi=10.1016%2Fj.jacc.2012.08.967"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Will Cholesteryl Ester Transfer Protein Inhibition Succeed Primarily by Lowering Low-Density Lipoprotein Cholesterol?</span></div><div class="casAuthors">Kathiresan, Sekar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2049-2052</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The research of Johannsen et al. (2012) entitled, 'Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects' is reviewed with commentary and refs.  Johannsen et al. tested the hypothesis that common genetic variation at the CETP gene relates to plasma lipids and risk for incident atherosclerotic cardiovascular disease (ASCVD).  They found that the alleles assocd. with lower CETP activity are assocd. with a range of lipid biomarkers including: 1) higher apolipoprotein A-I contg. lipoproteins (as measured by HDL cholesterol); 2) lower apolipoprotein B-contg. lipoproteins (as measured by low-d. lipoprotein [LDL] cholesterol and triglycerides); and 3) lower plasma lipoprotein(a).  They also tested whether these polymorphisms assoc. with traits relevant to the side effects of pharmacol. CETP inhibition and found no such assocns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokzSFc0Ywm8rVg90H21EOLACvtfcHk0ljfSyLEseLAFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1OlurnN&md5=ba768abf96e691c3a83184fcf391b7aa</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2012.08.967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2012.08.967%26sid%3Dliteratum%253Aachs%26aulast%3DKathiresan%26aufirst%3DS.%26atitle%3DWill%2520Cholesteryl%2520Ester%2520Transfer%2520Protein%2520Inhibition%2520Succeed%2520Primarily%2520by%2520Lowering%2520Low--Density%2520Lipoprotein%2520Cholesterol%253F%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2012%26volume%3D60%26spage%3D2049%26epage%3D2052%26doi%3D10.1016%2Fj.jacc.2012.08.967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Berenson, A.</span><span> </span><span class="NLM_article-title">Pfizer ends studies on drug for heart disease</span>.  <span class="citation_source-journal">The New York Times</span>; <span class="NLM_publisher-name">The New York Times Company</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">; </span><span class="NLM_issue">Dec 3</span> issue.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&issue=Dec+3&author=A.+Berenson&title=Pfizer+ends+studies+on+drug+for+heart+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerenson%26aufirst%3DA.%26atitle%3DPfizer%2520ends%2520studies%2520on%2520drug%2520for%2520heart%2520disease%26jtitle%3DThe%2520New%2520York%2520Times%26pub%3DThe%2520New%2520York%2520Times%2520Company%26date%3D2006%26issue%3DDec%25203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Barter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caulfield, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastelein, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komajda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Sendon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tardif, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shear, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Revkin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhr, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tall, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, B.</span><span> </span><span class="NLM_article-title">Effects of torcetrapib in patients at high risk for coronary events</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">2109</span><span class="NLM_x">â</span> <span class="NLM_lpage">2122</span><span class="refDoi">Â DOI: 10.1056/NEJMoa0706628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1056%2FNEJMoa0706628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=17984165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGns7bL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2007&pages=2109-2122&author=P.+J.+Barterauthor=M.+Caulfieldauthor=M.+Erikssonauthor=S.+M.+Grundyauthor=J.+J.+Kasteleinauthor=M.+Komajdaauthor=J.+Lopez-Sendonauthor=L.+Moscaauthor=J.-C.+Tardifauthor=D.+D.+Watersauthor=C.+L.+Shearauthor=J.+H.+Revkinauthor=K.+A.+Buhrauthor=M.+R.+Fisherauthor=A.+R.+Tallauthor=B.+Brewer&title=Effects+of+torcetrapib+in+patients+at+high+risk+for+coronary+events&doi=10.1056%2FNEJMoa0706628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of torcetrapib in patients at high risk for coronary events</span></div><div class="casAuthors">Barter, Philip J.; Caulfield, Mark; Eriksson, Mats; Grundy, Scott M.; Kastelein, John J. P.; Komajda, Michel; Lopez-Sendon, Jose; Mosca, Lori; Tardif, Jean-Claude; Waters, David D.; Shear, Charles L.; Revkin, James H.; Buhr, Kevin A.; Fisher, Marian R.; Tall, Alan R.; Brewer, Bryan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2109-2122</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels.  We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events.  The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib.  Methods: We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk.  The patients received either torcetrapib plus atorvastatin or atorvastatin alone.  The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina.  Results: At 12 mo in patients who received torcetrapib, there was an increase of 72.1% in high-d. lipoprotein cholesterol and a decrease of 24.9% in low-d. lipoprotein cholesterol, as compared with baseline (P < 0.001 for both comparisons), in addn. to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone (P < 0.001 for all comparisons).  There was also an increased risk of cardiovascular events (hazard ratio, 1.25; 95% confidence interval [CI], 1.09 to 1.44; P = 0.001) and death from any cause (hazard ratio, 1.58; 95% CI, 1.14 to 2.19; P = 0.006).  Post hoc analyses showed an increased risk of death in patients treated with torcetrapib whose redn. in potassium or increase in bicarbonate was greater than the median change.  Conclusions: Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism.  Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrjJJlK3IwJbVg90H21EOLACvtfcHk0ljfSyLEseLAFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGns7bL&md5=36913112326b0998658eaf6ea95b3ff9</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0706628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0706628%26sid%3Dliteratum%253Aachs%26aulast%3DBarter%26aufirst%3DP.%2BJ.%26aulast%3DCaulfield%26aufirst%3DM.%26aulast%3DEriksson%26aufirst%3DM.%26aulast%3DGrundy%26aufirst%3DS.%2BM.%26aulast%3DKastelein%26aufirst%3DJ.%2BJ.%26aulast%3DKomajda%26aufirst%3DM.%26aulast%3DLopez-Sendon%26aufirst%3DJ.%26aulast%3DMosca%26aufirst%3DL.%26aulast%3DTardif%26aufirst%3DJ.-C.%26aulast%3DWaters%26aufirst%3DD.%2BD.%26aulast%3DShear%26aufirst%3DC.%2BL.%26aulast%3DRevkin%26aufirst%3DJ.%2BH.%26aulast%3DBuhr%26aufirst%3DK.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BR.%26aulast%3DTall%26aufirst%3DA.%2BR.%26aulast%3DBrewer%26aufirst%3DB.%26atitle%3DEffects%2520of%2520torcetrapib%2520in%2520patients%2520at%2520high%2520risk%2520for%2520coronary%2520events%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D357%26spage%3D2109%26epage%3D2122%26doi%3D10.1056%2FNEJMoa0706628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tall, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yvan-Charvet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, N.</span><span> </span><span class="NLM_article-title">The failure of torcetrapib. Was it the molecule or the mechanism?</span> <span class="citation_source-journal">Arterioscler., Thromb., Vasc. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">â</span> <span class="NLM_lpage">260</span><span class="refDoi">Â DOI: 10.1161/01.ATV.0000256728.60226.77</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1161%2F01.ATV.0000256728.60226.77" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=17229967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGjt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=257-260&author=A.+R.+Tallauthor=L.+Yvan-Charvetauthor=N.+Wang&title=The+failure+of+torcetrapib.+Was+it+the+molecule+or+the+mechanism%3F&doi=10.1161%2F01.ATV.0000256728.60226.77"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">The failure of Torcetrapib: Was it the molecular or the mechanism?</span></div><div class="casAuthors">Tall, Alan R.; Yvan-Charvet, Laurent; Wang, Nan</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-260</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-GoP3oD2qXLVg90H21EOLACvtfcHk0likIZ7s2yFrmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGjt70%253D&md5=b14566b1132be7e285d4df2d1dfd34e5</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1161%2F01.ATV.0000256728.60226.77&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.ATV.0000256728.60226.77%26sid%3Dliteratum%253Aachs%26aulast%3DTall%26aufirst%3DA.%2BR.%26aulast%3DYvan-Charvet%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DN.%26atitle%3DThe%2520failure%2520of%2520torcetrapib.%2520Was%2520it%2520the%2520molecule%2520or%2520the%2520mechanism%253F%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2007%26volume%3D27%26spage%3D257%26epage%3D260%26doi%3D10.1161%2F01.ATV.0000256728.60226.77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Stroes, E. S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastelein, J. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benardeau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhlmann, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clerc, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niesor, E. J.</span><span> </span><span class="NLM_article-title">Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the reninâangiotensinâaldosterone system in rats</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">1763</span><span class="NLM_x">â</span> <span class="NLM_lpage">1770</span><span class="refDoi">Â DOI: 10.1111/j.1476-5381.2009.00460.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1111%2Fj.1476-5381.2009.00460.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=19917065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Whtr%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=1763-1770&author=E.+S.+G.+Stroesauthor=J.+J.+P.+Kasteleinauthor=A.+Benardeauauthor=O.+Kuhlmannauthor=D.+Blumauthor=L.+A.+Camposauthor=R.+G.+Clercauthor=E.+J.+Niesor&title=Dalcetrapib%3A+no+off-target+toxicity+on+blood+pressure+or+on+genes+related+to+the+renin%E2%80%93angiotensin%E2%80%93aldosterone+system+in+rats&doi=10.1111%2Fj.1476-5381.2009.00460.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats</span></div><div class="casAuthors">Stroes, E. S. G.; Kastelein, J. J. P.; Benardeau, A.; Kuhlmann, O.; Blum, D.; Campos, L. A.; Clerc, R. G.; Niesor, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1763-1770</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The assocn. between torcetrapib and its off-target effects on blood pressure suggested a possible class-specific effect.  The effects of dalcetrapib (RO4607381/JTT-705) and torcetrapib on haemodynamics and the renin-angiotensin-aldosterone system (RAAS) were therefore assessed in a rat model.  Arterial pressure (AP) and heart rate were measured by telemetry in normotensive and spontaneously hypertensive rats (SHR) receiving torcetrapib 10, 40, or 80 mg/kg-1/day-1; dalcetrapib 100, 300, or 500 mg-1/kg/day-1; or vehicle (placebo) for 5 days.  Expression of RAAS genes in adrenal gland, kidney, aorta and lung from normotensive rats following 5 days' treatment with torcetrapib 40 mg/kg-1/day-1, dalcetrapib 500 mg/kg-1/day-1 or vehicle was measured by quant. polymerase chain reaction.  Torcetrapib transiently increased mean AP in normotensive rats (+3.7 Â± 0.1 mmHg), whereas treatment in SHR resulted in a dose-dependent and sustained increase [+6.5 Â± 0.6 mmHg with 40 mg/kg-1/day-1 at day 1 (P < 0.05 vs. placebo)], which lasted over the treatment period.  No changes in AP or heart rate were obsd. with dalcetrapib.  Torcetrapib, but not dalcetrapib, increased RAAS-related mRNAs in adrenal glands and aortas.  In contrast to torcetrapib, dalcetrapib did not increase blood pressure or RAAS-related gene expression in rats, suggesting that the off-target effects of torcetrapib are not a common feature of all compds. acting on cholesteryl ester transfer protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4SJRkg9vZAbVg90H21EOLACvtfcHk0likIZ7s2yFrmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Whtr%252FL&md5=f907da070f24a4fe86e1398869c86de8</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00460.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00460.x%26sid%3Dliteratum%253Aachs%26aulast%3DStroes%26aufirst%3DE.%2BS.%2BG.%26aulast%3DKastelein%26aufirst%3DJ.%2BJ.%2BP.%26aulast%3DBenardeau%26aufirst%3DA.%26aulast%3DKuhlmann%26aufirst%3DO.%26aulast%3DBlum%26aufirst%3DD.%26aulast%3DCampos%26aufirst%3DL.%2BA.%26aulast%3DClerc%26aufirst%3DR.%2BG.%26aulast%3DNiesor%26aufirst%3DE.%2BJ.%26atitle%3DDalcetrapib%253A%2520no%2520off-target%2520toxicity%2520on%2520blood%2520pressure%2520or%2520on%2520genes%2520related%2520to%2520the%2520renin%25E2%2580%2593angiotensin%25E2%2580%2593aldosterone%2520system%2520in%2520rats%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D158%26spage%3D1763%26epage%3D1770%26doi%3D10.1111%2Fj.1476-5381.2009.00460.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loging, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, J.</span><span> </span><span class="NLM_article-title">Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">150</span><span class="NLM_x">, </span> <span class="NLM_fpage">2211</span><span class="NLM_x">â</span> <span class="NLM_lpage">2219</span><span class="refDoi">Â DOI: 10.1210/en.2008-1512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1210%2Fen.2008-1512" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2009&pages=2211-2219&author=X.+Huauthor=J.+D.+Dietzauthor=C.+Xiaauthor=D.+R.+Knightauthor=W.+T.+Logingauthor=A.+H.+Smithauthor=H.+Yuanauthor=D.+A.+Perryauthor=J.+Keiser&title=Torcetrapib+induces+aldosterone+and+cortisol+production+by+an+intracellular+calcium-mediated+mechanism+independently+of+cholesteryl+ester+transfer+protein+inhibition&doi=10.1210%2Fen.2008-1512"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1210%2Fen.2008-1512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2008-1512%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.%26aulast%3DDietz%26aufirst%3DJ.%2BD.%26aulast%3DXia%26aufirst%3DC.%26aulast%3DKnight%26aufirst%3DD.%2BR.%26aulast%3DLoging%26aufirst%3DW.%2BT.%26aulast%3DSmith%26aufirst%3DA.%2BH.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DPerry%26aufirst%3DD.%2BA.%26aulast%3DKeiser%26aufirst%3DJ.%26atitle%3DTorcetrapib%2520induces%2520aldosterone%2520and%2520cortisol%2520production%2520by%2520an%2520intracellular%2520calcium-mediated%2520mechanism%2520independently%2520of%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibition%26jtitle%3DEndocrinology%26date%3D2009%26volume%3D150%26spage%3D2211%26epage%3D2219%26doi%3D10.1210%2Fen.2008-1512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Forrest, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloomfield, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briscoe, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumiskey, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrhart, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hershey, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif-Rodriguez, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegl, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinclair, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparrow, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woltmann, R. F.</span><span> </span><span class="NLM_article-title">Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x">, </span> <span class="NLM_fpage">1465</span><span class="NLM_x">â</span> <span class="NLM_lpage">1473</span><span class="refDoi">Â DOI: 10.1038/bjp.2008.229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1038%2Fbjp.2008.229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=18536749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVajs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1465-1473&author=M.+J.+Forrestauthor=D.+Bloomfieldauthor=R.+J.+Briscoeauthor=P.+N.+Brownauthor=A.+M.+Cumiskeyauthor=J.+Ehrhartauthor=J.+C.+Hersheyauthor=W.+J.+Kellerauthor=X.+Maauthor=H.+E.+McPhersonauthor=E.+Messinaauthor=L.+B.+Petersonauthor=W.+Sharif-Rodriguezauthor=P.+K.+Sieglauthor=P.+J.+Sinclairauthor=C.+P.+Sparrowauthor=A.+S.+Stevensonauthor=S.+Y.+Sunauthor=C.+Tsaiauthor=H.+Vargasauthor=M.+Walkerauthor=S.+H.+Westauthor=V.+Whiteauthor=R.+F.+Woltmann&title=Torcetrapib-induced+blood+pressure+elevation+is+independent+of+CETP+inhibition+and+is+accompanied+by+increased+circulating+levels+of+aldosterone&doi=10.1038%2Fbjp.2008.229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6fR"><div class="casContent"><span class="casTitleNuber">6f</span><div class="casTitle"><span class="NLM_cas:atitle">Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone</span></div><div class="casAuthors">Forrest, M. J.; Bloomfield, D.; Briscoe, R. J.; Brown, P. N.; Cumiskey, A.-M.; Ehrhart, J.; Hershey, J. C.; Keller, W. J.; Ma, X.; McPherson, H. E.; Messina, E.; Peterson, L. B.; Sharif-Rodriguez, W.; Siegl, P. K. S.; Sinclair, P. J.; Sparrow, C. P.; Stevenson, A. S.; Sun, S.-Y.; Tsai, C.; Vargas, H.; Walker, M., III; West, S. H.; White, V.; Woltmann, R. F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1465-1473</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of cholesteryl ester transfer protein (CETP) with torcetrapib in humans increases plasma high d. lipoprotein (HDL) cholesterol levels but is assocd. with increased blood pressure.  In a phase 3 clin. study, evaluating the effects of torcetrapib in atherosclerosis, there was an excess of deaths and adverse cardiovascular events in patients taking torcetrapib.  The studies reported herein sought to evaluate off-target effects of torcetrapib.  Cardiovascular effects of the CETP inhibitors torcetrapib and anacetrapib were evaluated in animal models.  Torcetrapib evoked an acute increase in blood pressure in all species evaluated whereas no increase was obsd. with anacetrapib.  The pressor effect of torcetrapib was not diminished in the presence of adrenoceptor, angiotensin II or endothelin receptor antagonists.  Torcetrapib did not have a contractile effect on vascular smooth muscle suggesting its effects in vivo are via the release of a secondary mediator.  Treatment with torcetrapib was assocd. with an increase in plasma levels of aldosterone and corticosterone and, in vitro, was shown to release aldosterone from adrenocortical cells.  Increased adrenal steroid levels were not obsd. with anacetrapib.  Inhibition of adrenal steroid synthesis did not inhibit the pressor response to torcetrapib whereas adrenalectomy prevented the ability of torcetrapib to increase blood pressure in rats.  Torcetrapib evoked an acute increase in blood pressure and an acute increase in plasma adrenal steroids.  The acute pressor response to torcetrapib was not mediated by adrenal steroids but was dependent on intact adrenal glands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEhvVtQh2IkLVg90H21EOLACvtfcHk0lj5-_zuXjftrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVajs7g%253D&md5=c24fd90f9cbd9e8c2ab9c7994f8b21c5</span></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.229%26sid%3Dliteratum%253Aachs%26aulast%3DForrest%26aufirst%3DM.%2BJ.%26aulast%3DBloomfield%26aufirst%3DD.%26aulast%3DBriscoe%26aufirst%3DR.%2BJ.%26aulast%3DBrown%26aufirst%3DP.%2BN.%26aulast%3DCumiskey%26aufirst%3DA.%2BM.%26aulast%3DEhrhart%26aufirst%3DJ.%26aulast%3DHershey%26aufirst%3DJ.%2BC.%26aulast%3DKeller%26aufirst%3DW.%2BJ.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DMcPherson%26aufirst%3DH.%2BE.%26aulast%3DMessina%26aufirst%3DE.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DSharif-Rodriguez%26aufirst%3DW.%26aulast%3DSiegl%26aufirst%3DP.%2BK.%26aulast%3DSinclair%26aufirst%3DP.%2BJ.%26aulast%3DSparrow%26aufirst%3DC.%2BP.%26aulast%3DStevenson%26aufirst%3DA.%2BS.%26aulast%3DSun%26aufirst%3DS.%2BY.%26aulast%3DTsai%26aufirst%3DC.%26aulast%3DVargas%26aufirst%3DH.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DWest%26aufirst%3DS.%2BH.%26aulast%3DWhite%26aufirst%3DV.%26aulast%3DWoltmann%26aufirst%3DR.%2BF.%26atitle%3DTorcetrapib-induced%2520blood%2520pressure%2520elevation%2520is%2520independent%2520of%2520CETP%2520inhibition%2520and%2520is%2520accompanied%2520by%2520increased%2520circulating%2520levels%2520of%2520aldosterone%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26spage%3D1465%26epage%3D1473%26doi%3D10.1038%2Fbjp.2008.229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Schwartz, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballantyne, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brumm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaitman, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holme, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallend, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiter, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leitersdorf, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurray, J. J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mundl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholls, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tardif, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. S.</span><span> </span><span class="NLM_article-title">For the dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">2089</span><span class="NLM_x">â</span> <span class="NLM_lpage">2099</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1206797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1056%2FNEJMoa1206797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=23126252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslyltrvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=2089-2099&author=G.+G.+Schwartzauthor=A.+G.+Olssonauthor=M.+Abtauthor=C.+M.+Ballantyneauthor=P.+J.+Barterauthor=J.+Brummauthor=B.+R.+Chaitmanauthor=I.+M.+Holmeauthor=D.+Kallendauthor=L.+A.+Leiterauthor=E.+Leitersdorfauthor=J.+J.+V.+McMurrayauthor=H.+Mundlauthor=S.+J.+Nichollsauthor=P.+K.+Shahauthor=J.-C.+Tardifauthor=R.+S.+Wright&title=For+the+dal-OUTCOMES+Investigators.+Effects+of+dalcetrapib+in+patients+with+a+recent+acute+coronary+syndrome&doi=10.1056%2FNEJMoa1206797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of dalcetrapib in patients with a recent acute coronary syndrome</span></div><div class="casAuthors">Schwartz, Gregory G.; Olsson, Anders G.; Abt, Markus; Ballantyne, Christie M.; Barter, Philip J.; Brumm, Jochen; Chaitman, Bernard R.; Holme, Ingar M.; Kallend, David; Leiter, Lawrence A.; Leitersdorf, Eran; McMurray, John J. V.; Mundl, Hardi; Nicholls, Stephen J.; Shah, Prediman K.; Tardif, Jean-Claude; Wright, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2089-2099</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BAckground: In observational analyses, higher levels of high-d. lipoprotein (HDL) cholesterol have been assocd. with a lower risk of coronary heart disease events.  However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain.  Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes.  Methods: We randomly assigned 15,871 patients who had had a recent acute coronary syndrome to receive the CETP inhibitor dalcetrapib, at a dose of 600 mg daily, or placebo, in addn. to the best available evidence-based care.  The primary efficacy end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest with resuscitation.  Results: At the time of randomization, the mean HDL cholesterol level was 42 mg per dL (1.1 mmol per L), and the mean low-d. lipoprotein (LDL) cholesterol level was 76 mg per dL (2.0 mmol per L).  Over the course of the trial, HDL cholesterol levels increased from baseline by 4 to 11% in the placebo group and by 31 to 40% in the dalcetrapib group.  Dalcetrapib had a minimal effect on LDL cholesterol levels.  Patients were followed for a median of 31 mo.  At a prespecified interim anal. that included 1135 primary end-point events (71% of the projected total no.), the independent data and safety monitoring board recommended termination of the trial for futility.  As compared with placebo, dalcetrapib did not alter the risk of the primary end point (cumulative event rate, 8.0% and 8.3%, resp.; hazard ratio with dalcetrapib, 1.04; 95% confidence interval, 0.93 to 1.16; P = 0.52) and did not have a significant effect on any component of the primary end point or total mortality.  The median C-reactive protein level was 0.2 mg per L higher and the mean systolic blood pressure was 0.6 mm Hg higher with dalcetrapib as compared with placebo (P<0.001 for both comparisons).  Conclusions: In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpppAqt1S8zjbVg90H21EOLACvtfcHk0lj5-_zuXjftrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslyltrvK&md5=a9bcd3b77461ed5ef7e14fdbd8101a7b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1206797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1206797%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DG.%2BG.%26aulast%3DOlsson%26aufirst%3DA.%2BG.%26aulast%3DAbt%26aufirst%3DM.%26aulast%3DBallantyne%26aufirst%3DC.%2BM.%26aulast%3DBarter%26aufirst%3DP.%2BJ.%26aulast%3DBrumm%26aufirst%3DJ.%26aulast%3DChaitman%26aufirst%3DB.%2BR.%26aulast%3DHolme%26aufirst%3DI.%2BM.%26aulast%3DKallend%26aufirst%3DD.%26aulast%3DLeiter%26aufirst%3DL.%2BA.%26aulast%3DLeitersdorf%26aufirst%3DE.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%2BV.%26aulast%3DMundl%26aufirst%3DH.%26aulast%3DNicholls%26aufirst%3DS.%2BJ.%26aulast%3DShah%26aufirst%3DP.%2BK.%26aulast%3DTardif%26aufirst%3DJ.-C.%26aulast%3DWright%26aufirst%3DR.%2BS.%26atitle%3DFor%2520the%2520dal-OUTCOMES%2520Investigators.%2520Effects%2520of%2520dalcetrapib%2520in%2520patients%2520with%2520a%2520recent%2520acute%2520coronary%2520syndrome%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D2089%26epage%3D2099%26doi%3D10.1056%2FNEJMoa1206797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="note"><p class="first last">Publications on DPPE derivatives as CETP inhibitors:</p></div><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Harikrishnan, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamau, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adam, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A. Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleph, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitkoff, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galella, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nirschl, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Kirk, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wexler, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, R. M.</span><span> </span><span class="NLM_article-title">DiPhenylPyridylEthanamine (DPPE) derivatives as cholesterol ester transfer protein (CETP) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6162</span><span class="NLM_x">â</span> <span class="NLM_lpage">6175</span><span class="refDoi">Â DOI: 10.1021/jm300611v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300611v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnsl2ms7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6162-6175&author=L.+S.+Harikrishnanauthor=H.+J.+Finlayauthor=J.+X.+Qiaoauthor=M.+G.+Kamauauthor=J.+Jiangauthor=T.+C.+Wangauthor=J.+Liauthor=C.+B.+Cooperauthor=M.+A.+Possauthor=L.+P.+Adamauthor=D.+S.+Taylorauthor=A.+Y.+A.+Chenauthor=X.+Yinauthor=P.+G.+Slephauthor=R.+Z.+Yangauthor=D.+F.+Sitkoffauthor=M.+A.+Galellaauthor=D.+S.+Nirschlauthor=K.+Van+Kirkauthor=A.+V.+Millerauthor=C.+S.+Huangauthor=M.+Changauthor=X.-Q.+Chenauthor=M.+E.+Salvatiauthor=R.+R.+Wexlerauthor=R.+M.+Lawrence&title=DiPhenylPyridylEthanamine+%28DPPE%29+derivatives+as+cholesterol+ester+transfer+protein+%28CETP%29+inhibitors&doi=10.1021%2Fjm300611v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Diphenylpyridylethanamine (DPPE) Derivatives as Cholesteryl Ester Transfer Protein (CETP) Inhibitors</span></div><div class="casAuthors">Harikrishnan, Lalgudi S.; Finlay, Heather J.; Qiao, Jennifer X.; Kamau, Muthoni G.; Jiang, Ji; Wang, Tammy C.; Li, James; Cooper, Christopher B.; Poss, Michael A.; Adam, Leonard P.; Taylor, David S.; Chen, Alice Ye A.; Yin, Xiaohong; Sleph, Paul G.; Yang, Richard Z.; Sitkoff, Doree F.; Galella, Michael A.; Nirschl, David S.; Van Kirk, Katy; Miller, Arthur V.; Huang, Christine S.; Chang, Ming; Chen, Xue-Qing; Salvati, Mark E.; Wexler, Ruth R.; Lawrence, R. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6162-6175</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of phenylpyridylethanamine (DPPE) derivs. I (R1 = H, Cl, F, CN; R2 = 3-F3CC6H4, 3-F3COC6H4, 3-F-5-CF3C6H3, etc.; R3 = H2C:CHCH2, MeO2C, Ph, 2-FC6H4, 1,2,4-triazol-3-yl, etc.; X = t-BuCH2CO2, PhCONH, CypNHCONH, etc.; Cyp = cyclopentyl) and II (R4 = Cl, MeO) was identified exhibiting potent CETP inhibition.  Replacing the labile ester functionality in the initial lead I (R1 = H; R2 = 3-F3CC6H4; R3 = Ph; X = t-BuCH2CO2) generated a series of amides and ureas.  Further optimization of the DPPE series for potency resulted in the discovery of cyclopentylurea (S)-I (R1 = Cl; R2 = 3-CHF2CF2O-5-FC6H4; R3 = Ph; X = CypNHCONH) which demonstrated a redn. in cholesterol ester transfer activity (48% of predose level) in hCETP/apoB-100 dual transgenic mice.  The PK profile of this compd. was suboptimal, and further optimization of the N-terminus resulted in the discovery of amide I (R1 = Cl; R2 = 3-CHF2CF2O-5-FC6H4; R3 = Ph; X = 3-CF3-4-FC6H3CONH) with an improved PK profile and robust efficacy in transgenic hCETP/apoB-100 mice and in hamsters.  The latter compd. demonstrated no significant changes in either mean arterial blood pressure or heart rate in telemeterized rats despite sustained high exposures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtXNZfx82j2LVg90H21EOLACvtfcHk0liKgcDlyh6guA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnsl2ms7c%253D&md5=bfa31186811777ce84c4bbc203accb9f</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1021%2Fjm300611v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300611v%26sid%3Dliteratum%253Aachs%26aulast%3DHarikrishnan%26aufirst%3DL.%2BS.%26aulast%3DFinlay%26aufirst%3DH.%2BJ.%26aulast%3DQiao%26aufirst%3DJ.%2BX.%26aulast%3DKamau%26aufirst%3DM.%2BG.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCooper%26aufirst%3DC.%2BB.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DAdam%26aufirst%3DL.%2BP.%26aulast%3DTaylor%26aufirst%3DD.%2BS.%26aulast%3DChen%26aufirst%3DA.%2BY.%2BA.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DSleph%26aufirst%3DP.%2BG.%26aulast%3DYang%26aufirst%3DR.%2BZ.%26aulast%3DSitkoff%26aufirst%3DD.%2BF.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DNirschl%26aufirst%3DD.%2BS.%26aulast%3DVan%2BKirk%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DA.%2BV.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DX.-Q.%26aulast%3DSalvati%26aufirst%3DM.%2BE.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26atitle%3DDiPhenylPyridylEthanamine%2520%2528DPPE%2529%2520derivatives%2520as%2520cholesterol%2520ester%2520transfer%2520protein%2520%2528CETP%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6162%26epage%3D6175%26doi%3D10.1021%2Fjm300611v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Miller, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nirschl, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harikrishnan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A. Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seethala, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wexler, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adam, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, M. E.</span><span> </span><span class="NLM_article-title">Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6503</span><span class="NLM_x">â</span> <span class="NLM_lpage">6508</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2012.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1016%2Fj.bmcl.2012.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=22995620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlymtLbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6503-6508&author=M.+M.+Millerauthor=Y.+Liuauthor=J.+Jiangauthor=J.+A.+Johnsonauthor=M.+Kamauauthor=D.+S.+Nirschlauthor=Y.+Wangauthor=L.+Harikrishnanauthor=D.+S.+Taylorauthor=A.+Y.+A.+Chenauthor=X.+Yinauthor=R.+Seethalaauthor=T.+L.+Petersonauthor=T.+Zvyagaauthor=J.+Zhangauthor=C.+S.+Huangauthor=R.+R.+Wexlerauthor=M.+A.+Possauthor=R.+M.+Lawrenceauthor=L.+P.+Adamauthor=M.+E.+Salvati&title=Identification+of+a+potent+and+metabolically+stable+series+of+fluorinated+diphenylpyridylethanamine-based+cholesteryl+ester+transfer+protein+inhibitors&doi=10.1016%2Fj.bmcl.2012.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors</span></div><div class="casAuthors">Miller, Michael M.; Liu, Yalei; Jiang, Ji; Johnson, James A.; Kamau, Muthoni; Nirschl, David S.; Wang, Yufeng; Harikrishnan, Lalgudi; Taylor, David S.; Chen, Alice Ye A.; Yin, Xiaohong; Seethala, Ramakrishna; Peterson, Tara L.; Zvyaga, Tatyana; Zhang, Jun; Huang, Christine S.; Wexler, Ruth R.; Poss, Michael A.; Michael Lawrence, R.; Adam, Leonard P.; Salvati, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6503-6508</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of diphenylpyridylethanamine-based inhibitors of cholesteryl ester transfer protein, e.g. I, is described.  Optimization of the urea moiety, particularly by incorporation of fluorine, is explored to balance in vitro metabolic stability with CETP potency in the whole plasma assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNLpqF9RExgLVg90H21EOLACvtfcHk0liKgcDlyh6guA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlymtLbF&md5=6473c4b4e6dbac03d5532e57932aa04c</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DJ.%2BA.%26aulast%3DKamau%26aufirst%3DM.%26aulast%3DNirschl%26aufirst%3DD.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHarikrishnan%26aufirst%3DL.%26aulast%3DTaylor%26aufirst%3DD.%2BS.%26aulast%3DChen%26aufirst%3DA.%2BY.%2BA.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DSeethala%26aufirst%3DR.%26aulast%3DPeterson%26aufirst%3DT.%2BL.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26aulast%3DAdam%26aufirst%3DL.%2BP.%26aulast%3DSalvati%26aufirst%3DM.%2BE.%26atitle%3DIdentification%2520of%2520a%2520potent%2520and%2520metabolically%2520stable%2520series%2520of%2520fluorinated%2520diphenylpyridylethanamine-based%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6503%26epage%3D6508%26doi%3D10.1016%2Fj.bmcl.2012.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="note"><p class="first last">The SPA is an enzymatic assay in which the CETP inhibitory activity was measured as the amount of [<sup>3</sup>H]cholesteryl ester ([<sup>3</sup>H]CE) transferred from HDL ([<sup>3</sup>H]CE/HDL) to biotinylated LDL and captured on avidin-SPA beads. See ref <a onclick="showRef(event, 'cit8a'); return false;" href="javascript:void(0);" class="ref cit8a">8a</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_001.pdf" class="ext-link">Supporting Information</a> for assay details.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="note"><p class="first last">For the transgenic mouse pharmacodynamic study, transgenic mice expressing human CETP and apoB-100 were used. Predose blood samples were collected by retro-orbital bleed. Compounds were formulated in ethanol/Cremophor/water at a 1:1:8 ratio and dosed at 10 mg/kg, po. At 2, 4, and 8 h after dosing, blood samples were collected. Cholesterol ester transfer activity was measured in all blood samples and normalized by the activity measured in the same animal at baseline (mean of four or five mice per dose).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="note"><p class="first last">For the hamster study, plasma HDL-C was measured in male Golden Syrian hamsters initially fed a moderately fat diet (2.5% coconut oil, 0.25% cholesterol) for 2 weeks. The hamsters were then dosed with vehicle or compound, po, q.d. At 2 h after dosing on day 3, plasma samples were obtained and HDL-C was measured and compared to the values measured before dosing.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Wang, T. C.; Qiao, J. X.; Chen, A. Y.; Taylor, D. S.; Yang, R. Z.; Paul, G.; Sleph, P. S.; Li, J. P.; Li, D.; Chang, M.; Chen, X.-Q.; Li, J.; Levesque, P.; Huang, C. S.; Adam, L. P.; Salvati, M. E.; Finlay, H.; Wexler, R. R.</span><span> </span><span class="NLM_article-title">Discovery and synthesis of triphenylethanamine derivatives as highly potent cholesteryl ester transfer protein inhibitors</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 249th National Meeting and Exposition of the American Chemical Society, Denver, CO, U.S., March 22â26, 2015; American Chemical Society: Washington, DC,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>MEDI-78.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=T.+C.+Wang&author=J.+X.+Qiao&author=A.+Y.+Chen&author=D.+S.+Taylor&author=R.+Z.+Yang&author=G.+Paul&author=P.+S.+Sleph&author=J.+P.+Li&author=D.+Li&author=M.+Chang&author=X.-Q.+Chen&author=J.+Li&author=P.+Levesque&author=C.+S.+Huang&author=L.+P.+Adam&author=M.+E.+Salvati&author=H.+Finlay&author=R.+R.+Wexler&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%2BC.%26atitle%3DDiscovery%2520and%2520synthesis%2520of%2520triphenylethanamine%2520derivatives%2520as%2520highly%2520potent%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibitors%26btitle%3DAbstracts%2520of%2520Papers%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kamau, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harikrishnan, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wexler, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, R. M.</span><span> </span><span class="NLM_article-title">Synthesis of tertiary carbinamines</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">2696</span><span class="NLM_x">â</span> <span class="NLM_lpage">2703</span><span class="refDoi">Â DOI: 10.1016/j.tet.2012.01.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1016%2Fj.tet.2012.01.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFSgsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=2696-2703&author=M.+G.+Kamauauthor=L.+S.+Harikrishnanauthor=H.+J.+Finlayauthor=J.+X.+Qiaoauthor=J.+Jiangauthor=M.+A.+Possauthor=M.+E.+Salvatiauthor=R.+R.+Wexlerauthor=R.+M.+Lawrence&title=Synthesis+of+tertiary+carbinamines&doi=10.1016%2Fj.tet.2012.01.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of tertiary carbinamines</span></div><div class="casAuthors">Kamau, Muthoni G.; Harikrishnan, Lalgudi S.; Finlay, Heather J.; Qiao, Jennifer X.; Jiang, Ji; Poss, Michael A.; Salvati, Mark E.; Wexler, Ruth R.; Lawrence, R. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2696-2703</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">An efficient synthesis of tertiary carbinamines using a one-pot, three-component reaction employing TMSCl activation of an intermediate imine salt followed by addn. of an organometallic is described.  E.g., reaction of 3-fluorobenzonitrile with BuLi, followed by treatment with TMSCl and BnMgCl, gave 29% tertiary amine (I).  An optimized second generation chiral synthesis of select tertiary carbinamines utilizing the Ellman sulfinamine was subsequently developed on a multi-gram scale and is also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6ERHpjrNS7bVg90H21EOLACvtfcHk0lhV4Av-102F2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFSgsL0%253D&md5=494845bb5bc38764a8cea6733791209c</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2012.01.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2012.01.050%26sid%3Dliteratum%253Aachs%26aulast%3DKamau%26aufirst%3DM.%2BG.%26aulast%3DHarikrishnan%26aufirst%3DL.%2BS.%26aulast%3DFinlay%26aufirst%3DH.%2BJ.%26aulast%3DQiao%26aufirst%3DJ.%2BX.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DSalvati%26aufirst%3DM.%2BE.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26atitle%3DSynthesis%2520of%2520tertiary%2520carbinamines%26jtitle%3DTetrahedron%26date%3D2012%26volume%3D68%26spage%3D2696%26epage%3D2703%26doi%3D10.1016%2Fj.tet.2012.01.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shaw, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deSolms, S. J.</span><span> </span><span class="NLM_article-title">Asymmetric synthesis of Î±,Î±-diaryl and Î±-aryl-Î±-heteroaryl alkylamines by organometallic additions to <i>N-tert</i>-butanesulfinyl ketimines</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">7173</span><span class="NLM_x">â</span> <span class="NLM_lpage">7176</span><span class="refDoi">Â DOI: 10.1016/S0040-4039(01)01513-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1016%2FS0040-4039%2801%2901513-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2001&pages=7173-7176&author=A.+W.+Shawauthor=S.+J.+deSolms&title=Asymmetric+synthesis+of+%CE%B1%2C%CE%B1-diaryl+and+%CE%B1-aryl-%CE%B1-heteroaryl+alkylamines+by+organometallic+additions+to+N-tert-butanesulfinyl+ketimines&doi=10.1016%2FS0040-4039%2801%2901513-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2901513-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252901513-1%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BW.%26aulast%3DdeSolms%26aufirst%3DS.%2BJ.%26atitle%3DAsymmetric%2520synthesis%2520of%2520%25CE%25B1%252C%25CE%25B1-diaryl%2520and%2520%25CE%25B1-aryl-%25CE%25B1-heteroaryl%2520alkylamines%2520by%2520organometallic%2520additions%2520to%2520N-tert-butanesulfinyl%2520ketimines%26jtitle%3DTetrahedron%2520Lett.%26date%3D2001%26volume%3D42%26spage%3D7173%26epage%3D7176%26doi%3D10.1016%2FS0040-4039%2801%2901513-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Davis, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoull, W.</span><span> </span><span class="NLM_article-title">Concise asymmetric synthesis of Î±-amino acid derivatives from <i>N</i>-sulfinylimino esters</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">3396</span><span class="NLM_x">â</span> <span class="NLM_lpage">3397</span><span class="refDoi">Â DOI: 10.1021/jo990303f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo990303f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=3396-3397&author=F.+A.+Davisauthor=W.+McCoull&title=Concise+asymmetric+synthesis+of+%CE%B1-amino+acid+derivatives+from+N-sulfinylimino+esters&doi=10.1021%2Fjo990303f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Fjo990303f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo990303f%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DF.%2BA.%26aulast%3DMcCoull%26aufirst%3DW.%26atitle%3DConcise%2520asymmetric%2520synthesis%2520of%2520%25CE%25B1-amino%2520acid%2520derivatives%2520from%2520N-sulfinylimino%2520esters%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1999%26volume%3D64%26spage%3D3396%26epage%3D3397%26doi%3D10.1021%2Fjo990303f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Davis, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczyk, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portonovo, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, P. J.</span><span> </span><span class="NLM_article-title">Asymmetric synthesis and properties of sulfinimines (thiooxime <i>S</i>-oxides)</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">2555</span><span class="NLM_x">â</span> <span class="NLM_lpage">2563</span><span class="refDoi">Â DOI: 10.1021/jo970077e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo970077e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADyaK2sXitFyltLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1997&pages=2555-2563&author=F.+A.+Davisauthor=R.+E.+Reddyauthor=J.+M.+Szewczykauthor=G.+V.+Reddyauthor=P.+S.+Portonovoauthor=H.+Zhangauthor=D.+Fanelliauthor=R.+T.+Reddyauthor=P.+Zhouauthor=P.+J.+Carroll&title=Asymmetric+synthesis+and+properties+of+sulfinimines+%28thiooxime+S-oxides%29&doi=10.1021%2Fjo970077e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric Synthesis and Properties of Sulfinimines (Thiooxime S-Oxides)</span></div><div class="casAuthors">Davis, Franklin A.; Reddy, Rajarathnam E.; Szewczyk, Joanna M.; Reddy, G. Venkat; Portonovo, Padma S.; Zhang, Huiming; Fanelli, Dean; Reddy, Thimma; Zhou, Ping; Carroll, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2555-2563</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Enantiomerically pure sulfinimines (thiooxime S-oxides), important building blocks in the asym. synthesis of amine derivs., are prepd. in good to excellent yields in one step from arom., heteroarom., and aliph. aldehydes.  This protocol involves treating com. available (R)- or (S)-menthyl p-toluenesufinate (Andersen reagent, I) with LiHMDS, followed by the aldehyde, affording the (E)-sulfinimine exclusively.  The sulfinimines are formed via a Peterson-type olefination reaction of silylsulfinamide anion with the aldehyde.  The silylsulfinamide anion is generated by reaction of lithium menthoxide with bis(trimethylsilyl)sulfinamide, which is formed in the reaction of I with LiHMDS.  The other product formed is O-(trimethylsilyl)menthol, which is isolated in >80% yield for recycling.  Two other less efficient methods for the asym. synthesis of sulfinimines are discussed: (i) the asym. oxidn. of sulfenimines with chiral nonracemic oxaziridines and (ii) the reaction of metal aldimines, prepd. from nitriles, with I.  All of these protocols fail with ketones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUwFtcNvzVAbVg90H21EOLACvtfcHk0lhV4Av-102F2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXitFyltLs%253D&md5=6950e2cc3cefe2884e88ac1eec86d630</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1021%2Fjo970077e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo970077e%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DF.%2BA.%26aulast%3DReddy%26aufirst%3DR.%2BE.%26aulast%3DSzewczyk%26aufirst%3DJ.%2BM.%26aulast%3DReddy%26aufirst%3DG.%2BV.%26aulast%3DPortonovo%26aufirst%3DP.%2BS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DFanelli%26aufirst%3DD.%26aulast%3DReddy%26aufirst%3DR.%2BT.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DCarroll%26aufirst%3DP.%2BJ.%26atitle%3DAsymmetric%2520synthesis%2520and%2520properties%2520of%2520sulfinimines%2520%2528thiooxime%2520S-oxides%2529%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1997%26volume%3D62%26spage%3D2555%26epage%3D2563%26doi%3D10.1021%2Fjo970077e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ellman, J. A.</span><span> </span><span class="NLM_article-title">Applications of <i>tert</i>-butanesulfinamide in the asymmetric synthesis of amines</span> <span class="citation_source-journal">Pure Appl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">â</span> <span class="NLM_lpage">46</span><div class="note"><p class="first last">and references therein</p></div><span class="refDoi">Â DOI: 10.1351/pac200375010039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1351%2Fpac200375010039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1Sisr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2003&pages=39-46&author=J.+A.+Ellman&title=Applications+of+tert-butanesulfinamide+in+the+asymmetric+synthesis+of+amines&doi=10.1351%2Fpac200375010039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of tert-butanesulfinamide in the asymmetric synthesis of amines</span></div><div class="casAuthors">Ellman, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Pure and Applied Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-46</span>CODEN:
                <span class="NLM_cas:coden">PACHAS</span>;
        ISSN:<span class="NLM_cas:issn">0033-4545</span>.
    
            (<span class="NLM_cas:orgname">International Union of Pure and Applied Chemistry</span>)
        </div><div class="casAbstract">A review.  Tert-Butanesulfinamide (2-methyl-2-propanesulfinamide) is prepd. using catalytic enantioselective methods in two steps from the extremely inexpensive oil waste byproduct, tert-Bu disulfide.  Direct condensation of tert-butanesulfinamide with aldehydes and ketones provides tert-butanesulfinyl imines in uniformly high yields.  The tert-butanesulfinyl group activates the imines for the addn. of many different classes of nucleophiles, serves as a powerful chiral directing group, and after nucleophilic addn. is readily cleaved by treatment with acid.  A wide range of highly enantioenriched amines, including a-branched and Î±,Î±-dibranched amines, Î±- and Î²-amino acids, 1,2- and 1,3-amino alcs. and Î±-trifluoromethyl amines are efficiently synthesized using this methodol.  A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreXHI36VE2U7Vg90H21EOLACvtfcHk0li9IND4Rg7iAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1Sisr8%253D&md5=d4f9b92b02e94084e0ca0285ecb30af3</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1351%2Fpac200375010039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1351%252Fpac200375010039%26sid%3Dliteratum%253Aachs%26aulast%3DEllman%26aufirst%3DJ.%2BA.%26atitle%3DApplications%2520of%2520tert-butanesulfinamide%2520in%2520the%2520asymmetric%2520synthesis%2520of%2520amines%26jtitle%3DPure%2520Appl.%2520Chem.%26date%3D2003%26volume%3D75%26spage%3D39%26epage%3D46%26doi%3D10.1351%2Fpac200375010039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span>Full crystallographic data have been deposited with the Cambridge Crystallographic Data Center under CCDC reference number 1422275. Copies of the data can be obtained free of charge via the Internet at <a href="http://www.ccdc.cam.ac.uk" class="extLink">http://www.ccdc.cam.ac.uk</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Full+crystallographic+data+have+been+deposited+with+the+Cambridge+Crystallographic+Data+Center+under+CCDC+reference+number+1422275.+Copies+of+the+data+can+be+obtained+free+of+charge+via+the+Internet+at+http%3A%2F%2Fwww.ccdc.cam.ac.uk."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnananthan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.-C.</span><span> </span><span class="NLM_article-title">Preparation of monofluorophenols via the reaction of difluorobenzene derivatives with potassium trimethylsilanoate</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2009</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">633</span><span class="NLM_x">â</span> <span class="NLM_lpage">637</span><span class="refDoi">Â DOI: 10.1055/s-0028-1087564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1055%2Fs-0028-1087564" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2009&publication_year=2009&pages=633-637&issue=4&author=J.+Liauthor=D.+Smithauthor=J.+X.+Qiaoauthor=S.+Huangauthor=S.+Krishnananthanauthor=H.+S.+Wongauthor=M.+E.+Salvatiauthor=B.+N.+Balasubramanianauthor=B.-C.+Chen&title=Preparation+of+monofluorophenols+via+the+reaction+of+difluorobenzene+derivatives+with+potassium+trimethylsilanoate&doi=10.1055%2Fs-0028-1087564"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1055%2Fs-0028-1087564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0028-1087564%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DQiao%26aufirst%3DJ.%2BX.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DKrishnananthan%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DH.%2BS.%26aulast%3DSalvati%26aufirst%3DM.%2BE.%26aulast%3DBalasubramanian%26aufirst%3DB.%2BN.%26aulast%3DChen%26aufirst%3DB.-C.%26atitle%3DPreparation%2520of%2520monofluorophenols%2520via%2520the%2520reaction%2520of%2520difluorobenzene%2520derivatives%2520with%2520potassium%2520trimethylsilanoate%26jtitle%3DSynlett%26date%3D2009%26volume%3D2009%26issue%3D4%26spage%3D633%26epage%3D637%26doi%3D10.1055%2Fs-0028-1087564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberge, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, B. N.</span><span> </span><span class="NLM_article-title">A practical synthesis of aryl tetrafluoroethyl ethers via the improved reaction of phenols with 1,2-dibromotetrafluoroethane</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7516</span><span class="NLM_x">â</span> <span class="NLM_lpage">7519</span><span class="refDoi">Â DOI: 10.1016/j.tetlet.2007.08.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1016%2Fj.tetlet.2007.08.065" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=7516-7519&author=J.+Liauthor=J.+X.+Qiaoauthor=D.+Smithauthor=B.-C.+Chenauthor=M.+E.+Salvatiauthor=J.+Y.+Robergeauthor=B.+N.+Balasubramanian&title=A+practical+synthesis+of+aryl+tetrafluoroethyl+ethers+via+the+improved+reaction+of+phenols+with+1%2C2-dibromotetrafluoroethane&doi=10.1016%2Fj.tetlet.2007.08.065"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2007.08.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2007.08.065%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DQiao%26aufirst%3DJ.%2BX.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DB.-C.%26aulast%3DSalvati%26aufirst%3DM.%2BE.%26aulast%3DRoberge%26aufirst%3DJ.%2BY.%26aulast%3DBalasubramanian%26aufirst%3DB.%2BN.%26atitle%3DA%2520practical%2520synthesis%2520of%2520aryl%2520tetrafluoroethyl%2520ethers%2520via%2520the%2520improved%2520reaction%2520of%2520phenols%2520with%25201%252C2-dibromotetrafluoroethane%26jtitle%3DTetrahedron%2520Lett.%26date%3D2007%26volume%3D48%26spage%3D7516%26epage%3D7519%26doi%3D10.1016%2Fj.tetlet.2007.08.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McKinley, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, D. F.</span><span> </span><span class="NLM_article-title">Efficient synthesis of aryl vinyl ethers exploiting 2,4,6-trivinylcyclotriboroxane as a vinylboronic acid equivalent</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">5087</span><span class="NLM_x">â</span> <span class="NLM_lpage">5092</span><span class="refDoi">Â DOI: 10.1021/jo049314l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo049314l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVKrsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=5087-5092&author=N.+F.+McKinleyauthor=D.+F.+O%E2%80%99Shea&title=Efficient+synthesis+of+aryl+vinyl+ethers+exploiting+2%2C4%2C6-trivinylcyclotriboroxane+as+a+vinylboronic+acid+equivalent&doi=10.1021%2Fjo049314l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient Synthesis of Aryl Vinyl Ethers Exploiting 2,4,6-Trivinylcyclotriboroxane as a Vinylboronic Acid Equivalent</span></div><div class="casAuthors">McKinley, Neola F.; O'Shea, Donal F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5087-5092</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of functionalized aryl vinyl ether derivs. can be readily achieved utilizing a room-temp. copper(II) acetate mediated coupling of substituted phenols with 2,4,6-trivinylcyclotriboroxane-pyridine complex in the presence of a suitable base.  The scope of the procedure was demonstrated by the generation of an array of substituted aryl vinyl ethers.  The reaction was seen to be tolerant of a diverse range of functional groups yielding products in high isolated yields.  It was shown that one role of an amine base in the reaction sequence is the in situ generation of an amine-coordinated boroxine ring.  An X-ray crystal structure and low temp. 11B NMR study of 2,4,6-trivinylcyclotriboroxane-pyridine complex demonstrated the nature of a tetracoordinate boron species, which may have a key role to play within the reaction sequence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCAdAkCsZPNLVg90H21EOLACvtfcHk0li9IND4Rg7iAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVKrsLY%253D&md5=13e595af6da99007cd4d6ea25a6b1633</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1021%2Fjo049314l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo049314l%26sid%3Dliteratum%253Aachs%26aulast%3DMcKinley%26aufirst%3DN.%2BF.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DD.%2BF.%26atitle%3DEfficient%2520synthesis%2520of%2520aryl%2520vinyl%2520ethers%2520exploiting%25202%252C4%252C6-trivinylcyclotriboroxane%2520as%2520a%2520vinylboronic%2520acid%2520equivalent%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D5087%26epage%3D5092%26doi%3D10.1021%2Fjo049314l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Okimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, Y.</span><span> </span><span class="NLM_article-title">Development of a highly efficient catalytic method for synthesis of vinyl ethers</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">1590</span><span class="NLM_x">â</span> <span class="NLM_lpage">1591</span><span class="refDoi">Â DOI: 10.1021/ja0173932</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0173932" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD38Xps1Wluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=1590-1591&author=Y.+Okimotoauthor=S.+Sakaguchiauthor=Y.+Ishii&title=Development+of+a+highly+efficient+catalytic+method+for+synthesis+of+vinyl+ethers&doi=10.1021%2Fja0173932"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Highly Efficient Catalytic Method for Synthesis of Vinyl Ethers</span></div><div class="casAuthors">Okimoto, Yoshio; Sakaguchi, Satoshi; Ishii, Yasutaka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1590-1591</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new method for the prepn. of alkyl vinyl ethers has been developed.  Thus, vinyl ethers ROCH:CH2 (R = Octyl, PhCH2, PhCHMe, Menthyl, Adamant-1-yl, Ph) were synthesized by the reaction of alcs. with vinyl acetate under the influence of a catalytic amt. of [Ir(cod)Cl]2 combined with Na2CO3 in good to excellent yields.  Similarly, divinyl ethers, e.g. CH2:CHOCH2(CH2)4CH2OCH:CH2 were also prepd. from the corresponding diols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrwt0CyT1Lv7Vg90H21EOLACvtfcHk0ljEi6aUpKWD4Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xps1Wluw%253D%253D&md5=23521ecc37aebf765c9f50810c7b2c08</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1021%2Fja0173932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0173932%26sid%3Dliteratum%253Aachs%26aulast%3DOkimoto%26aufirst%3DY.%26aulast%3DSakaguchi%26aufirst%3DS.%26aulast%3DIshii%26aufirst%3DY.%26atitle%3DDevelopment%2520of%2520a%2520highly%2520efficient%2520catalytic%2520method%2520for%2520synthesis%2520of%2520vinyl%2520ethers%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26spage%3D1590%26epage%3D1591%26doi%3D10.1021%2Fja0173932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><div class="note"><p class="first last">CETP facilitates the removal of cholesteryl esters (CE) from HDL and thus reduces HDL-C levels, while PLTP promotes the transfer of phospholipids (PL) from triglyceride-rich lipoproteins into HDL and increases HDL-C levels. PLTP activity was measured as described previously</p></div> ( <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">907</span><span class="NLM_x">â</span> <span class="NLM_lpage">914</span>) <div class="note"><p class="first last">with modifications. See <a href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_001.pdf" class="ext-link">Supporting Information</a> for more details.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CETP+facilitates+the+removal+of+cholesteryl+esters+%28CE%29+from+HDL+and+thus+reduces+HDL-C+levels%2C+while+PLTP+promotes+the+transfer+of+phospholipids+%28PL%29+from+triglyceride-rich+lipoproteins+into+HDL+and+increases+HDL-C+levels.+PLTP+activity+was+measured+as+described+previously+%28J.+Clin.+Invest.+1999%2C+103%2C+907%E2%80%93914%29+with+modifications.+See+Supporting+Information+for+more+details."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1999%26volume%3D103%26spage%3D907%26epage%3D914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="note"><p class="first last">Lipoprotein disruption assay: Lipoprotein disruption components (human origin, Biomedical Technologies, Inc.) were diluted in assay buffer [50 mM HEPEs (pH 7.4), 150 mM NaCl, 0.05% NaN<sub>3</sub> (w/v)] to concentrations utilized in the aforementioned SPA assay. LDL and HDL were diluted to 5 and 16 Î¼g/mL, respectively. In-house generated [<sup>3</sup>H]cholesterol ester-HDL was diluted 30-fold in the reaction mix which was subsequently incubated in the absence and presence of CETP inhibitors for 4 h at 37 Â°C. Lipoprotein associated [<sup>3</sup>H]cholesterol ester was resolved by agarose gel electrophoresis and imaged by quantitative phosphor imaging autoradiography.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="note"><p class="first last">Tg WPA: Measurement of cholesterol ester transfer activity in plasma samples obtained from compound-treated human CETP/apoB100 dual transgenic mice (Taconic Laboratories) was obtained following the described variation of the hWPA methodology. See <a href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_001.pdf" class="ext-link">Supporting Information</a> for details.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Lloyd, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lira, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durham, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preston, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnette, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanzetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milos, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, J. F.</span><span> </span><span class="NLM_article-title">Cholesteryl ester transfer protein variants have differential stability but uniform inhibition by torcetrapib</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">14918</span><span class="NLM_x">â</span> <span class="NLM_lpage">14922</span><span class="refDoi">Â DOI: 10.1074/jbc.M500523200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1074%2Fjbc.M500523200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=14918-14922&author=D.+B.+Lloydauthor=M.+E.+Liraauthor=L.+S.+Woodauthor=L.+K.+Durhamauthor=T.+B.+Freemanauthor=G.+M.+Prestonauthor=X.+Qiuauthor=E.+Sugarmanauthor=P.+Bonnetteauthor=A.+Lanzettiauthor=P.+M.+Milosauthor=J.+F.+Thompson&title=Cholesteryl+ester+transfer+protein+variants+have+differential+stability+but+uniform+inhibition+by+torcetrapib&doi=10.1074%2Fjbc.M500523200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M500523200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M500523200%26sid%3Dliteratum%253Aachs%26aulast%3DLloyd%26aufirst%3DD.%2BB.%26aulast%3DLira%26aufirst%3DM.%2BE.%26aulast%3DWood%26aufirst%3DL.%2BS.%26aulast%3DDurham%26aufirst%3DL.%2BK.%26aulast%3DFreeman%26aufirst%3DT.%2BB.%26aulast%3DPreston%26aufirst%3DG.%2BM.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DSugarman%26aufirst%3DE.%26aulast%3DBonnette%26aufirst%3DP.%26aulast%3DLanzetti%26aufirst%3DA.%26aulast%3DMilos%26aufirst%3DP.%2BM.%26aulast%3DThompson%26aufirst%3DJ.%2BF.%26atitle%3DCholesteryl%2520ester%2520transfer%2520protein%2520variants%2520have%2520differential%2520stability%2520but%2520uniform%2520inhibition%2520by%2520torcetrapib%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D14918%26epage%3D14922%26doi%3D10.1074%2Fjbc.M500523200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="note"><p class="first last">A survey of the literature reports from 1950 to 2004 on BP studies in different animal species showed that rats were the most widely used animal species for preclinical BP study. It is believed that common mechanisms might affect BP in rats and humans and it might be predictive for BP effects in human. In our in-house telemeterized mice studies, BP and HR effects of various known clinical agents were reproduced in telemetry rats at clinically relevant doses/exposures; sensitivity to detect â¥5â10% changes.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c','cit1aa','cit1bb','cit1cc'],'ref2':['cit2'],'ref3':['cit3a','cit3aa'],'ref4':['cit4a','cit4b','cit4c'],'ref5':['cit5a','cit5b','cit5c'],'ref6':['cit6a','cit6b','cit6c','cit6d','cit6e','cit6f'],'ref7':['cit7'],'ref8':['cit8a','cit8b'],'ref9':[],'ref10':[],'ref11':[],'ref12':['cit12'],'ref13':['cit13a','cit13b'],'ref14':['cit14a','cit14b','cit14c'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18a','cit18b'],'ref19':['cit19'],'ref20':[],'ref21':[],'ref22':['cit22'],'ref23':[]}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Heather J. Finlay, Ji Jiang, Richard Rampulla, Mark E. Salvati, Jennifer X. Qiao, Tammy C. Wang, R. Michael Lawrence, Lalgudi S. Harikrishnan, Muthoni G. Kamau, David S. Taylor, Alice Ye A. Chen, Xiaohong Yin, Christine S. Huang, Ming Chang, Xue-Qing Chen, Paul G. Sleph, Carrie Xu, Julia Li, Paul Levesque, Leonard P. Adam, <span class="NLM_string-name hlFld-ContribAuthor">Ruth R. Wexler</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Lead Triphenylethanamine Cholesterol Ester Transfer Protein (CETP) Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (6)
                                     , 911-916. <a href="https://doi.org/10.1021/acsmedchemlett.9b00086" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00086</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00086%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BLead%252BTriphenylethanamine%252BCholesterol%252BEster%252BTransfer%252BProtein%252B%252528CETP%252529%252BInhibitor%26aulast%3DFinlay%26aufirst%3DHeather%2BJ.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D04032019%26date%3D30042019%26date%3D06052019%26volume%3D10%26issue%3D6%26spage%3D911%26epage%3D916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Venkat R.  Chirasani</span>, <span class="hlFld-ContribAuthor ">Revathi  Sankar</span>, and <span class="hlFld-ContribAuthor ">Sanjib  Senapati</span>  . </span><span class="cited-content_cbyCitation_article-title">Mechanism of Inhibition of Cholesteryl Ester Transfer Protein by Small Molecule Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Physical Chemistry B</span><span> <strong>2016,</strong> <em>120 </em>
                                    (33)
                                     , 8254-8263. <a href="https://doi.org/10.1021/acs.jpcb.6b01928" title="DOI URL">https://doi.org/10.1021/acs.jpcb.6b01928</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jpcb.6b01928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jpcb.6b01928%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Physical%2520Chemistry%2520B%26atitle%3DMechanism%252Bof%252BInhibition%252Bof%252BCholesteryl%252BEster%252BTransfer%252BProtein%252Bby%252BSmall%252BMolecule%252BInhibitors%26aulast%3DChirasani%26aufirst%3DVenkat%2BR.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D25022016%26date%3D20042016%26date%3D04052016%26date%3D25082016%26date%3D25042016%26volume%3D120%26issue%3D33%26spage%3D8254%26epage%3D8263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wilson Alberto  TÃ¡rraga</span>, <span class="hlFld-ContribAuthor ">Horacio Alberto  Garda</span>, <span class="hlFld-ContribAuthor ">Juan Domingo  Toledo</span>, <span class="hlFld-ContribAuthor ">Marina Cecilia  Gonzalez</span>. </span><span class="cited-content_cbyCitation_article-title">Potential Inhibitors of the Activity of the Cholesterol-Ester Transfer Protein. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computational Biology</span><span> <strong>2019,</strong> <em>26 </em>
                                    (12)
                                     , 1458-1469. <a href="https://doi.org/10.1089/cmb.2018.0227" title="DOI URL">https://doi.org/10.1089/cmb.2018.0227</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1089/cmb.2018.0227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1089%2Fcmb.2018.0227%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computational%2520Biology%26atitle%3DPotential%252BInhibitors%252Bof%252Bthe%252BActivity%252Bof%252Bthe%252BCholesterol-Ester%252BTransfer%252BProtein%26aulast%3DT%25C3%25A1rraga%26aufirst%3DWilson%2BAlberto%26date%3D2019%26volume%3D26%26issue%3D12%26spage%3D1458%26epage%3D1469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Melissa A.  Herbage</span>, <span class="hlFld-ContribAuthor ">Jolaine  Savoie</span>, <span class="hlFld-ContribAuthor ">Joshua D.  Sieber</span>, <span class="hlFld-ContribAuthor ">Jean-Nicolas  Desrosiers</span>, <span class="hlFld-ContribAuthor ">Yongda  Zhang</span>, <span class="hlFld-ContribAuthor ">Maurice A.  Marsini</span>, <span class="hlFld-ContribAuthor ">Keith R.  Fandrick</span>, <span class="hlFld-ContribAuthor ">Daniel  Rivalti</span>, <span class="hlFld-ContribAuthor ">Chris H.  Senanayake</span>. </span><span class="cited-content_cbyCitation_article-title">Addition of Non-Stabilized Carbon-Based Nucleophilic Reagents to Chiral
              N
              -Sulfinyl Imines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 1-422. <a href="https://doi.org/10.1002/0471264180.or099.01" title="DOI URL">https://doi.org/10.1002/0471264180.or099.01</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471264180.or099.01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471264180.or099.01%26sid%3Dliteratum%253Aachs%26atitle%3DAddition%252Bof%252BNon-Stabilized%252BCarbon-Based%252BNucleophilic%252BReagents%252Bto%252BChiral%252BN%252B-Sulfinyl%252BImines%26aulast%3DHerbage%26aufirst%3DMelissa%2BA.%26date%3D2019%26date%3D2019%26spage%3D1%26epage%3D422%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DOrganic%252BReactions%26date%3D2004%26date%3D2004%26volume%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xue-Qing  Chen</span>, <span class="hlFld-ContribAuthor ">Theresa  Ziemba</span>, <span class="hlFld-ContribAuthor ">Christine  Huang</span>, <span class="hlFld-ContribAuthor ">Ming  Chang</span>, <span class="hlFld-ContribAuthor ">Carrie  Xu</span>, <span class="hlFld-ContribAuthor ">Jennifer X.  Qiao</span>, <span class="hlFld-ContribAuthor ">Tammy C.  Wang</span>, <span class="hlFld-ContribAuthor ">Heather J.  Finlay</span>, <span class="hlFld-ContribAuthor ">Mark E.  Salvati</span>, <span class="hlFld-ContribAuthor ">Leonard P.  Adam</span>, <span class="hlFld-ContribAuthor ">Olafur  Gudmundsson</span>, <span class="hlFld-ContribAuthor ">Michael J.  Hageman</span>. </span><span class="cited-content_cbyCitation_article-title">Oral Delivery of Highly Lipophilic, Poorly Water-Soluble Drugs: Self-Emulsifying Drug Delivery Systems to Improve Oral AbsorptionÂ and Enable High-Dose Toxicology Studies of a CholesterylÂ Ester Transfer Protein Inhibitor in Preclinical Species. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical Sciences</span><span> <strong>2018,</strong> <em>107 </em>
                                    (5)
                                     , 1352-1360. <a href="https://doi.org/10.1016/j.xphs.2018.01.003" title="DOI URL">https://doi.org/10.1016/j.xphs.2018.01.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.xphs.2018.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.xphs.2018.01.003%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DOral%252BDelivery%252Bof%252BHighly%252BLipophilic%25252C%252BPoorly%252BWater-Soluble%252BDrugs%25253A%252BSelf-Emulsifying%252BDrug%252BDelivery%252BSystems%252Bto%252BImprove%252BOral%252BAbsorption%2525C2%2525A0and%252BEnable%252BHigh-Dose%252BToxicology%252BStudies%252Bof%252Ba%252BCholesteryl%2525C2%2525A0Ester%252BTransfer%252BProtein%252BInhibitor%252Bin%252BPreclinical%252BSpecies%26aulast%3DChen%26aufirst%3DXue-Qing%26date%3D2018%26volume%3D107%26issue%3D5%26spage%3D1352%26epage%3D1360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Venkat R.  Chirasani</span>, <span class="hlFld-ContribAuthor ">Sanjib  Senapati</span>. </span><span class="cited-content_cbyCitation_article-title">How cholesteryl ester transfer protein can also be a potential triglyceride transporter. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2017,</strong> <em>7 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-017-05449-z" title="DOI URL">https://doi.org/10.1038/s41598-017-05449-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-017-05449-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-017-05449-z%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DHow%252Bcholesteryl%252Bester%252Btransfer%252Bprotein%252Bcan%252Balso%252Bbe%252Ba%252Bpotential%252Btriglyceride%252Btransporter%26aulast%3DChirasani%26aufirst%3DVenkat%2BR.%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tammy C.  Wang</span>, <span class="hlFld-ContribAuthor ">Jennifer X.  Qiao</span>. </span><span class="cited-content_cbyCitation_article-title">Microwave-assisted transamidation of ureas. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2016,</strong> <em>57 </em>
                                    (18)
                                     , 1941-1943. <a href="https://doi.org/10.1016/j.tetlet.2016.02.103" title="DOI URL">https://doi.org/10.1016/j.tetlet.2016.02.103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2016.02.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2016.02.103%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DMicrowave-assisted%252Btransamidation%252Bof%252Bureas%26aulast%3DWang%26aufirst%3DTammy%2BC.%26date%3D2016%26volume%3D57%26issue%3D18%26spage%3D1941%26epage%3D1943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) CETP inhibitors <b>1</b>â<b>4</b> that have entered phase III clinical trials. (B) Diphenylpyridylethanamine (DPPE) lead <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>n-</i>BuLi (2.5 M in hexanes, 1.1 equiv), Et<sub>2</sub>O, â78 Â°C, 30 min, 4-fluoro-3-(trifluoromethyl)benzonitrile (1.0 equiv), â78 Â°C, 2 h, TMSCl, THF, â78 Â°C to rt, 2 h; BnMgBr (2.0 M in THF, 2 equiv), â78 Â°C to rt, 16 h, 1 N HCl, 19â87%; (b) NCO-cyclopentyl, 1,4-dioxane, 16 h, 55â67%; (c) chiral preparative HPLC, AD column (10% isopropanol/heptane/0.1% DEA, isocratic); <b>8c</b>, fast eluting, 44%; <b>8b</b>, slow eluting, 42%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>n</i>-BuLi, 4-fluorobenzonitrile, Et<sub>2</sub>O, â78 Â°C, then 1 N HCl, 87%; (b) (<i>R</i>)-(+)-2-methylpropane-2-sulfinamide, Ti(OEt)<sub>4</sub>, THF, reflux, 81%; (c) BnMgBr (1.0 M in Et<sub>2</sub>O, 2 equiv), BF<sub>3</sub>Â·Et<sub>2</sub>O (2 equiv), â78 Â°C, 1.5 h, CH<sub>2</sub>Cl<sub>2</sub>, dr (<i>R</i>,<i>R</i>s)-<b>17</b>/(<i>S</i>,<i>R</i>s)-<b>17</b> = 5.3:1, isolated yield for (<i>R</i>,<i>R</i>s)-<b>17</b>, 81%; (d) 4 N HCl in dioxane, MeOH, 82%; (e) NCO-cyclopentyl, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 70%; (f) 4-fluoro-3-(trifluoromethyl)benzoyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 5 h, 95%; (g) <i>p</i>-nitrophenyl chloroformate, K<sub>2</sub>CO<sub>3</sub>, THF, rt; then (1<i>S</i>)-3,3-difluorocyclopentan-1-amine,<a onclick="showRef(event, 'cit8b'); return false;" href="javascript:void(0);" class="ref cit8b">(8b)</a> DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, SFC separation, 35%; (h) 4,4,4-trifluorobutanoic acid, PyBOP, <i>N</i>-methylmorpholine, CH<sub>2</sub>Cl<sub>2</sub>, rt, 8 h, 66%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0010.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>tert</i>-butyldiphenylsilyl chloride, imidazole, 0 Â°C to rt, 18 h, 58%; (b) <i>n</i>-BuLi (2.5 M in hexanes, 1.1 equiv), Et<sub>2</sub>O, â78 Â°C, 30 min; 4-fluoro-3-trifluoromethylbenzonitrile, â78 Â°C, 1.5 h; 1 N HCl, 79%; (c) (<i>S</i>)-(â)-2-methylpropane-2-sulfinamide, Ti(OEt)<sub>4</sub>, THF, reflux, 83%; (d) BF<sub>3</sub>Â·Et<sub>2</sub>O (2 equiv), BnMgCl in Et<sub>2</sub>O (2.8 equiv), CH<sub>2</sub>Cl<sub>2</sub>, â78 Â°C, dr, (<i>R</i>,<i>S</i>s)-<b>23</b>/(<i>S</i>,<i>S</i>s)-<b>23</b> = 5:1, yield for (<i>R</i>,<i>S</i>s)-<b>23</b>, 62%; (e) 4 N HCl dioxane/MeOH; (f) isopropenyl chloroformate, K<sub>2</sub>CO<sub>3</sub>, THF/H<sub>2</sub>O, rt, 4 h; (g) NH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>, <i>N</i>-methylpyrrolidine (cat.), THF/DMSO, microwave irradiation, 180 Â°C, 20 min, 82% for 3 steps; (h) TBAF, THF, 0 Â°C, 45 min, 77%; (i) ICF<sub>2</sub>CF<sub>2</sub>H, K<sub>2</sub>CO<sub>3</sub>, DMSO, 70 Â°C, 16 h, 58%.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0011.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) KOSiMe<sub>3</sub> (3.5 equiv), diglyme, 120 Â°C, 5 h, 92%; (b) BrCF<sub>2</sub>CF<sub>2</sub>Br, DMSO, Cs<sub>2</sub>CO<sub>3</sub> (1.5 equiv), 50 Â°C, 5 h, 94%; (c) Zn, HOAc, 50 Â°C, 1 h, 87%.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0012.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 Â°C to rt, 2 h, 100%; (b) ethyl iodide, K<sub>2</sub>CO<sub>3</sub>, 50 Â°C, DMF, 90%; (c) isopropyl iodide, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 Â°C, 16 h, 86%; (d) 1,1-di-<i>tert</i>-butoxy-<i>N</i>,<i>N</i>-dimethylmethanamine, DMF, 110 Â°C, 5 h, 81%; (e) ethyl 2-bromopropanoate, K<sub>2</sub>CO<sub>3</sub>, rt, 16 h, then NaBH<sub>4</sub>, THF, 0 Â°C to rt, 16 h, 27% for 2 steps; (f) 2,4,6-trivinylcyclotriboroxaneâpyridine complex, Cu(OAc)<sub>2</sub>, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 days, 93%; (g) ethenyl acetate, [Ir(COD)Cl]<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, toluene, 100 Â°C, 77%; (h) 2-chloroethyl 4-methylbenzene-1-sulfonate (1.75 equiv), Cs<sub>2</sub>CO<sub>3</sub> (1.1 equiv), Triton X-405 (5% w/w), THF; KO-<i>t</i>-Bu (5 equiv), 0â7 Â°C, 76â80% for 2 steps; (i) Et<sub>2</sub>Zn, TFA, CH<sub>2</sub>I<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, â10 Â°C to rt, 78â83%.</p></p></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0013.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PEPPSI-IPr (0.2 equiv), isobutylzinc(II) bromide (6 equiv), NMP, THF, 75 Â°C, 2 h, rt, 3 days, 36%; (b) 4-fluoro-3-(trifluoromethyl)benzoyl chloride, Na<sub>2</sub>CO<sub>3</sub>, THF, rt, 2 h, 48%; (b) cyclopropylboronic acid, palladium(II) acetate (5 mol %), tricyclohexylphosphine (10 mol %), K<sub>3</sub>PO<sub>4</sub>, toluene, 100 Â°C, microwave irradiation, 15 min, 30%; (d) 1,1-di-<i>tert</i>-butoxy-<i>N</i>,<i>N</i>-dimethylmethanamine; (e) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 175 Â°C, 90%; (f) NaBH<sub>4</sub>, NiCl<sub>2</sub>, Boc<sub>2</sub>O, MeOH, 0 Â°C to rt, 6 h, 85%; (g) DessâMartin periodinane, CH<sub>2</sub>Cl<sub>2</sub>/H<sub>2</sub>O, rt, 3 h, 33%; (h) (<i>R</i>)-(+)-2-methylpropane-2-sulfinamide, Ti(OEt)<sub>4</sub>, THF, 75 Â°C, 16 h, 58%; (i) BF<sub>3</sub>.OEt<sub>2</sub> (2 equiv), BnMgCl (3 equiv), CH<sub>2</sub>Cl<sub>2</sub>, â78 Â°C to rt, 3 h; (j) 4 N HCl, dioxane/MeOH; (k) (Boc)<sub>2</sub>O, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 Â°C, 1.5 h, 72% for 3 steps; (l) 4-fluoro-3-(trifluoromethyl)benzoyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 Â°C to rt, 16 h, 91%; (m) 1 N HCl/Et<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h; (n) formaldehyde, NaCNBH<sub>3</sub>, AcOH, MeOH, rt, 1 h, 33% for two steps.</p></p></figure><figure data-id="fig2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Elevation in HDL-C for compounds <b>9d</b>, <b>9e</b>, <b>1</b>, and <b>5</b> in moderately fat-fed hamsters. (A) Plasma HDL-C and (B) percent changes in HDL-C after dosing compounds (po, q.d.) for 3 days. Vehicle: EtOH/Cremophor/water, 1/1/8. Plasma was obtained before dosing and 2 h after the last dose (48 h after the initiation of dosing) to determine the effects of drug treatment on HDL-C levels. HDL-C levels were measured using an automated lipid analyzer (Lipi+plus from Polymedco on a COBAS MIRA chemistry analyzer): (âââ) <i>p</i> < 0.001, (ââ) <i>p</i> < 0.01, (â) <i>p</i> < 0.05 vs vehicle (<i>n</i> = 6/group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Inhibition of plasma CE transfer activity by compound <b>10g</b> (1 and 3 mg/kg) and compound <b>1</b> (10 mg/kg) in Tg mice. (B) Exposure levels of <b>10g</b> (dose, 3 mg/kg <b>10g</b> in blue, 1 mg/kg of <b>10g</b> in red) and <b>1</b> (dose, 10 mg/kg in black), respectively, in Tg mice studies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0005.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Effect of compound <b>10g</b> (3 and 10 mg/kg, po) and compound <b>1</b> (10 mg/kg, po) on HDL-C in moderately high-fat fed hamsters dosed for 3 days (q.d.). One-way ANOVA (Dunnettâs) test: (ââ) <i>p</i> < 0.01, <i>n</i> = 6. (B) Cholesterol profiles of plasma from hamsters before and after dosing for 3 days with <b>10g</b> (10 mg/kg, po) after FPLC fractionation. (C) Cholesterol profiles of plasma from hamsters before and after dosing for 3 days with <b>1</b> (10 mg/kg, po) after FPLC fractionation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0006.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Effect of compound <b>10g</b> on BP (8 mg/kg, iv infusion) in telemeterized rats. (B) Effect of compound <b>1</b> on BP (10 mg/kg, po, and 30 mg/kg, po, respectively) in telemeterized rats. Compound <b>1</b> increased mean arterial pressure (MAP) by 8 and 15 mmHg at 10 and 30 mg/kg (<i>C</i><sub>max</sub> of 3.0 and 6.5 Î¼M), respectively. Compound or vehicle (ethanol/Cremophor/water at 1/1/8) was dosed orally to designated groups of telemeterized rats (male SpragueâDawley, â¼450 g, 17 weeks), and BP was averaged over either a 10 min or 1 h time frame. Each data point is expressed as the mean Â± SEM. Data were compared between compound and vehicle group using repeated ANOVA with Dunnettâs post hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/medium/jm-2015-01363k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0007.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of compound <b>1</b> and <b>10g</b> on CYP11B2 expression in H295R cells. Compounds were incubated with the cells at the indicated concentrations for 24 h, and CYP11B2 mRNA levels were measured and compared to the levels in vehicle (DMSO)-treated cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b01363/20151119/images/large/jm-2015-01363k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01363&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i32">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30616" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30616" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 23 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gordon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelli, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjortland, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kannel, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawber, T. R.</span><span> </span><span class="NLM_article-title">High density lipoprotein as a protective factor against coronary heart disease. The Framingham study</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">707</span><span class="NLM_x">â</span> <span class="NLM_lpage">714</span><span class="refDoi">Â DOI: 10.1016/0002-9343(77)90874-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1016%2F0002-9343%2877%2990874-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=193398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADyaE2sXhvVOhtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1977&pages=707-714&author=T.+Gordonauthor=W.+P.+Castelliauthor=M.+C.+Hjortlandauthor=W.+B.+Kannelauthor=T.+R.+Dawber&title=High+density+lipoprotein+as+a+protective+factor+against+coronary+heart+disease.+The+Framingham+study&doi=10.1016%2F0002-9343%2877%2990874-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">High density lipoprotein as a protective factor against coronary heart disease.  The framingham study</span></div><div class="casAuthors">Gordon, Tavia; Castelli, William P.; Hjortland, Marthana C.; Kannel, William B.; Dawber, Thomas R.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medicine</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">707-14</span>CODEN:
                <span class="NLM_cas:coden">AJMEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    </div><div class="casAbstract">Lipid and lipoprotein values, including fasting triglycerides and high d. lipoproteins (HDL), low d. lipoproteins (LDL), and total cholesterol levels, were obtained on 2815 men and women aged 49-82 years chiefly between 1969 and 1971 at Framingham.  In the â¼4 years following the characterization of lipids, coronary heart disease developed in 79 of the 1025 men and 63 of the 1445 women free of coronary heart diseases.  At these older ages the major potent lipid risk factor was HDL cholesterol.  This lipid was assocd. with each major manifestation of coronary heart disease.  Triglycerides were assocd. with the incidence of coronary heart disease only in women and then only when the level of other lipids was not taken into account.  At these ages total cholesterol was not assocd. with the risk of coronary heart disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd43DXOPo8vrVg90H21EOLACvtfcHk0lg27o52QJb7Uw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXhvVOhtbg%253D&md5=4627db810c609ea43992d8f508b7ec08</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1016%2F0002-9343%2877%2990874-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9343%252877%252990874-9%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DT.%26aulast%3DCastelli%26aufirst%3DW.%2BP.%26aulast%3DHjortland%26aufirst%3DM.%2BC.%26aulast%3DKannel%26aufirst%3DW.%2BB.%26aulast%3DDawber%26aufirst%3DT.%2BR.%26atitle%3DHigh%2520density%2520lipoprotein%2520as%2520a%2520protective%2520factor%2520against%2520coronary%2520heart%2520disease.%2520The%2520Framingham%2520study%26jtitle%3DAm.%2520J.%2520Med.%26date%3D1977%26volume%3D62%26spage%3D707%26epage%3D714%26doi%3D10.1016%2F0002-9343%2877%2990874-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Drexel, H.</span><span> </span><span class="NLM_article-title">Reducing risk by raising HDL-cholesterol: the evidence</span> <span class="citation_source-journal">Eur. Heart J. Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">F23</span><span class="NLM_x">â</span> <span class="NLM_lpage">F29</span><span class="refDoi">Â DOI: 10.1093/eurheartj/sul037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1093%2Feurheartj%2Fsul037" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=F23-F29&author=H.+Drexel&title=Reducing+risk+by+raising+HDL-cholesterol%3A+the+evidence&doi=10.1093%2Feurheartj%2Fsul037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fsul037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fsul037%26sid%3Dliteratum%253Aachs%26aulast%3DDrexel%26aufirst%3DH.%26atitle%3DReducing%2520risk%2520by%2520raising%2520HDL-cholesterol%253A%2520the%2520evidence%26jtitle%3DEur.%2520Heart%2520J.%2520Suppl.%26date%3D2006%26volume%3D8%26spage%3DF23%26epage%3DF29%26doi%3D10.1093%2Feurheartj%2Fsul037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Di Angelantonio, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarwar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptoge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewington, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sattar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packard, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danesh, J.</span><span> </span><span class="NLM_article-title">Major lipids, apolipoproteins, and risk of vascular disease</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">1993</span><span class="NLM_x">â</span> <span class="NLM_lpage">2000</span><span class="refDoi">Â DOI: 10.1001/jama.2009.1619</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1001%2Fjama.2009.1619" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=19903920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSktLjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2009&pages=1993-2000&author=E.+Di+Angelantonioauthor=N.+Sarwarauthor=P.+Perryauthor=S.+Kaptogeauthor=K.+K.+Rayauthor=A.+Thompsonauthor=A.+M.+Woodauthor=S.+Lewingtonauthor=N.+Sattarauthor=C.+J.+Packardauthor=R.+Collinsauthor=S.+G.+Thompsonauthor=J.+Danesh&title=Major+lipids%2C+apolipoproteins%2C+and+risk+of+vascular+disease&doi=10.1001%2Fjama.2009.1619"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Major lipids, apolipoproteins, and risk of vascular disease</span></div><div class="casAuthors">Di Angelantonio, Emanuele; Sarwar, Nadeem; Perry, Philip; Kaptoge, Stephen; Ray, Kausik K.; Thompson, Alexander; Wood, Angela M.; Lewington, Sarah; Sattar, Naveed; Packard, Chris J.; Collins, Rory; Thompson, Simon G.; Danesh, John; Tipping, R. W.; Ford, C. E.; Pressel, S. L.; Walldius, G.; Jungner, I.; Folsom, A. R.; Chambless, L. E.; Panagiotakos, D. B.; Pitsavos, C.; Chrysohoou, C.; Stefanadis, C.; Knuiman, M.; Goldbourt, U.; Benderly, M.; Tanne, D.; Whincup, P. H.; Wannamethee, S. G.; Morris, R. W.; Kiechl, S.; Willeit, J.; Santer, P.; Mayr, A.; Wald, N.; Ebrahim, S.; Lawlor, D. A.; Yarnell, J. W. G.; Gallacher, J.; Casiglia, E.; Tikhonoff, V.; Nietert, P. J.; Sutherland, S. E.; Bachman, D. L.; Keil, J. E.; Cushman, M.; Psaty, B. M.; Tracy, R. P.; Tybjaerg-Hansen, A.; Nordestgaard, B. G.; Benn, M.; Frikke-Schmidt, R.; Giampaoli, S.; Palmieri, L.; Panico, S.; Vanuzzo, D.; Pilotto, L.; Gomez de la Camara, A.; Gomez-Gerique, J. A.; Simons, L.; McCallum, J.; Friedlander, Y.; Fowkes, F. G. R.; Lee, A. J.; Smith, F. B.; Taylor, J.; Guralnik, J. M.; Phillips, C. L.; Wallace, R.; Guralnik, J.; Phillips, C. L.; Blazer, D. G.; Guralnik, J. M.; Khaw, K.-T.; Brenner, H.; Raum, E.; Muller, H.; Rothenbacher, D.; Jansson, J. H.; Wennberg, P.; Nissinen, A.; Donfrancesco, C.; Giampaoli, S.; Salomaa, V.; Harald, K.; Jousilahti, P.; Vartiainen, E.; Woodward, M.; D'Agostino, R. B.; Wolf, P. A.; Vasan, R. S.; Pencina, M. J.; Bladbjerg, E. M.; Jorgensen, T.; Moller, L.; Jespersen, J.; Dankner, R.; Chetrit, A.; Lubin, F.; Rosengren, A.; Wilhelmsen, L.; Lappas, G.; Eriksson, H.; Bjorkelund, C.; Lissner, L.; Bengtsson, C.; Cremer, P.; Nagel, Dd; Tilvis, R. S.; Strandberg, T. E.; Rodriguez, B.; Dekker, J. M.; Nijpels, G.; Stehouwer, C. D. A.; Rimm, E.; Pai, J. K.; Sato, S.; Iso, H.; Kitamura, A.; Noda, H.; Salonen, J. T.; Nyyssonen, K.; Tuomainen, T.-P.; Deeg, J. H.; Poppelaars, J. L.; Meade, T. W.; Cooper, J. A.; Hedblad, B.; Berglund, G.; Engstrom, G.; Verschuren, W. M. M.; Blokstra, A.; Doring, A.; Koenig, W.; Meisinger, C.; Mraz, W.; Verschuren, W. M. M.; Blokstra, A.; Bueno-de-Mesquita, H. Bas; Wilhelmsen, L.; Rosengren, A.; Lappas, G.; Kuller, L. H.; Grandits, G.; Selmer, R.; Tverdal, A.; Nystad, W.; Gillum, R.; Mussolino, M.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1993-2000</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context Assocns. of major lipids and apolipoproteins with the risk of vascular disease have not been reliably quantified.  Objective To assess major lipids and apolipoproteins in vascular risk.  Design, Setting, and Participants Individual records were supplied on 302 430 people without initial vascular disease from 68 long-term prospective studies, mostly in Europe and North America.  During 2.79 million person-years of follow-up, there were 8857 nonfatal myocardial infarctions, 3928 coronary heart disease [CHD] deaths, 2534 ischemic strokes, 513 hemorrhagic strokes, and 2536 unclassified strokes.  Main Outcome Measures Hazard ratios (HRs), adjusted for several conventional factors, were calcd. for 1-SD higher values: 0.52 loge triglyceride, 15 mg/dL high-d. lipoprotein cholesterol (HDL-C), 43 mg/dL non-HDL-C, 29 mg/dL apolipoprotein Al, 29 mg/dL apolipoprotein B, and 33 mg/dL directly measured low-d. lipoprotein cholesterol (LDL-C).  Within-study regression analyses were adjusted for within-person variation and combined using meta-anal.  Results The rates of CHD per 1000 person-years in the bottom and top thirds of baseline lipid distributions, resp., were 2.6 and 6.2 with triglyceride, 6.4 and 2.4 with HDL-C, and 2.3 and 6.7 with non-HDL-C.  Adjusted HRs for CHD were 0.99 (95% CI, 0.94-1.05) with triglyceride, 0.78 (95% CI, 0.74-0.82) with HDL-C, and 1.50 (95% CI, 1.39-1.61) with non-HDL-C.  Hazard ratios were at least as strong in participants who did not fast as in those who did.  The HR for CHD was 0.35 (95% CI, 0.30-0.42) with a combination of 80 mg/dL lower non-HDL-C and 15 mg/dL higher HDL-C.  For the subset with apolipoproteins or directly measured LDL-C, HRs were 1.50 (95% CI, 1.38-1.62) with the ratio non-HDL-C/HDL-C, 1.49 (95% CI, 1.39-1.60) with the ratio apo B/apo Al, 1.42 (95% CI, 1.06-1.91) with non-HDL-C, and 1.38 (95% CI, 1.09-1.73) with directly measured LDL-C.  Hazard ratios for ischemic stroke were 1.02 (95% CI, 0.94-1.11) with triglyceride, 0.93 (95% CI, 0.84-1.02) with HDL-C, and 1.12 (95% CI, 1.04-1.20) with non-HDL-C.  Conclusion Lipid assessment in vascular disease can be simplified by measurement of either total and HDL cholesterol levels or apolipoproteins without the need to fast and without regard to triglyceride.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK5NOuPaBMcrVg90H21EOLACvtfcHk0lh6r_qX2o_yLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSktLjN&md5=97d12d893f26b4de09cdfb71cf294d51</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1001%2Fjama.2009.1619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2009.1619%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BAngelantonio%26aufirst%3DE.%26aulast%3DSarwar%26aufirst%3DN.%26aulast%3DPerry%26aufirst%3DP.%26aulast%3DKaptoge%26aufirst%3DS.%26aulast%3DRay%26aufirst%3DK.%2BK.%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DWood%26aufirst%3DA.%2BM.%26aulast%3DLewington%26aufirst%3DS.%26aulast%3DSattar%26aufirst%3DN.%26aulast%3DPackard%26aufirst%3DC.%2BJ.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DThompson%26aufirst%3DS.%2BG.%26aulast%3DDanesh%26aufirst%3DJ.%26atitle%3DMajor%2520lipids%252C%2520apolipoproteins%252C%2520and%2520risk%2520of%2520vascular%2520disease%26jtitle%3DJAMA%26date%3D2009%26volume%3D302%26spage%3D1993%26epage%3D2000%26doi%3D10.1001%2Fjama.2009.1619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1aa"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Rhoads, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulbrandsen, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagan, A.</span><span> </span><span class="NLM_article-title">Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">294</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">â</span> <span class="NLM_lpage">298</span><span class="refDoi">Â DOI: 10.1056/NEJM197602052940601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1aa&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1056%2FNEJM197602052940601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1aa&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=173994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1aa&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A280%3ADyaE287gtVKgsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=1976&pages=293-298&author=G.+G.+Rhoadsauthor=C.+L.+Gulbrandsenauthor=A.+Kagan&title=Serum+lipoproteins+and+coronary+heart+disease+in+a+population+study+of+Hawaii+Japanese+men&doi=10.1056%2FNEJM197602052940601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aaR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men</span></div><div class="casAuthors">Rhoads G G; Gulbrandsen C L; Kagan A</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">293-8</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">To ascertain the frequency of defined hyperlipoproteinemia and to investigate the relation between lipoprotein fractions and coronary heart disease, we measured serum lipoprotein cholesterol levels in a population-based sample of Hawaii Japanese men 50 to 72 years old.  Type II hyperlipoproteinemia was present in 3 per cent of 1859 men, and Type IV in 26 per cent.  Relative risks for coronary heart disease, based on 264 prevalence cases, were found to be 1.8, 1.8 and 0.46, between the upper and lower quartiles of total, beta, and alpha cholesterol, respectively.  We found no significant relation between triglyceride and coronary heart disease.  The inverse relation of alpha cholesterol of prevalence of coronary heart disease was independent of beta cholesterol, obesity, and other factors.  The data suggest the need for further evaluation of the protective effect of the alpha lipoprotein fraction on the development of coronary heart disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0SY02znK7rJPlX7E30qdzfW6udTcc2eYm9OSBr4hrF7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE287gtVKgsw%253D%253D&md5=4a9f19dd74b088b5b1b9df214a2bb91d</span></div><a href="/servlet/linkout?suffix=cit1aa&amp;dbid=16384&amp;doi=10.1056%2FNEJM197602052940601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM197602052940601%26sid%3Dliteratum%253Aachs%26aulast%3DRhoads%26aufirst%3DG.%2BG.%26aulast%3DGulbrandsen%26aufirst%3DC.%2BL.%26aulast%3DKagan%26aufirst%3DA.%26atitle%3DSerum%2520lipoproteins%2520and%2520coronary%2520heart%2520disease%2520in%2520a%2520population%2520study%2520of%2520Hawaii%2520Japanese%2520men%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1976%26volume%3D294%26spage%3D293%26epage%3D298%26doi%3D10.1056%2FNEJM197602052940601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1bb"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Castelli, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrison, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbott, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalousdian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kannel, W. B.</span><span> </span><span class="NLM_article-title">Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">256</span><span class="NLM_x">, </span> <span class="NLM_fpage">2835</span><span class="NLM_x">â</span> <span class="NLM_lpage">2838</span><span class="refDoi">Â DOI: 10.1001/jama.1986.03380200073024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1bb&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1001%2Fjama.1986.03380200073024" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1986&pages=2835-2838&author=W.+P.+Castelliauthor=R.+J.+Garrisonauthor=P.+W.+Wilsonauthor=R.+D.+Abbottauthor=S.+Kalousdianauthor=W.+B.+Kannel&title=Incidence+of+coronary+heart+disease+and+lipoprotein+cholesterol+levels.+The+Framingham+Study&doi=10.1001%2Fjama.1986.03380200073024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1bb&amp;dbid=16384&amp;doi=10.1001%2Fjama.1986.03380200073024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.1986.03380200073024%26sid%3Dliteratum%253Aachs%26aulast%3DCastelli%26aufirst%3DW.%2BP.%26aulast%3DGarrison%26aufirst%3DR.%2BJ.%26aulast%3DWilson%26aufirst%3DP.%2BW.%26aulast%3DAbbott%26aufirst%3DR.%2BD.%26aulast%3DKalousdian%26aufirst%3DS.%26aulast%3DKannel%26aufirst%3DW.%2BB.%26atitle%3DIncidence%2520of%2520coronary%2520heart%2520disease%2520and%2520lipoprotein%2520cholesterol%2520levels.%2520The%2520Framingham%2520Study%26jtitle%3DJAMA%26date%3D1986%26volume%3D256%26spage%3D2835%26epage%3D2838%26doi%3D10.1001%2Fjama.1986.03380200073024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1cc"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Kannel, W. B.</span><span> </span><span class="NLM_article-title">Range of serum cholesterol values in the population developing coronary artery disease</span> <span class="citation_source-journal">Am. J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">69c</span><span class="NLM_x">â</span> <span class="NLM_lpage">77c</span><span class="refDoi">Â DOI: 10.1016/S0002-9149(99)80474-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1cc&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1016%2FS0002-9149%2899%2980474-3" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1995&pages=69c-77c&author=W.+B.+Kannel&title=Range+of+serum+cholesterol+values+in+the+population+developing+coronary+artery+disease&doi=10.1016%2FS0002-9149%2899%2980474-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1cc&amp;dbid=16384&amp;doi=10.1016%2FS0002-9149%2899%2980474-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9149%252899%252980474-3%26sid%3Dliteratum%253Aachs%26aulast%3DKannel%26aufirst%3DW.%2BB.%26atitle%3DRange%2520of%2520serum%2520cholesterol%2520values%2520in%2520the%2520population%2520developing%2520coronary%2520artery%2520disease%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D1995%26volume%3D76%26spage%3D69c%26epage%3D77c%26doi%3D10.1016%2FS0002-9149%2899%2980474-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Barter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennekens, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rader, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tall, A. R.</span><span> </span><span class="NLM_article-title">Cholesteryl ester transfer protein</span> <span class="citation_source-journal">Arterioscler., Thromb., Vasc. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">160</span><span class="NLM_x">â</span> <span class="NLM_lpage">167</span><span class="refDoi">Â DOI: 10.1161/01.ATV.0000054658.91146.64</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1161%2F01.ATV.0000054658.91146.64" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=12588754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptF2jsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=160-167&author=P.+J.+Barterauthor=H.+B.+Brewerauthor=M.+J.+Chapmanauthor=C.+H.+Hennekensauthor=D.+J.+Raderauthor=A.+R.+Tall&title=Cholesteryl+ester+transfer+protein&doi=10.1161%2F01.ATV.0000054658.91146.64"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cholesteryl Ester Transfer Protein</span></div><div class="casAuthors">Barter, Philip J.; Brewer, H. Bryan; Chapman, M. John; Hennekens, Charles H.; Rader, Daniel J.; Tall, Alan R.</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">160-167</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Cholesteryl ester transfer protein (CETP) promotes the transfer of cholesteryl esters from antiatherogenic HDLs to proatherogenic apolipoprotein B (apoB)-contg. lipoproteins, including VLDLs, VLDL remnants, IDLs, and LDLs.  A deficiency of CETP is assocd. with increased HDL levels and decreased LDL levels, a profile that is typically antiatherogenic.  Studies in rabbits, a species with naturally high levels of CETP, support the therapeutic potential of CETP inhibition as an approach to retarding atherogenesis.  Studies in mice, a species that lacks CETP activity, have provided mixed results.  Human subjects with heterozygous CETP deficiency and an HDL cholesterol level >60 mg/dL have a reduced risk of coronary heart disease.  Evidence that atherosclerosis may be increased in CETP-deficient subjects whose HDL levels are not increased is difficult to interpret and may reflect confounding or bias.  Small-mol. inhibitors of CETP have now been tested in human subjects and shown to increase the concn. of HDL cholesterol while decreasing that of LDL cholesterol and apoB.  Thus, it seems important and timely to test the hypothesis in randomized trials of humans that pharmacol. inhibition of CETP retards the development of atherosclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGBGX_CUbamrVg90H21EOLACvtfcHk0lgp1Co_CykMCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptF2jsw%253D%253D&md5=1cf83327815b82a906915c61e355e891</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1161%2F01.ATV.0000054658.91146.64&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.ATV.0000054658.91146.64%26sid%3Dliteratum%253Aachs%26aulast%3DBarter%26aufirst%3DP.%2BJ.%26aulast%3DBrewer%26aufirst%3DH.%2BB.%26aulast%3DChapman%26aufirst%3DM.%2BJ.%26aulast%3DHennekens%26aufirst%3DC.%2BH.%26aulast%3DRader%26aufirst%3DD.%2BJ.%26aulast%3DTall%26aufirst%3DA.%2BR.%26atitle%3DCholesteryl%2520ester%2520transfer%2520protein%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2003%26volume%3D23%26spage%3D160%26epage%3D167%26doi%3D10.1161%2F01.ATV.0000054658.91146.64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="note"><p class="first last">For recent reviews on CETP inhibitors, see the following:</p></div><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mantlo, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escribano, A.</span><span> </span><span class="NLM_article-title">Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">17</span><div class="note"><p class="first last">and references therein</p></div><span class="refDoi">Â DOI: 10.1021/jm400574e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400574e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OjtbjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1-17&author=N.+B.+Mantloauthor=A.+Escribano&title=Update+on+the+discovery+and+development+of+cholesteryl+ester+transfer+protein+inhibitors+for+reducing+residual+cardiovascular+risk&doi=10.1021%2Fjm400574e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Update on the Discovery and Development of Cholesteryl Ester Transfer Protein Inhibitors for Reducing Residual Cardiovascular Risk</span></div><div class="casAuthors">Mantlo, Nathan B.; Escribano, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-17</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cholesteryl ester transfer protein (CETP) facilitates the transfer of cholesteryl ester and triglycerides between plasma lipoprotein particles HDL and LDL/VLDL, resulting in equilibration between these lipoprotein fractions.  Therapy that modulates HDL metab. to increase HDL-c levels could be an effective strategy to reduce residual cardiovascular risk since it is estd. that for each mg/dL increase in plasma HDL cholesterol, there could be a 2-3% decrease in cardiovascular risk.  Modification of the lipoprotein profile by CETP inhibitors is promising, but the beneficial effect of reducing coronary heart disease risk has not yet been proven.  To date, four CETP inhibitors have advanced to phase 3 cardiovascular outcome clin. trials, and two have been terminated for off-target adverse effects and lack of efficacy.  This perspective will summarize recent events, new research developments, and the discovery of new classes of CETP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHidqL01H0brVg90H21EOLACvtfcHk0lgp1Co_CykMCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OjtbjL&md5=1b54b68fd41896b2d513161e20c7c432</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1021%2Fjm400574e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400574e%26sid%3Dliteratum%253Aachs%26aulast%3DMantlo%26aufirst%3DN.%2BB.%26aulast%3DEscribano%26aufirst%3DA.%26atitle%3DUpdate%2520on%2520the%2520discovery%2520and%2520development%2520of%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibitors%2520for%2520reducing%2520residual%2520cardiovascular%2520risk%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1%26epage%3D17%26doi%3D10.1021%2Fjm400574e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3aa"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sikorski, J. A.</span><span> </span><span class="NLM_article-title">Oral cholesteryl ester transfer protein (CETP) inhibitors: a potent approach for treating coronary artery disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">22</span><div class="note"><p class="first last">and references therein</p></div><span class="refDoi">Â DOI: 10.1021/jm058224l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058224l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=1-22&author=J.+A.+Sikorski&title=Oral+cholesteryl+ester+transfer+protein+%28CETP%29+inhibitors%3A+a+potent+approach+for+treating+coronary+artery+disease&doi=10.1021%2Fjm058224l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3aa&amp;dbid=16384&amp;doi=10.1021%2Fjm058224l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058224l%26sid%3Dliteratum%253Aachs%26aulast%3DSikorski%26aufirst%3DJ.%2BA.%26atitle%3DOral%2520cholesteryl%2520ester%2520transfer%2520protein%2520%2528CETP%2529%2520inhibitors%253A%2520a%2520potent%2520approach%2520for%2520treating%2520coronary%2520artery%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D1%26epage%3D22%26doi%3D10.1021%2Fjm058224l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chapman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeGoff, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kontush, A.</span><span> </span><span class="NLM_article-title">Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors</span> <span class="citation_source-journal">Eur. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">149</span><span class="NLM_x">â</span> <span class="NLM_lpage">164</span><span class="refDoi">Â DOI: 10.1093/eurheartj/ehp399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1093%2Feurheartj%2Fehp399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=19825813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlKksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=149-164&author=M.+J.+Chapmanauthor=W.+LeGoffauthor=M.+Guerinauthor=A.+Kontush&title=Cholesteryl+ester+transfer+protein%3A+at+the+heart+of+the+action+of+lipid-modulating+therapy+with+statins%2C+fibrates%2C+niacin%2C+and+cholesteryl+ester+transfer+protein+inhibitors&doi=10.1093%2Feurheartj%2Fehp399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors</span></div><div class="casAuthors">Chapman, M. John; Le Goff, Wilfried; Guerin, Maryse; Kontush, Anatol</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">149-164</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Subnormal plasma levels of high-d. lipoprotein cholesterol (HDL-C) constitute a major cardiovascular risk factor; raising low HDL-C levels may therefore reduce the residual cardiovascular risk that frequently presents in dyslipidemic subjects despite statin therapy.  Cholesteryl ester transfer protein (CETP), a key modulator not only of the intravascular metab. of HDL and apolipoprotein (apo) A-I but also of triglyceride (TG)-rich particles and low-d. lipoprotein (LDL), mediates the transfer of cholesteryl esters from HDL to pro-atherogenic apoB-lipoproteins, with heterotransfer of TG mainly from very low-d. lipoprotein to HDL.  Cholesteryl ester transfer protein activity is elevated in the dyslipidemias of metabolic disease involving insulin resistance and moderate to marked hypertriglyceridemia, and is intimately assocd. with premature atherosclerosis and high cardiovascular risk.  Cholesteryl ester transfer protein inhibition therefore presents a preferential target for elevation of HDL-C and redn. in atherosclerosis.  This review appraises recent evidence for a central role of CETP in the action of current lipid-modulating agents with HDL-raising potential, i.e. statins, fibrates, and niacin, and compares their mechanisms of action with those of pharmacol. agents under development which directly inhibit CETP.  New CETP inhibitors, such as dalcetrapib and anacetrapib, are targeted to normalize HDL/apoA-I levels and anti-atherogenic activities of HDL particles.  Further studies of these CETP inhibitors, in particular in long-term, large-scale outcome trials, will provide essential information on their safety and efficacy in reducing residual cardiovascular risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotgbYNLr-Yu7Vg90H21EOLACvtfcHk0lg5ObGEn9G7Ew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlKksg%253D%253D&md5=1440a28e8f4a63f45c21cf926476ae47</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehp399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehp399%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DM.%2BJ.%26aulast%3DLeGoff%26aufirst%3DW.%26aulast%3DGuerin%26aufirst%3DM.%26aulast%3DKontush%26aufirst%3DA.%26atitle%3DCholesteryl%2520ester%2520transfer%2520protein%253A%2520at%2520the%2520heart%2520of%2520the%2520action%2520of%2520lipid-modulating%2520therapy%2520with%2520statins%252C%2520fibrates%252C%2520niacin%252C%2520and%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibitors%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2010%26volume%3D31%26spage%3D149%26epage%3D164%26doi%3D10.1093%2Feurheartj%2Fehp399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Linsel-Nitschke, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tall, A. R.</span><span> </span><span class="NLM_article-title">HDL as a target in the treatment of atherosclerotic cardiovascular disease</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">â</span> <span class="NLM_lpage">205</span><div class="note"><p class="first last">and references therein</p></div><span class="refDoi">Â DOI: 10.1038/nrd1658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1038%2Fnrd1658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=15738977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslSnsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=193-205&author=P.+Linsel-Nitschkeauthor=A.+R.+Tall&title=HDL+as+a+target+in+the+treatment+of+atherosclerotic+cardiovascular+disease&doi=10.1038%2Fnrd1658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">HDL as a target in the treatment of atherosclerotic cardiovascular disease</span></div><div class="casAuthors">Linsel-Nitschke, Patrick; Tall, Alan R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-205</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Lipid abnormalities are among the key risk factors for cardiovascular disease.  Indeed, lipid-modifying drugs - in particular, the statins, which primarily lower plasma levels of low-d. lipoprotein (LDL) cholesterol - considerably reduce the risk of cardiovascular events, leading to their widespread use.  Nevertheless, it seems that there might be limits to the degree of benefit that can be achieved by lowering LDL-cholesterol levels alone, which has led to increased interest in targeting other lipid-related risk factors for cardiovascular disease, such as low levels of high-d. lipoprotein (HDL) cholesterol.  In this article, we first consider the mechanisms that underlie the protective effect of HDL cholesterol, and then discuss several strategies that have recently emerged to increase levels of HDL cholesterol to treat cardiovascular disease, including nuclear receptor modulation, inhibition of cholesteryl ester transfer protein and infusion of apolipoprotein/phospholipid complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw-z_u0WhLTrVg90H21EOLACvtfcHk0lg5ObGEn9G7Ew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslSnsrc%253D&md5=57392b9ff6c31d13de45511d7ac993f3</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1038%2Fnrd1658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1658%26sid%3Dliteratum%253Aachs%26aulast%3DLinsel-Nitschke%26aufirst%3DP.%26aulast%3DTall%26aufirst%3DA.%2BR.%26atitle%3DHDL%2520as%2520a%2520target%2520in%2520the%2520treatment%2520of%2520atherosclerotic%2520cardiovascular%2520disease%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D193%26epage%3D205%26doi%3D10.1038%2Fnrd1658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Briand, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieblemont, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzotte, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burr, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbain, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulpice, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johns, D. G.</span><span> </span><span class="NLM_article-title">Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">740</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">â</span> <span class="NLM_lpage">143</span><span class="refDoi">Â DOI: 10.1016/j.ejphar.2014.06.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1016%2Fj.ejphar.2014.06.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=25008069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GrtLzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=740&publication_year=2014&pages=135-143&author=F.+Briandauthor=Q.+Thieblemontauthor=E.+Muzotteauthor=N.+Burrauthor=I.+Urbainauthor=T.+Sulpiceauthor=D.+G.+Johns&title=Anacetrapib+and+dalcetrapib+differentially+alters+HDL+metabolism+and+macrophage-to-feces+reverse+cholesterol+transport+at+similar+levels+of+CETP+inhibition+in+hamsters&doi=10.1016%2Fj.ejphar.2014.06.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters</span></div><div class="casAuthors">Briand, Francois; Thieblemont, Quentin; Muzotte, Elodie; Burr, Noemie; Urbain, Isabelle; Sulpice, Thierry; Johns, Douglas G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">740</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">135-143</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cholesteryl ester transfer protein (CETP) inhibitors dalcetrapib and anacetrapib differentially alter LDL- and HDL-cholesterol levels, which might be related to the potency of each drug to inhibit CETP activity.  We evaluated the effects of both drugs at similar levels of CETP inhibition on macrophage-to-feces reverse cholesterol transport (RCT) in hamsters.  In normolipidemic hamsters, both anacetrapib 30 mg/kg QD and dalcetrapib 200 mg/kg BID inhibited CETP activity by â¼60%.  After injection of 3H-cholesteryl oleate labeled HDL, anacetrapib and dalcetrapib reduced HDL-cholesteryl esters fractional catabolic rate (FCR) by 30% and 26% (both P<0.001 vs. vehicle) resp., but only dalcetrapib increased HDL-derived 3H-tracer fecal excretion by 30% (P<0.05 vs. vehicle).  After 3H-cholesterol labeled macrophage i.p. injection, anacetrapib stimulated 3H-tracer appearance in HDL, but both drugs did not promote macrophage-derived 3H-tracer fecal excretion.  In dyslipidemic hamsters, both anacetrapib 1 mg/kg QD and dalcetrapib 200 mg/kg BID inhibited CETP activity by â¼65% and reduced HDL-cholesteryl ester FCR by 36% (both P<0.001 vs. vehicle), but only anacetrapib increased HDL-derived 3H-tracer fecal excretion significantly by 39%.  After 3H-cholesterol labeled macrophage injection, only anacetrapib 1 mg/kg QD stimulated macrophage-derived 3H-tracer appearance in HDL.  These effects remained weaker than those obsd. with anacetrapib 60 mg/kg QD, which induced a maximal inhibition of CETP and stimulation of macrophage-derived 3H-tracer fecal excretion.  In contrast, dalcetrapib 200 mg/kg BID reduced macrophage-derived 3H-tracer fecal excretion by 23% (P<0.05 vs. vehicle).  In conclusion, anacetrapib and dalcetrapib differentially alter HDL metab. and RCT in hamsters.  A stronger inhibition of CETP may be required to promote macrophage-to-feces reverse cholesterol transport in dyslipidemic hamsters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIW5Yxk_tQrbVg90H21EOLACvtfcHk0lg5ObGEn9G7Ew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GrtLzJ&md5=8d51917b8f01f614f9c320414b2ef0c7</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2014.06.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2014.06.022%26sid%3Dliteratum%253Aachs%26aulast%3DBriand%26aufirst%3DF.%26aulast%3DThieblemont%26aufirst%3DQ.%26aulast%3DMuzotte%26aufirst%3DE.%26aulast%3DBurr%26aufirst%3DN.%26aulast%3DUrbain%26aufirst%3DI.%26aulast%3DSulpice%26aufirst%3DT.%26aulast%3DJohns%26aufirst%3DD.%2BG.%26atitle%3DAnacetrapib%2520and%2520dalcetrapib%2520differentially%2520alters%2520HDL%2520metabolism%2520and%2520macrophage-to-feces%2520reverse%2520cholesterol%2520transport%2520at%2520similar%2520levels%2520of%2520CETP%2520inhibition%2520in%2520hamsters%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D740%26spage%3D135%26epage%3D143%26doi%3D10.1016%2Fj.ejphar.2014.06.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cannon, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansky, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotto, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stepanavage, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashraf, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zafarino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchel, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barter, P. N.</span><span> </span><span class="NLM_article-title">Safety of anacetrapib in patients with or at high risk for coronary heart disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">2406</span><span class="NLM_x">â</span> <span class="NLM_lpage">2415</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1009744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1056%2FNEJMoa1009744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=21082868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2ltLfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=2406-2415&author=C.+P.+Cannonauthor=S.+Shahauthor=H.+M.+Danskyauthor=M.+Davidsonauthor=E.+A.+Brintonauthor=A.+M.+Gottoauthor=M.+Stepanavageauthor=S.+X.+Liuauthor=P.+Gibbonsauthor=T.+B.+Ashrafauthor=J.+Zafarinoauthor=Y.+Mitchelauthor=P.+N.+Barter&title=Safety+of+anacetrapib+in+patients+with+or+at+high+risk+for+coronary+heart+disease&doi=10.1056%2FNEJMoa1009744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of anacetrapib in patients with or at high risk for coronary heart disease</span></div><div class="casAuthors">Cannon, Christopher P.; Shah, Sukrut; Dansky, Hayes M.; Davidson, Michael; Brinton, Eliot A.; Gotto, Antonio M., Jr.; Phil, D.; Stepanavage, Michael; Liu, Sherry Xueyu; Gibbons, Patrice; Ashraf, Tanya B.; Zafarino, Jennifer; Mitchel, Yale; Barter, Philip</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2406-2415</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-d. lipoprotein (HDL) cholesterol and reduces low-d. lipoprotein (LDL) cholesterol.  METHODS: We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety profile of anacetrapib in patients with coronary heart disease or at high risk for coronary heart disease.  Eligible patients who were taking a statin and who had an LDL cholesterol level that was consistent with that recommended in guidelines were assigned to receive 100 mg of anacetrapib or placebo daily for 18 mo.  The primary end points were the percent change from baseline in LDL cholesterol at 24 wk (HDL cholesterol level was a secondary end point) and the safety and side-effect profile of anacetrapib through 76 wk.  Cardiovascular events and deaths were prospectively adjudicated.  RESULTS: A total of 1623 patients underwent randomization.  By 24 wk, the LDL cholesterol level had been reduced from 81 mg per dL (2.1 mmol per L) to 45 mg per dL (1.2 mmol per L) in the anacetrapib group, as compared with a redn. from 82 mg per dL (2.1 mmol per L) to 77 mg per dL (2.0 mmol per L) in the placebo group (P < 0.001) - a 39.8% redn. with anacetrapib beyond that seen with placebo.  In addn., the HDL cholesterol level increased from 41 mg per dL (1.0 mmol per L) to 101 mg per dL (2.6 mmol per L) in the anacetrapib group, as compared with an increase from 40 mg per dL (1.0 mmol per L) to 46 mg per dL (1.2 mmol per L) in the placebo group (P < 0.001) - a 138.1% increase with anacetrapib beyond that seen with placebo.  Through 76 wk, no changes were noted in blood pressure or electrolyte or aldosterone levels with anacetrapib as compared with placebo.  Prespecified adjudicated cardiovascular events occurred in 16 patients treated with anacetrapib (2.0%) and 21 patients receiving placebo (2.6%) (P = 0.40).  The prespecified Bayesian anal. indicated that this event distribution provided a predictive probability (confidence) of 94% that anacetrapib would not be assocd. with a 25% increase in cardiovascular events, as seen with torcetrapib.  CONCLUSIONS Treatment with anacetrapib had robust effects on LDL and HDL cholesterol, had an acceptable side-effect profile, and, within the limits of the power of this study, did not result in the adverse cardiovascular effects obsd. with torcetrapib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3bzMvd54bDLVg90H21EOLACvtfcHk0lhg8Rw9_OqHlQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2ltLfL&md5=df74ea8dd8273e576fa26dc70805e719</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1009744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1009744%26sid%3Dliteratum%253Aachs%26aulast%3DCannon%26aufirst%3DC.%2BP.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DDansky%26aufirst%3DH.%2BM.%26aulast%3DDavidson%26aufirst%3DM.%26aulast%3DBrinton%26aufirst%3DE.%2BA.%26aulast%3DGotto%26aufirst%3DA.%2BM.%26aulast%3DStepanavage%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%2BX.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DAshraf%26aufirst%3DT.%2BB.%26aulast%3DZafarino%26aufirst%3DJ.%26aulast%3DMitchel%26aufirst%3DY.%26aulast%3DBarter%26aufirst%3DP.%2BN.%26atitle%3DSafety%2520of%2520anacetrapib%2520in%2520patients%2520with%2520or%2520at%2520high%2520risk%2520for%2520coronary%2520heart%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D2406%26epage%3D2415%26doi%3D10.1056%2FNEJMoa1009744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nicholls, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastelein, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McErlean, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nissen, S. E.</span><span> </span><span class="NLM_article-title">Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: A randomized controlled trial</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">306</span><span class="NLM_x">, </span> <span class="NLM_fpage">2099</span><span class="NLM_x">â</span> <span class="NLM_lpage">2109</span><span class="refDoi">Â DOI: 10.1001/jama.2011.1649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1001%2Fjama.2011.1649" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2011&pages=2099-2109&author=S.+J.+Nichollsauthor=H.+B.+Brewerauthor=J.+J.+Kasteleinauthor=K.+A.+Kruegerauthor=M.+D.+Wangauthor=M.+Shaoauthor=B.+Huauthor=E.+McErleanauthor=S.+E.+Nissen&title=Effects+of+the+CETP+inhibitor+evacetrapib+administered+as+monotherapy+or+in+combination+with+statins+on+HDL+and+LDL+cholesterol%3A+A+randomized+controlled+trial&doi=10.1001%2Fjama.2011.1649"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1001%2Fjama.2011.1649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2011.1649%26sid%3Dliteratum%253Aachs%26aulast%3DNicholls%26aufirst%3DS.%2BJ.%26aulast%3DBrewer%26aufirst%3DH.%2BB.%26aulast%3DKastelein%26aufirst%3DJ.%2BJ.%26aulast%3DKrueger%26aufirst%3DK.%2BA.%26aulast%3DWang%26aufirst%3DM.%2BD.%26aulast%3DShao%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DMcErlean%26aufirst%3DE.%26aulast%3DNissen%26aufirst%3DS.%2BE.%26atitle%3DEffects%2520of%2520the%2520CETP%2520inhibitor%2520evacetrapib%2520administered%2520as%2520monotherapy%2520or%2520in%2520combination%2520with%2520statins%2520on%2520HDL%2520and%2520LDL%2520cholesterol%253A%2520A%2520randomized%2520controlled%2520trial%26jtitle%3DJAMA%26date%3D2011%26volume%3D306%26spage%3D2099%26epage%3D2109%26doi%3D10.1001%2Fjama.2011.1649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kathiresan, S.</span><span> </span><span class="NLM_article-title">Will Cholesteryl Ester Transfer Protein Inhibition Succeed Primarily by Lowering Low--Density Lipoprotein Cholesterol?</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2049</span><span class="NLM_x">â</span> <span class="NLM_lpage">2052</span><span class="refDoi">Â DOI: 10.1016/j.jacc.2012.08.967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1016%2Fj.jacc.2012.08.967" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=23083775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1OlurnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2012&pages=2049-2052&author=S.+Kathiresan&title=Will+Cholesteryl+Ester+Transfer+Protein+Inhibition+Succeed+Primarily+by+Lowering+Low%2D%2DDensity+Lipoprotein+Cholesterol%3F&doi=10.1016%2Fj.jacc.2012.08.967"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Will Cholesteryl Ester Transfer Protein Inhibition Succeed Primarily by Lowering Low-Density Lipoprotein Cholesterol?</span></div><div class="casAuthors">Kathiresan, Sekar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2049-2052</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The research of Johannsen et al. (2012) entitled, 'Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects' is reviewed with commentary and refs.  Johannsen et al. tested the hypothesis that common genetic variation at the CETP gene relates to plasma lipids and risk for incident atherosclerotic cardiovascular disease (ASCVD).  They found that the alleles assocd. with lower CETP activity are assocd. with a range of lipid biomarkers including: 1) higher apolipoprotein A-I contg. lipoproteins (as measured by HDL cholesterol); 2) lower apolipoprotein B-contg. lipoproteins (as measured by low-d. lipoprotein [LDL] cholesterol and triglycerides); and 3) lower plasma lipoprotein(a).  They also tested whether these polymorphisms assoc. with traits relevant to the side effects of pharmacol. CETP inhibition and found no such assocns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokzSFc0Ywm8rVg90H21EOLACvtfcHk0lhg8Rw9_OqHlQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1OlurnN&md5=ba768abf96e691c3a83184fcf391b7aa</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2012.08.967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2012.08.967%26sid%3Dliteratum%253Aachs%26aulast%3DKathiresan%26aufirst%3DS.%26atitle%3DWill%2520Cholesteryl%2520Ester%2520Transfer%2520Protein%2520Inhibition%2520Succeed%2520Primarily%2520by%2520Lowering%2520Low--Density%2520Lipoprotein%2520Cholesterol%253F%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2012%26volume%3D60%26spage%3D2049%26epage%3D2052%26doi%3D10.1016%2Fj.jacc.2012.08.967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Berenson, A.</span><span> </span><span class="NLM_article-title">Pfizer ends studies on drug for heart disease</span>.  <span class="citation_source-journal">The New York Times</span>; <span class="NLM_publisher-name">The New York Times Company</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">; </span><span class="NLM_issue">Dec 3</span> issue.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&issue=Dec+3&author=A.+Berenson&title=Pfizer+ends+studies+on+drug+for+heart+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerenson%26aufirst%3DA.%26atitle%3DPfizer%2520ends%2520studies%2520on%2520drug%2520for%2520heart%2520disease%26jtitle%3DThe%2520New%2520York%2520Times%26pub%3DThe%2520New%2520York%2520Times%2520Company%26date%3D2006%26issue%3DDec%25203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Barter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caulfield, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastelein, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komajda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Sendon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tardif, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shear, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Revkin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhr, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tall, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, B.</span><span> </span><span class="NLM_article-title">Effects of torcetrapib in patients at high risk for coronary events</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">2109</span><span class="NLM_x">â</span> <span class="NLM_lpage">2122</span><span class="refDoi">Â DOI: 10.1056/NEJMoa0706628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1056%2FNEJMoa0706628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=17984165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGns7bL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2007&pages=2109-2122&author=P.+J.+Barterauthor=M.+Caulfieldauthor=M.+Erikssonauthor=S.+M.+Grundyauthor=J.+J.+Kasteleinauthor=M.+Komajdaauthor=J.+Lopez-Sendonauthor=L.+Moscaauthor=J.-C.+Tardifauthor=D.+D.+Watersauthor=C.+L.+Shearauthor=J.+H.+Revkinauthor=K.+A.+Buhrauthor=M.+R.+Fisherauthor=A.+R.+Tallauthor=B.+Brewer&title=Effects+of+torcetrapib+in+patients+at+high+risk+for+coronary+events&doi=10.1056%2FNEJMoa0706628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of torcetrapib in patients at high risk for coronary events</span></div><div class="casAuthors">Barter, Philip J.; Caulfield, Mark; Eriksson, Mats; Grundy, Scott M.; Kastelein, John J. P.; Komajda, Michel; Lopez-Sendon, Jose; Mosca, Lori; Tardif, Jean-Claude; Waters, David D.; Shear, Charles L.; Revkin, James H.; Buhr, Kevin A.; Fisher, Marian R.; Tall, Alan R.; Brewer, Bryan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2109-2122</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels.  We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events.  The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib.  Methods: We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk.  The patients received either torcetrapib plus atorvastatin or atorvastatin alone.  The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina.  Results: At 12 mo in patients who received torcetrapib, there was an increase of 72.1% in high-d. lipoprotein cholesterol and a decrease of 24.9% in low-d. lipoprotein cholesterol, as compared with baseline (P < 0.001 for both comparisons), in addn. to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone (P < 0.001 for all comparisons).  There was also an increased risk of cardiovascular events (hazard ratio, 1.25; 95% confidence interval [CI], 1.09 to 1.44; P = 0.001) and death from any cause (hazard ratio, 1.58; 95% CI, 1.14 to 2.19; P = 0.006).  Post hoc analyses showed an increased risk of death in patients treated with torcetrapib whose redn. in potassium or increase in bicarbonate was greater than the median change.  Conclusions: Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism.  Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrjJJlK3IwJbVg90H21EOLACvtfcHk0lhVYsFuslWhKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGns7bL&md5=36913112326b0998658eaf6ea95b3ff9</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0706628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0706628%26sid%3Dliteratum%253Aachs%26aulast%3DBarter%26aufirst%3DP.%2BJ.%26aulast%3DCaulfield%26aufirst%3DM.%26aulast%3DEriksson%26aufirst%3DM.%26aulast%3DGrundy%26aufirst%3DS.%2BM.%26aulast%3DKastelein%26aufirst%3DJ.%2BJ.%26aulast%3DKomajda%26aufirst%3DM.%26aulast%3DLopez-Sendon%26aufirst%3DJ.%26aulast%3DMosca%26aufirst%3DL.%26aulast%3DTardif%26aufirst%3DJ.-C.%26aulast%3DWaters%26aufirst%3DD.%2BD.%26aulast%3DShear%26aufirst%3DC.%2BL.%26aulast%3DRevkin%26aufirst%3DJ.%2BH.%26aulast%3DBuhr%26aufirst%3DK.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BR.%26aulast%3DTall%26aufirst%3DA.%2BR.%26aulast%3DBrewer%26aufirst%3DB.%26atitle%3DEffects%2520of%2520torcetrapib%2520in%2520patients%2520at%2520high%2520risk%2520for%2520coronary%2520events%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D357%26spage%3D2109%26epage%3D2122%26doi%3D10.1056%2FNEJMoa0706628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tall, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yvan-Charvet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, N.</span><span> </span><span class="NLM_article-title">The failure of torcetrapib. Was it the molecule or the mechanism?</span> <span class="citation_source-journal">Arterioscler., Thromb., Vasc. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">â</span> <span class="NLM_lpage">260</span><span class="refDoi">Â DOI: 10.1161/01.ATV.0000256728.60226.77</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1161%2F01.ATV.0000256728.60226.77" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=17229967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGjt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=257-260&author=A.+R.+Tallauthor=L.+Yvan-Charvetauthor=N.+Wang&title=The+failure+of+torcetrapib.+Was+it+the+molecule+or+the+mechanism%3F&doi=10.1161%2F01.ATV.0000256728.60226.77"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">The failure of Torcetrapib: Was it the molecular or the mechanism?</span></div><div class="casAuthors">Tall, Alan R.; Yvan-Charvet, Laurent; Wang, Nan</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-260</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-GoP3oD2qXLVg90H21EOLACvtfcHk0lhVYsFuslWhKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGjt70%253D&md5=b14566b1132be7e285d4df2d1dfd34e5</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1161%2F01.ATV.0000256728.60226.77&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.ATV.0000256728.60226.77%26sid%3Dliteratum%253Aachs%26aulast%3DTall%26aufirst%3DA.%2BR.%26aulast%3DYvan-Charvet%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DN.%26atitle%3DThe%2520failure%2520of%2520torcetrapib.%2520Was%2520it%2520the%2520molecule%2520or%2520the%2520mechanism%253F%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2007%26volume%3D27%26spage%3D257%26epage%3D260%26doi%3D10.1161%2F01.ATV.0000256728.60226.77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Stroes, E. S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastelein, J. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benardeau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhlmann, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clerc, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niesor, E. J.</span><span> </span><span class="NLM_article-title">Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the reninâangiotensinâaldosterone system in rats</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">1763</span><span class="NLM_x">â</span> <span class="NLM_lpage">1770</span><span class="refDoi">Â DOI: 10.1111/j.1476-5381.2009.00460.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1111%2Fj.1476-5381.2009.00460.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=19917065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Whtr%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=1763-1770&author=E.+S.+G.+Stroesauthor=J.+J.+P.+Kasteleinauthor=A.+Benardeauauthor=O.+Kuhlmannauthor=D.+Blumauthor=L.+A.+Camposauthor=R.+G.+Clercauthor=E.+J.+Niesor&title=Dalcetrapib%3A+no+off-target+toxicity+on+blood+pressure+or+on+genes+related+to+the+renin%E2%80%93angiotensin%E2%80%93aldosterone+system+in+rats&doi=10.1111%2Fj.1476-5381.2009.00460.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats</span></div><div class="casAuthors">Stroes, E. S. G.; Kastelein, J. J. P.; Benardeau, A.; Kuhlmann, O.; Blum, D.; Campos, L. A.; Clerc, R. G.; Niesor, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1763-1770</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The assocn. between torcetrapib and its off-target effects on blood pressure suggested a possible class-specific effect.  The effects of dalcetrapib (RO4607381/JTT-705) and torcetrapib on haemodynamics and the renin-angiotensin-aldosterone system (RAAS) were therefore assessed in a rat model.  Arterial pressure (AP) and heart rate were measured by telemetry in normotensive and spontaneously hypertensive rats (SHR) receiving torcetrapib 10, 40, or 80 mg/kg-1/day-1; dalcetrapib 100, 300, or 500 mg-1/kg/day-1; or vehicle (placebo) for 5 days.  Expression of RAAS genes in adrenal gland, kidney, aorta and lung from normotensive rats following 5 days' treatment with torcetrapib 40 mg/kg-1/day-1, dalcetrapib 500 mg/kg-1/day-1 or vehicle was measured by quant. polymerase chain reaction.  Torcetrapib transiently increased mean AP in normotensive rats (+3.7 Â± 0.1 mmHg), whereas treatment in SHR resulted in a dose-dependent and sustained increase [+6.5 Â± 0.6 mmHg with 40 mg/kg-1/day-1 at day 1 (P < 0.05 vs. placebo)], which lasted over the treatment period.  No changes in AP or heart rate were obsd. with dalcetrapib.  Torcetrapib, but not dalcetrapib, increased RAAS-related mRNAs in adrenal glands and aortas.  In contrast to torcetrapib, dalcetrapib did not increase blood pressure or RAAS-related gene expression in rats, suggesting that the off-target effects of torcetrapib are not a common feature of all compds. acting on cholesteryl ester transfer protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4SJRkg9vZAbVg90H21EOLACvtfcHk0lhVYsFuslWhKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Whtr%252FL&md5=f907da070f24a4fe86e1398869c86de8</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00460.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00460.x%26sid%3Dliteratum%253Aachs%26aulast%3DStroes%26aufirst%3DE.%2BS.%2BG.%26aulast%3DKastelein%26aufirst%3DJ.%2BJ.%2BP.%26aulast%3DBenardeau%26aufirst%3DA.%26aulast%3DKuhlmann%26aufirst%3DO.%26aulast%3DBlum%26aufirst%3DD.%26aulast%3DCampos%26aufirst%3DL.%2BA.%26aulast%3DClerc%26aufirst%3DR.%2BG.%26aulast%3DNiesor%26aufirst%3DE.%2BJ.%26atitle%3DDalcetrapib%253A%2520no%2520off-target%2520toxicity%2520on%2520blood%2520pressure%2520or%2520on%2520genes%2520related%2520to%2520the%2520renin%25E2%2580%2593angiotensin%25E2%2580%2593aldosterone%2520system%2520in%2520rats%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D158%26spage%3D1763%26epage%3D1770%26doi%3D10.1111%2Fj.1476-5381.2009.00460.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loging, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, J.</span><span> </span><span class="NLM_article-title">Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">150</span><span class="NLM_x">, </span> <span class="NLM_fpage">2211</span><span class="NLM_x">â</span> <span class="NLM_lpage">2219</span><span class="refDoi">Â DOI: 10.1210/en.2008-1512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1210%2Fen.2008-1512" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2009&pages=2211-2219&author=X.+Huauthor=J.+D.+Dietzauthor=C.+Xiaauthor=D.+R.+Knightauthor=W.+T.+Logingauthor=A.+H.+Smithauthor=H.+Yuanauthor=D.+A.+Perryauthor=J.+Keiser&title=Torcetrapib+induces+aldosterone+and+cortisol+production+by+an+intracellular+calcium-mediated+mechanism+independently+of+cholesteryl+ester+transfer+protein+inhibition&doi=10.1210%2Fen.2008-1512"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1210%2Fen.2008-1512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2008-1512%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.%26aulast%3DDietz%26aufirst%3DJ.%2BD.%26aulast%3DXia%26aufirst%3DC.%26aulast%3DKnight%26aufirst%3DD.%2BR.%26aulast%3DLoging%26aufirst%3DW.%2BT.%26aulast%3DSmith%26aufirst%3DA.%2BH.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DPerry%26aufirst%3DD.%2BA.%26aulast%3DKeiser%26aufirst%3DJ.%26atitle%3DTorcetrapib%2520induces%2520aldosterone%2520and%2520cortisol%2520production%2520by%2520an%2520intracellular%2520calcium-mediated%2520mechanism%2520independently%2520of%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibition%26jtitle%3DEndocrinology%26date%3D2009%26volume%3D150%26spage%3D2211%26epage%3D2219%26doi%3D10.1210%2Fen.2008-1512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Forrest, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloomfield, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briscoe, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumiskey, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrhart, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hershey, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif-Rodriguez, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegl, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinclair, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparrow, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woltmann, R. F.</span><span> </span><span class="NLM_article-title">Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x">, </span> <span class="NLM_fpage">1465</span><span class="NLM_x">â</span> <span class="NLM_lpage">1473</span><span class="refDoi">Â DOI: 10.1038/bjp.2008.229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1038%2Fbjp.2008.229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=18536749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVajs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1465-1473&author=M.+J.+Forrestauthor=D.+Bloomfieldauthor=R.+J.+Briscoeauthor=P.+N.+Brownauthor=A.+M.+Cumiskeyauthor=J.+Ehrhartauthor=J.+C.+Hersheyauthor=W.+J.+Kellerauthor=X.+Maauthor=H.+E.+McPhersonauthor=E.+Messinaauthor=L.+B.+Petersonauthor=W.+Sharif-Rodriguezauthor=P.+K.+Sieglauthor=P.+J.+Sinclairauthor=C.+P.+Sparrowauthor=A.+S.+Stevensonauthor=S.+Y.+Sunauthor=C.+Tsaiauthor=H.+Vargasauthor=M.+Walkerauthor=S.+H.+Westauthor=V.+Whiteauthor=R.+F.+Woltmann&title=Torcetrapib-induced+blood+pressure+elevation+is+independent+of+CETP+inhibition+and+is+accompanied+by+increased+circulating+levels+of+aldosterone&doi=10.1038%2Fbjp.2008.229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6fR"><div class="casContent"><span class="casTitleNuber">6f</span><div class="casTitle"><span class="NLM_cas:atitle">Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone</span></div><div class="casAuthors">Forrest, M. J.; Bloomfield, D.; Briscoe, R. J.; Brown, P. N.; Cumiskey, A.-M.; Ehrhart, J.; Hershey, J. C.; Keller, W. J.; Ma, X.; McPherson, H. E.; Messina, E.; Peterson, L. B.; Sharif-Rodriguez, W.; Siegl, P. K. S.; Sinclair, P. J.; Sparrow, C. P.; Stevenson, A. S.; Sun, S.-Y.; Tsai, C.; Vargas, H.; Walker, M., III; West, S. H.; White, V.; Woltmann, R. F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1465-1473</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of cholesteryl ester transfer protein (CETP) with torcetrapib in humans increases plasma high d. lipoprotein (HDL) cholesterol levels but is assocd. with increased blood pressure.  In a phase 3 clin. study, evaluating the effects of torcetrapib in atherosclerosis, there was an excess of deaths and adverse cardiovascular events in patients taking torcetrapib.  The studies reported herein sought to evaluate off-target effects of torcetrapib.  Cardiovascular effects of the CETP inhibitors torcetrapib and anacetrapib were evaluated in animal models.  Torcetrapib evoked an acute increase in blood pressure in all species evaluated whereas no increase was obsd. with anacetrapib.  The pressor effect of torcetrapib was not diminished in the presence of adrenoceptor, angiotensin II or endothelin receptor antagonists.  Torcetrapib did not have a contractile effect on vascular smooth muscle suggesting its effects in vivo are via the release of a secondary mediator.  Treatment with torcetrapib was assocd. with an increase in plasma levels of aldosterone and corticosterone and, in vitro, was shown to release aldosterone from adrenocortical cells.  Increased adrenal steroid levels were not obsd. with anacetrapib.  Inhibition of adrenal steroid synthesis did not inhibit the pressor response to torcetrapib whereas adrenalectomy prevented the ability of torcetrapib to increase blood pressure in rats.  Torcetrapib evoked an acute increase in blood pressure and an acute increase in plasma adrenal steroids.  The acute pressor response to torcetrapib was not mediated by adrenal steroids but was dependent on intact adrenal glands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEhvVtQh2IkLVg90H21EOLACvtfcHk0ljGMz050QSudw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVajs7g%253D&md5=c24fd90f9cbd9e8c2ab9c7994f8b21c5</span></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.229%26sid%3Dliteratum%253Aachs%26aulast%3DForrest%26aufirst%3DM.%2BJ.%26aulast%3DBloomfield%26aufirst%3DD.%26aulast%3DBriscoe%26aufirst%3DR.%2BJ.%26aulast%3DBrown%26aufirst%3DP.%2BN.%26aulast%3DCumiskey%26aufirst%3DA.%2BM.%26aulast%3DEhrhart%26aufirst%3DJ.%26aulast%3DHershey%26aufirst%3DJ.%2BC.%26aulast%3DKeller%26aufirst%3DW.%2BJ.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DMcPherson%26aufirst%3DH.%2BE.%26aulast%3DMessina%26aufirst%3DE.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DSharif-Rodriguez%26aufirst%3DW.%26aulast%3DSiegl%26aufirst%3DP.%2BK.%26aulast%3DSinclair%26aufirst%3DP.%2BJ.%26aulast%3DSparrow%26aufirst%3DC.%2BP.%26aulast%3DStevenson%26aufirst%3DA.%2BS.%26aulast%3DSun%26aufirst%3DS.%2BY.%26aulast%3DTsai%26aufirst%3DC.%26aulast%3DVargas%26aufirst%3DH.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DWest%26aufirst%3DS.%2BH.%26aulast%3DWhite%26aufirst%3DV.%26aulast%3DWoltmann%26aufirst%3DR.%2BF.%26atitle%3DTorcetrapib-induced%2520blood%2520pressure%2520elevation%2520is%2520independent%2520of%2520CETP%2520inhibition%2520and%2520is%2520accompanied%2520by%2520increased%2520circulating%2520levels%2520of%2520aldosterone%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26spage%3D1465%26epage%3D1473%26doi%3D10.1038%2Fbjp.2008.229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Schwartz, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballantyne, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brumm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaitman, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holme, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallend, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiter, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leitersdorf, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurray, J. J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mundl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholls, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tardif, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. S.</span><span> </span><span class="NLM_article-title">For the dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">2089</span><span class="NLM_x">â</span> <span class="NLM_lpage">2099</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1206797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1056%2FNEJMoa1206797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=23126252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslyltrvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=2089-2099&author=G.+G.+Schwartzauthor=A.+G.+Olssonauthor=M.+Abtauthor=C.+M.+Ballantyneauthor=P.+J.+Barterauthor=J.+Brummauthor=B.+R.+Chaitmanauthor=I.+M.+Holmeauthor=D.+Kallendauthor=L.+A.+Leiterauthor=E.+Leitersdorfauthor=J.+J.+V.+McMurrayauthor=H.+Mundlauthor=S.+J.+Nichollsauthor=P.+K.+Shahauthor=J.-C.+Tardifauthor=R.+S.+Wright&title=For+the+dal-OUTCOMES+Investigators.+Effects+of+dalcetrapib+in+patients+with+a+recent+acute+coronary+syndrome&doi=10.1056%2FNEJMoa1206797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of dalcetrapib in patients with a recent acute coronary syndrome</span></div><div class="casAuthors">Schwartz, Gregory G.; Olsson, Anders G.; Abt, Markus; Ballantyne, Christie M.; Barter, Philip J.; Brumm, Jochen; Chaitman, Bernard R.; Holme, Ingar M.; Kallend, David; Leiter, Lawrence A.; Leitersdorf, Eran; McMurray, John J. V.; Mundl, Hardi; Nicholls, Stephen J.; Shah, Prediman K.; Tardif, Jean-Claude; Wright, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2089-2099</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BAckground: In observational analyses, higher levels of high-d. lipoprotein (HDL) cholesterol have been assocd. with a lower risk of coronary heart disease events.  However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain.  Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes.  Methods: We randomly assigned 15,871 patients who had had a recent acute coronary syndrome to receive the CETP inhibitor dalcetrapib, at a dose of 600 mg daily, or placebo, in addn. to the best available evidence-based care.  The primary efficacy end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest with resuscitation.  Results: At the time of randomization, the mean HDL cholesterol level was 42 mg per dL (1.1 mmol per L), and the mean low-d. lipoprotein (LDL) cholesterol level was 76 mg per dL (2.0 mmol per L).  Over the course of the trial, HDL cholesterol levels increased from baseline by 4 to 11% in the placebo group and by 31 to 40% in the dalcetrapib group.  Dalcetrapib had a minimal effect on LDL cholesterol levels.  Patients were followed for a median of 31 mo.  At a prespecified interim anal. that included 1135 primary end-point events (71% of the projected total no.), the independent data and safety monitoring board recommended termination of the trial for futility.  As compared with placebo, dalcetrapib did not alter the risk of the primary end point (cumulative event rate, 8.0% and 8.3%, resp.; hazard ratio with dalcetrapib, 1.04; 95% confidence interval, 0.93 to 1.16; P = 0.52) and did not have a significant effect on any component of the primary end point or total mortality.  The median C-reactive protein level was 0.2 mg per L higher and the mean systolic blood pressure was 0.6 mm Hg higher with dalcetrapib as compared with placebo (P<0.001 for both comparisons).  Conclusions: In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpppAqt1S8zjbVg90H21EOLACvtfcHk0ljGMz050QSudw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslyltrvK&md5=a9bcd3b77461ed5ef7e14fdbd8101a7b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1206797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1206797%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DG.%2BG.%26aulast%3DOlsson%26aufirst%3DA.%2BG.%26aulast%3DAbt%26aufirst%3DM.%26aulast%3DBallantyne%26aufirst%3DC.%2BM.%26aulast%3DBarter%26aufirst%3DP.%2BJ.%26aulast%3DBrumm%26aufirst%3DJ.%26aulast%3DChaitman%26aufirst%3DB.%2BR.%26aulast%3DHolme%26aufirst%3DI.%2BM.%26aulast%3DKallend%26aufirst%3DD.%26aulast%3DLeiter%26aufirst%3DL.%2BA.%26aulast%3DLeitersdorf%26aufirst%3DE.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%2BV.%26aulast%3DMundl%26aufirst%3DH.%26aulast%3DNicholls%26aufirst%3DS.%2BJ.%26aulast%3DShah%26aufirst%3DP.%2BK.%26aulast%3DTardif%26aufirst%3DJ.-C.%26aulast%3DWright%26aufirst%3DR.%2BS.%26atitle%3DFor%2520the%2520dal-OUTCOMES%2520Investigators.%2520Effects%2520of%2520dalcetrapib%2520in%2520patients%2520with%2520a%2520recent%2520acute%2520coronary%2520syndrome%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D2089%26epage%3D2099%26doi%3D10.1056%2FNEJMoa1206797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="note"><p class="first last">Publications on DPPE derivatives as CETP inhibitors:</p></div><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Harikrishnan, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamau, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adam, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A. Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleph, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitkoff, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galella, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nirschl, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Kirk, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wexler, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, R. M.</span><span> </span><span class="NLM_article-title">DiPhenylPyridylEthanamine (DPPE) derivatives as cholesterol ester transfer protein (CETP) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6162</span><span class="NLM_x">â</span> <span class="NLM_lpage">6175</span><span class="refDoi">Â DOI: 10.1021/jm300611v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300611v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnsl2ms7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6162-6175&author=L.+S.+Harikrishnanauthor=H.+J.+Finlayauthor=J.+X.+Qiaoauthor=M.+G.+Kamauauthor=J.+Jiangauthor=T.+C.+Wangauthor=J.+Liauthor=C.+B.+Cooperauthor=M.+A.+Possauthor=L.+P.+Adamauthor=D.+S.+Taylorauthor=A.+Y.+A.+Chenauthor=X.+Yinauthor=P.+G.+Slephauthor=R.+Z.+Yangauthor=D.+F.+Sitkoffauthor=M.+A.+Galellaauthor=D.+S.+Nirschlauthor=K.+Van+Kirkauthor=A.+V.+Millerauthor=C.+S.+Huangauthor=M.+Changauthor=X.-Q.+Chenauthor=M.+E.+Salvatiauthor=R.+R.+Wexlerauthor=R.+M.+Lawrence&title=DiPhenylPyridylEthanamine+%28DPPE%29+derivatives+as+cholesterol+ester+transfer+protein+%28CETP%29+inhibitors&doi=10.1021%2Fjm300611v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Diphenylpyridylethanamine (DPPE) Derivatives as Cholesteryl Ester Transfer Protein (CETP) Inhibitors</span></div><div class="casAuthors">Harikrishnan, Lalgudi S.; Finlay, Heather J.; Qiao, Jennifer X.; Kamau, Muthoni G.; Jiang, Ji; Wang, Tammy C.; Li, James; Cooper, Christopher B.; Poss, Michael A.; Adam, Leonard P.; Taylor, David S.; Chen, Alice Ye A.; Yin, Xiaohong; Sleph, Paul G.; Yang, Richard Z.; Sitkoff, Doree F.; Galella, Michael A.; Nirschl, David S.; Van Kirk, Katy; Miller, Arthur V.; Huang, Christine S.; Chang, Ming; Chen, Xue-Qing; Salvati, Mark E.; Wexler, Ruth R.; Lawrence, R. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6162-6175</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of phenylpyridylethanamine (DPPE) derivs. I (R1 = H, Cl, F, CN; R2 = 3-F3CC6H4, 3-F3COC6H4, 3-F-5-CF3C6H3, etc.; R3 = H2C:CHCH2, MeO2C, Ph, 2-FC6H4, 1,2,4-triazol-3-yl, etc.; X = t-BuCH2CO2, PhCONH, CypNHCONH, etc.; Cyp = cyclopentyl) and II (R4 = Cl, MeO) was identified exhibiting potent CETP inhibition.  Replacing the labile ester functionality in the initial lead I (R1 = H; R2 = 3-F3CC6H4; R3 = Ph; X = t-BuCH2CO2) generated a series of amides and ureas.  Further optimization of the DPPE series for potency resulted in the discovery of cyclopentylurea (S)-I (R1 = Cl; R2 = 3-CHF2CF2O-5-FC6H4; R3 = Ph; X = CypNHCONH) which demonstrated a redn. in cholesterol ester transfer activity (48% of predose level) in hCETP/apoB-100 dual transgenic mice.  The PK profile of this compd. was suboptimal, and further optimization of the N-terminus resulted in the discovery of amide I (R1 = Cl; R2 = 3-CHF2CF2O-5-FC6H4; R3 = Ph; X = 3-CF3-4-FC6H3CONH) with an improved PK profile and robust efficacy in transgenic hCETP/apoB-100 mice and in hamsters.  The latter compd. demonstrated no significant changes in either mean arterial blood pressure or heart rate in telemeterized rats despite sustained high exposures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtXNZfx82j2LVg90H21EOLACvtfcHk0lgInXdkv-_JFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnsl2ms7c%253D&md5=bfa31186811777ce84c4bbc203accb9f</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1021%2Fjm300611v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300611v%26sid%3Dliteratum%253Aachs%26aulast%3DHarikrishnan%26aufirst%3DL.%2BS.%26aulast%3DFinlay%26aufirst%3DH.%2BJ.%26aulast%3DQiao%26aufirst%3DJ.%2BX.%26aulast%3DKamau%26aufirst%3DM.%2BG.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCooper%26aufirst%3DC.%2BB.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DAdam%26aufirst%3DL.%2BP.%26aulast%3DTaylor%26aufirst%3DD.%2BS.%26aulast%3DChen%26aufirst%3DA.%2BY.%2BA.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DSleph%26aufirst%3DP.%2BG.%26aulast%3DYang%26aufirst%3DR.%2BZ.%26aulast%3DSitkoff%26aufirst%3DD.%2BF.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DNirschl%26aufirst%3DD.%2BS.%26aulast%3DVan%2BKirk%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DA.%2BV.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DX.-Q.%26aulast%3DSalvati%26aufirst%3DM.%2BE.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26atitle%3DDiPhenylPyridylEthanamine%2520%2528DPPE%2529%2520derivatives%2520as%2520cholesterol%2520ester%2520transfer%2520protein%2520%2528CETP%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6162%26epage%3D6175%26doi%3D10.1021%2Fjm300611v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Miller, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nirschl, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harikrishnan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A. Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seethala, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wexler, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adam, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, M. E.</span><span> </span><span class="NLM_article-title">Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6503</span><span class="NLM_x">â</span> <span class="NLM_lpage">6508</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2012.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1016%2Fj.bmcl.2012.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=22995620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlymtLbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6503-6508&author=M.+M.+Millerauthor=Y.+Liuauthor=J.+Jiangauthor=J.+A.+Johnsonauthor=M.+Kamauauthor=D.+S.+Nirschlauthor=Y.+Wangauthor=L.+Harikrishnanauthor=D.+S.+Taylorauthor=A.+Y.+A.+Chenauthor=X.+Yinauthor=R.+Seethalaauthor=T.+L.+Petersonauthor=T.+Zvyagaauthor=J.+Zhangauthor=C.+S.+Huangauthor=R.+R.+Wexlerauthor=M.+A.+Possauthor=R.+M.+Lawrenceauthor=L.+P.+Adamauthor=M.+E.+Salvati&title=Identification+of+a+potent+and+metabolically+stable+series+of+fluorinated+diphenylpyridylethanamine-based+cholesteryl+ester+transfer+protein+inhibitors&doi=10.1016%2Fj.bmcl.2012.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors</span></div><div class="casAuthors">Miller, Michael M.; Liu, Yalei; Jiang, Ji; Johnson, James A.; Kamau, Muthoni; Nirschl, David S.; Wang, Yufeng; Harikrishnan, Lalgudi; Taylor, David S.; Chen, Alice Ye A.; Yin, Xiaohong; Seethala, Ramakrishna; Peterson, Tara L.; Zvyaga, Tatyana; Zhang, Jun; Huang, Christine S.; Wexler, Ruth R.; Poss, Michael A.; Michael Lawrence, R.; Adam, Leonard P.; Salvati, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6503-6508</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of diphenylpyridylethanamine-based inhibitors of cholesteryl ester transfer protein, e.g. I, is described.  Optimization of the urea moiety, particularly by incorporation of fluorine, is explored to balance in vitro metabolic stability with CETP potency in the whole plasma assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNLpqF9RExgLVg90H21EOLACvtfcHk0lgInXdkv-_JFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlymtLbF&md5=6473c4b4e6dbac03d5532e57932aa04c</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DJ.%2BA.%26aulast%3DKamau%26aufirst%3DM.%26aulast%3DNirschl%26aufirst%3DD.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHarikrishnan%26aufirst%3DL.%26aulast%3DTaylor%26aufirst%3DD.%2BS.%26aulast%3DChen%26aufirst%3DA.%2BY.%2BA.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DSeethala%26aufirst%3DR.%26aulast%3DPeterson%26aufirst%3DT.%2BL.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26aulast%3DAdam%26aufirst%3DL.%2BP.%26aulast%3DSalvati%26aufirst%3DM.%2BE.%26atitle%3DIdentification%2520of%2520a%2520potent%2520and%2520metabolically%2520stable%2520series%2520of%2520fluorinated%2520diphenylpyridylethanamine-based%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6503%26epage%3D6508%26doi%3D10.1016%2Fj.bmcl.2012.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="note"><p class="first last">The SPA is an enzymatic assay in which the CETP inhibitory activity was measured as the amount of [<sup>3</sup>H]cholesteryl ester ([<sup>3</sup>H]CE) transferred from HDL ([<sup>3</sup>H]CE/HDL) to biotinylated LDL and captured on avidin-SPA beads. See ref <a onclick="showRef(event, 'cit8a'); return false;" href="javascript:void(0);" class="ref cit8a">8a</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_001.pdf" class="ext-link">Supporting Information</a> for assay details.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="note"><p class="first last">For the transgenic mouse pharmacodynamic study, transgenic mice expressing human CETP and apoB-100 were used. Predose blood samples were collected by retro-orbital bleed. Compounds were formulated in ethanol/Cremophor/water at a 1:1:8 ratio and dosed at 10 mg/kg, po. At 2, 4, and 8 h after dosing, blood samples were collected. Cholesterol ester transfer activity was measured in all blood samples and normalized by the activity measured in the same animal at baseline (mean of four or five mice per dose).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="note"><p class="first last">For the hamster study, plasma HDL-C was measured in male Golden Syrian hamsters initially fed a moderately fat diet (2.5% coconut oil, 0.25% cholesterol) for 2 weeks. The hamsters were then dosed with vehicle or compound, po, q.d. At 2 h after dosing on day 3, plasma samples were obtained and HDL-C was measured and compared to the values measured before dosing.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Wang, T. C.; Qiao, J. X.; Chen, A. Y.; Taylor, D. S.; Yang, R. Z.; Paul, G.; Sleph, P. S.; Li, J. P.; Li, D.; Chang, M.; Chen, X.-Q.; Li, J.; Levesque, P.; Huang, C. S.; Adam, L. P.; Salvati, M. E.; Finlay, H.; Wexler, R. R.</span><span> </span><span class="NLM_article-title">Discovery and synthesis of triphenylethanamine derivatives as highly potent cholesteryl ester transfer protein inhibitors</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 249th National Meeting and Exposition of the American Chemical Society, Denver, CO, U.S., March 22â26, 2015; American Chemical Society: Washington, DC,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>MEDI-78.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=T.+C.+Wang&author=J.+X.+Qiao&author=A.+Y.+Chen&author=D.+S.+Taylor&author=R.+Z.+Yang&author=G.+Paul&author=P.+S.+Sleph&author=J.+P.+Li&author=D.+Li&author=M.+Chang&author=X.-Q.+Chen&author=J.+Li&author=P.+Levesque&author=C.+S.+Huang&author=L.+P.+Adam&author=M.+E.+Salvati&author=H.+Finlay&author=R.+R.+Wexler&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%2BC.%26atitle%3DDiscovery%2520and%2520synthesis%2520of%2520triphenylethanamine%2520derivatives%2520as%2520highly%2520potent%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibitors%26btitle%3DAbstracts%2520of%2520Papers%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kamau, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harikrishnan, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wexler, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, R. M.</span><span> </span><span class="NLM_article-title">Synthesis of tertiary carbinamines</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">2696</span><span class="NLM_x">â</span> <span class="NLM_lpage">2703</span><span class="refDoi">Â DOI: 10.1016/j.tet.2012.01.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1016%2Fj.tet.2012.01.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFSgsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=2696-2703&author=M.+G.+Kamauauthor=L.+S.+Harikrishnanauthor=H.+J.+Finlayauthor=J.+X.+Qiaoauthor=J.+Jiangauthor=M.+A.+Possauthor=M.+E.+Salvatiauthor=R.+R.+Wexlerauthor=R.+M.+Lawrence&title=Synthesis+of+tertiary+carbinamines&doi=10.1016%2Fj.tet.2012.01.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of tertiary carbinamines</span></div><div class="casAuthors">Kamau, Muthoni G.; Harikrishnan, Lalgudi S.; Finlay, Heather J.; Qiao, Jennifer X.; Jiang, Ji; Poss, Michael A.; Salvati, Mark E.; Wexler, Ruth R.; Lawrence, R. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2696-2703</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">An efficient synthesis of tertiary carbinamines using a one-pot, three-component reaction employing TMSCl activation of an intermediate imine salt followed by addn. of an organometallic is described.  E.g., reaction of 3-fluorobenzonitrile with BuLi, followed by treatment with TMSCl and BnMgCl, gave 29% tertiary amine (I).  An optimized second generation chiral synthesis of select tertiary carbinamines utilizing the Ellman sulfinamine was subsequently developed on a multi-gram scale and is also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6ERHpjrNS7bVg90H21EOLACvtfcHk0lh0paMfzHnKlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFSgsL0%253D&md5=494845bb5bc38764a8cea6733791209c</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2012.01.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2012.01.050%26sid%3Dliteratum%253Aachs%26aulast%3DKamau%26aufirst%3DM.%2BG.%26aulast%3DHarikrishnan%26aufirst%3DL.%2BS.%26aulast%3DFinlay%26aufirst%3DH.%2BJ.%26aulast%3DQiao%26aufirst%3DJ.%2BX.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DSalvati%26aufirst%3DM.%2BE.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26atitle%3DSynthesis%2520of%2520tertiary%2520carbinamines%26jtitle%3DTetrahedron%26date%3D2012%26volume%3D68%26spage%3D2696%26epage%3D2703%26doi%3D10.1016%2Fj.tet.2012.01.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shaw, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deSolms, S. J.</span><span> </span><span class="NLM_article-title">Asymmetric synthesis of Î±,Î±-diaryl and Î±-aryl-Î±-heteroaryl alkylamines by organometallic additions to <i>N-tert</i>-butanesulfinyl ketimines</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">7173</span><span class="NLM_x">â</span> <span class="NLM_lpage">7176</span><span class="refDoi">Â DOI: 10.1016/S0040-4039(01)01513-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1016%2FS0040-4039%2801%2901513-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2001&pages=7173-7176&author=A.+W.+Shawauthor=S.+J.+deSolms&title=Asymmetric+synthesis+of+%CE%B1%2C%CE%B1-diaryl+and+%CE%B1-aryl-%CE%B1-heteroaryl+alkylamines+by+organometallic+additions+to+N-tert-butanesulfinyl+ketimines&doi=10.1016%2FS0040-4039%2801%2901513-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2901513-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252901513-1%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BW.%26aulast%3DdeSolms%26aufirst%3DS.%2BJ.%26atitle%3DAsymmetric%2520synthesis%2520of%2520%25CE%25B1%252C%25CE%25B1-diaryl%2520and%2520%25CE%25B1-aryl-%25CE%25B1-heteroaryl%2520alkylamines%2520by%2520organometallic%2520additions%2520to%2520N-tert-butanesulfinyl%2520ketimines%26jtitle%3DTetrahedron%2520Lett.%26date%3D2001%26volume%3D42%26spage%3D7173%26epage%3D7176%26doi%3D10.1016%2FS0040-4039%2801%2901513-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Davis, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoull, W.</span><span> </span><span class="NLM_article-title">Concise asymmetric synthesis of Î±-amino acid derivatives from <i>N</i>-sulfinylimino esters</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">3396</span><span class="NLM_x">â</span> <span class="NLM_lpage">3397</span><span class="refDoi">Â DOI: 10.1021/jo990303f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo990303f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=3396-3397&author=F.+A.+Davisauthor=W.+McCoull&title=Concise+asymmetric+synthesis+of+%CE%B1-amino+acid+derivatives+from+N-sulfinylimino+esters&doi=10.1021%2Fjo990303f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Fjo990303f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo990303f%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DF.%2BA.%26aulast%3DMcCoull%26aufirst%3DW.%26atitle%3DConcise%2520asymmetric%2520synthesis%2520of%2520%25CE%25B1-amino%2520acid%2520derivatives%2520from%2520N-sulfinylimino%2520esters%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1999%26volume%3D64%26spage%3D3396%26epage%3D3397%26doi%3D10.1021%2Fjo990303f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Davis, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczyk, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portonovo, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, P. J.</span><span> </span><span class="NLM_article-title">Asymmetric synthesis and properties of sulfinimines (thiooxime <i>S</i>-oxides)</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">2555</span><span class="NLM_x">â</span> <span class="NLM_lpage">2563</span><span class="refDoi">Â DOI: 10.1021/jo970077e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo970077e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADyaK2sXitFyltLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1997&pages=2555-2563&author=F.+A.+Davisauthor=R.+E.+Reddyauthor=J.+M.+Szewczykauthor=G.+V.+Reddyauthor=P.+S.+Portonovoauthor=H.+Zhangauthor=D.+Fanelliauthor=R.+T.+Reddyauthor=P.+Zhouauthor=P.+J.+Carroll&title=Asymmetric+synthesis+and+properties+of+sulfinimines+%28thiooxime+S-oxides%29&doi=10.1021%2Fjo970077e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric Synthesis and Properties of Sulfinimines (Thiooxime S-Oxides)</span></div><div class="casAuthors">Davis, Franklin A.; Reddy, Rajarathnam E.; Szewczyk, Joanna M.; Reddy, G. Venkat; Portonovo, Padma S.; Zhang, Huiming; Fanelli, Dean; Reddy, Thimma; Zhou, Ping; Carroll, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2555-2563</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Enantiomerically pure sulfinimines (thiooxime S-oxides), important building blocks in the asym. synthesis of amine derivs., are prepd. in good to excellent yields in one step from arom., heteroarom., and aliph. aldehydes.  This protocol involves treating com. available (R)- or (S)-menthyl p-toluenesufinate (Andersen reagent, I) with LiHMDS, followed by the aldehyde, affording the (E)-sulfinimine exclusively.  The sulfinimines are formed via a Peterson-type olefination reaction of silylsulfinamide anion with the aldehyde.  The silylsulfinamide anion is generated by reaction of lithium menthoxide with bis(trimethylsilyl)sulfinamide, which is formed in the reaction of I with LiHMDS.  The other product formed is O-(trimethylsilyl)menthol, which is isolated in >80% yield for recycling.  Two other less efficient methods for the asym. synthesis of sulfinimines are discussed: (i) the asym. oxidn. of sulfenimines with chiral nonracemic oxaziridines and (ii) the reaction of metal aldimines, prepd. from nitriles, with I.  All of these protocols fail with ketones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUwFtcNvzVAbVg90H21EOLACvtfcHk0lh0paMfzHnKlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXitFyltLs%253D&md5=6950e2cc3cefe2884e88ac1eec86d630</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1021%2Fjo970077e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo970077e%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DF.%2BA.%26aulast%3DReddy%26aufirst%3DR.%2BE.%26aulast%3DSzewczyk%26aufirst%3DJ.%2BM.%26aulast%3DReddy%26aufirst%3DG.%2BV.%26aulast%3DPortonovo%26aufirst%3DP.%2BS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DFanelli%26aufirst%3DD.%26aulast%3DReddy%26aufirst%3DR.%2BT.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DCarroll%26aufirst%3DP.%2BJ.%26atitle%3DAsymmetric%2520synthesis%2520and%2520properties%2520of%2520sulfinimines%2520%2528thiooxime%2520S-oxides%2529%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1997%26volume%3D62%26spage%3D2555%26epage%3D2563%26doi%3D10.1021%2Fjo970077e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ellman, J. A.</span><span> </span><span class="NLM_article-title">Applications of <i>tert</i>-butanesulfinamide in the asymmetric synthesis of amines</span> <span class="citation_source-journal">Pure Appl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">â</span> <span class="NLM_lpage">46</span><div class="note"><p class="first last">and references therein</p></div><span class="refDoi">Â DOI: 10.1351/pac200375010039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1351%2Fpac200375010039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1Sisr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2003&pages=39-46&author=J.+A.+Ellman&title=Applications+of+tert-butanesulfinamide+in+the+asymmetric+synthesis+of+amines&doi=10.1351%2Fpac200375010039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of tert-butanesulfinamide in the asymmetric synthesis of amines</span></div><div class="casAuthors">Ellman, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Pure and Applied Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-46</span>CODEN:
                <span class="NLM_cas:coden">PACHAS</span>;
        ISSN:<span class="NLM_cas:issn">0033-4545</span>.
    
            (<span class="NLM_cas:orgname">International Union of Pure and Applied Chemistry</span>)
        </div><div class="casAbstract">A review.  Tert-Butanesulfinamide (2-methyl-2-propanesulfinamide) is prepd. using catalytic enantioselective methods in two steps from the extremely inexpensive oil waste byproduct, tert-Bu disulfide.  Direct condensation of tert-butanesulfinamide with aldehydes and ketones provides tert-butanesulfinyl imines in uniformly high yields.  The tert-butanesulfinyl group activates the imines for the addn. of many different classes of nucleophiles, serves as a powerful chiral directing group, and after nucleophilic addn. is readily cleaved by treatment with acid.  A wide range of highly enantioenriched amines, including a-branched and Î±,Î±-dibranched amines, Î±- and Î²-amino acids, 1,2- and 1,3-amino alcs. and Î±-trifluoromethyl amines are efficiently synthesized using this methodol.  A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreXHI36VE2U7Vg90H21EOLACvtfcHk0lj3AhvFs5BDvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1Sisr8%253D&md5=d4f9b92b02e94084e0ca0285ecb30af3</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1351%2Fpac200375010039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1351%252Fpac200375010039%26sid%3Dliteratum%253Aachs%26aulast%3DEllman%26aufirst%3DJ.%2BA.%26atitle%3DApplications%2520of%2520tert-butanesulfinamide%2520in%2520the%2520asymmetric%2520synthesis%2520of%2520amines%26jtitle%3DPure%2520Appl.%2520Chem.%26date%3D2003%26volume%3D75%26spage%3D39%26epage%3D46%26doi%3D10.1351%2Fpac200375010039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span>Full crystallographic data have been deposited with the Cambridge Crystallographic Data Center under CCDC reference number 1422275. Copies of the data can be obtained free of charge via the Internet at <a href="http://www.ccdc.cam.ac.uk" class="extLink">http://www.ccdc.cam.ac.uk</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Full+crystallographic+data+have+been+deposited+with+the+Cambridge+Crystallographic+Data+Center+under+CCDC+reference+number+1422275.+Copies+of+the+data+can+be+obtained+free+of+charge+via+the+Internet+at+http%3A%2F%2Fwww.ccdc.cam.ac.uk."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnananthan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.-C.</span><span> </span><span class="NLM_article-title">Preparation of monofluorophenols via the reaction of difluorobenzene derivatives with potassium trimethylsilanoate</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2009</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">633</span><span class="NLM_x">â</span> <span class="NLM_lpage">637</span><span class="refDoi">Â DOI: 10.1055/s-0028-1087564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1055%2Fs-0028-1087564" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2009&publication_year=2009&pages=633-637&issue=4&author=J.+Liauthor=D.+Smithauthor=J.+X.+Qiaoauthor=S.+Huangauthor=S.+Krishnananthanauthor=H.+S.+Wongauthor=M.+E.+Salvatiauthor=B.+N.+Balasubramanianauthor=B.-C.+Chen&title=Preparation+of+monofluorophenols+via+the+reaction+of+difluorobenzene+derivatives+with+potassium+trimethylsilanoate&doi=10.1055%2Fs-0028-1087564"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1055%2Fs-0028-1087564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0028-1087564%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DQiao%26aufirst%3DJ.%2BX.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DKrishnananthan%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DH.%2BS.%26aulast%3DSalvati%26aufirst%3DM.%2BE.%26aulast%3DBalasubramanian%26aufirst%3DB.%2BN.%26aulast%3DChen%26aufirst%3DB.-C.%26atitle%3DPreparation%2520of%2520monofluorophenols%2520via%2520the%2520reaction%2520of%2520difluorobenzene%2520derivatives%2520with%2520potassium%2520trimethylsilanoate%26jtitle%3DSynlett%26date%3D2009%26volume%3D2009%26issue%3D4%26spage%3D633%26epage%3D637%26doi%3D10.1055%2Fs-0028-1087564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberge, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, B. N.</span><span> </span><span class="NLM_article-title">A practical synthesis of aryl tetrafluoroethyl ethers via the improved reaction of phenols with 1,2-dibromotetrafluoroethane</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7516</span><span class="NLM_x">â</span> <span class="NLM_lpage">7519</span><span class="refDoi">Â DOI: 10.1016/j.tetlet.2007.08.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1016%2Fj.tetlet.2007.08.065" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=7516-7519&author=J.+Liauthor=J.+X.+Qiaoauthor=D.+Smithauthor=B.-C.+Chenauthor=M.+E.+Salvatiauthor=J.+Y.+Robergeauthor=B.+N.+Balasubramanian&title=A+practical+synthesis+of+aryl+tetrafluoroethyl+ethers+via+the+improved+reaction+of+phenols+with+1%2C2-dibromotetrafluoroethane&doi=10.1016%2Fj.tetlet.2007.08.065"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2007.08.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2007.08.065%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DQiao%26aufirst%3DJ.%2BX.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DB.-C.%26aulast%3DSalvati%26aufirst%3DM.%2BE.%26aulast%3DRoberge%26aufirst%3DJ.%2BY.%26aulast%3DBalasubramanian%26aufirst%3DB.%2BN.%26atitle%3DA%2520practical%2520synthesis%2520of%2520aryl%2520tetrafluoroethyl%2520ethers%2520via%2520the%2520improved%2520reaction%2520of%2520phenols%2520with%25201%252C2-dibromotetrafluoroethane%26jtitle%3DTetrahedron%2520Lett.%26date%3D2007%26volume%3D48%26spage%3D7516%26epage%3D7519%26doi%3D10.1016%2Fj.tetlet.2007.08.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McKinley, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, D. F.</span><span> </span><span class="NLM_article-title">Efficient synthesis of aryl vinyl ethers exploiting 2,4,6-trivinylcyclotriboroxane as a vinylboronic acid equivalent</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">5087</span><span class="NLM_x">â</span> <span class="NLM_lpage">5092</span><span class="refDoi">Â DOI: 10.1021/jo049314l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo049314l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVKrsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=5087-5092&author=N.+F.+McKinleyauthor=D.+F.+O%E2%80%99Shea&title=Efficient+synthesis+of+aryl+vinyl+ethers+exploiting+2%2C4%2C6-trivinylcyclotriboroxane+as+a+vinylboronic+acid+equivalent&doi=10.1021%2Fjo049314l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient Synthesis of Aryl Vinyl Ethers Exploiting 2,4,6-Trivinylcyclotriboroxane as a Vinylboronic Acid Equivalent</span></div><div class="casAuthors">McKinley, Neola F.; O'Shea, Donal F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5087-5092</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of functionalized aryl vinyl ether derivs. can be readily achieved utilizing a room-temp. copper(II) acetate mediated coupling of substituted phenols with 2,4,6-trivinylcyclotriboroxane-pyridine complex in the presence of a suitable base.  The scope of the procedure was demonstrated by the generation of an array of substituted aryl vinyl ethers.  The reaction was seen to be tolerant of a diverse range of functional groups yielding products in high isolated yields.  It was shown that one role of an amine base in the reaction sequence is the in situ generation of an amine-coordinated boroxine ring.  An X-ray crystal structure and low temp. 11B NMR study of 2,4,6-trivinylcyclotriboroxane-pyridine complex demonstrated the nature of a tetracoordinate boron species, which may have a key role to play within the reaction sequence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCAdAkCsZPNLVg90H21EOLACvtfcHk0limsTy5Xq1PEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVKrsLY%253D&md5=13e595af6da99007cd4d6ea25a6b1633</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1021%2Fjo049314l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo049314l%26sid%3Dliteratum%253Aachs%26aulast%3DMcKinley%26aufirst%3DN.%2BF.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DD.%2BF.%26atitle%3DEfficient%2520synthesis%2520of%2520aryl%2520vinyl%2520ethers%2520exploiting%25202%252C4%252C6-trivinylcyclotriboroxane%2520as%2520a%2520vinylboronic%2520acid%2520equivalent%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D5087%26epage%3D5092%26doi%3D10.1021%2Fjo049314l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Okimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, Y.</span><span> </span><span class="NLM_article-title">Development of a highly efficient catalytic method for synthesis of vinyl ethers</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">1590</span><span class="NLM_x">â</span> <span class="NLM_lpage">1591</span><span class="refDoi">Â DOI: 10.1021/ja0173932</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0173932" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=1%3ACAS%3A528%3ADC%252BD38Xps1Wluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=1590-1591&author=Y.+Okimotoauthor=S.+Sakaguchiauthor=Y.+Ishii&title=Development+of+a+highly+efficient+catalytic+method+for+synthesis+of+vinyl+ethers&doi=10.1021%2Fja0173932"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Highly Efficient Catalytic Method for Synthesis of Vinyl Ethers</span></div><div class="casAuthors">Okimoto, Yoshio; Sakaguchi, Satoshi; Ishii, Yasutaka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1590-1591</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new method for the prepn. of alkyl vinyl ethers has been developed.  Thus, vinyl ethers ROCH:CH2 (R = Octyl, PhCH2, PhCHMe, Menthyl, Adamant-1-yl, Ph) were synthesized by the reaction of alcs. with vinyl acetate under the influence of a catalytic amt. of [Ir(cod)Cl]2 combined with Na2CO3 in good to excellent yields.  Similarly, divinyl ethers, e.g. CH2:CHOCH2(CH2)4CH2OCH:CH2 were also prepd. from the corresponding diols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrwt0CyT1Lv7Vg90H21EOLACvtfcHk0limsTy5Xq1PEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xps1Wluw%253D%253D&md5=23521ecc37aebf765c9f50810c7b2c08</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1021%2Fja0173932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0173932%26sid%3Dliteratum%253Aachs%26aulast%3DOkimoto%26aufirst%3DY.%26aulast%3DSakaguchi%26aufirst%3DS.%26aulast%3DIshii%26aufirst%3DY.%26atitle%3DDevelopment%2520of%2520a%2520highly%2520efficient%2520catalytic%2520method%2520for%2520synthesis%2520of%2520vinyl%2520ethers%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26spage%3D1590%26epage%3D1591%26doi%3D10.1021%2Fja0173932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><div class="note"><p class="first last">CETP facilitates the removal of cholesteryl esters (CE) from HDL and thus reduces HDL-C levels, while PLTP promotes the transfer of phospholipids (PL) from triglyceride-rich lipoproteins into HDL and increases HDL-C levels. PLTP activity was measured as described previously</p></div> ( <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">907</span><span class="NLM_x">â</span> <span class="NLM_lpage">914</span>) <div class="note"><p class="first last">with modifications. See <a href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_001.pdf" class="ext-link">Supporting Information</a> for more details.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CETP+facilitates+the+removal+of+cholesteryl+esters+%28CE%29+from+HDL+and+thus+reduces+HDL-C+levels%2C+while+PLTP+promotes+the+transfer+of+phospholipids+%28PL%29+from+triglyceride-rich+lipoproteins+into+HDL+and+increases+HDL-C+levels.+PLTP+activity+was+measured+as+described+previously+%28J.+Clin.+Invest.+1999%2C+103%2C+907%E2%80%93914%29+with+modifications.+See+Supporting+Information+for+more+details."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1999%26volume%3D103%26spage%3D907%26epage%3D914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="note"><p class="first last">Lipoprotein disruption assay: Lipoprotein disruption components (human origin, Biomedical Technologies, Inc.) were diluted in assay buffer [50 mM HEPEs (pH 7.4), 150 mM NaCl, 0.05% NaN<sub>3</sub> (w/v)] to concentrations utilized in the aforementioned SPA assay. LDL and HDL were diluted to 5 and 16 Î¼g/mL, respectively. In-house generated [<sup>3</sup>H]cholesterol ester-HDL was diluted 30-fold in the reaction mix which was subsequently incubated in the absence and presence of CETP inhibitors for 4 h at 37 Â°C. Lipoprotein associated [<sup>3</sup>H]cholesterol ester was resolved by agarose gel electrophoresis and imaged by quantitative phosphor imaging autoradiography.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="note"><p class="first last">Tg WPA: Measurement of cholesterol ester transfer activity in plasma samples obtained from compound-treated human CETP/apoB100 dual transgenic mice (Taconic Laboratories) was obtained following the described variation of the hWPA methodology. See <a href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_001.pdf" class="ext-link">Supporting Information</a> for details.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Lloyd, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lira, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durham, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preston, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnette, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanzetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milos, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, J. F.</span><span> </span><span class="NLM_article-title">Cholesteryl ester transfer protein variants have differential stability but uniform inhibition by torcetrapib</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">14918</span><span class="NLM_x">â</span> <span class="NLM_lpage">14922</span><span class="refDoi">Â DOI: 10.1074/jbc.M500523200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;key=10.1074%2Fjbc.M500523200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=14918-14922&author=D.+B.+Lloydauthor=M.+E.+Liraauthor=L.+S.+Woodauthor=L.+K.+Durhamauthor=T.+B.+Freemanauthor=G.+M.+Prestonauthor=X.+Qiuauthor=E.+Sugarmanauthor=P.+Bonnetteauthor=A.+Lanzettiauthor=P.+M.+Milosauthor=J.+F.+Thompson&title=Cholesteryl+ester+transfer+protein+variants+have+differential+stability+but+uniform+inhibition+by+torcetrapib&doi=10.1074%2Fjbc.M500523200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M500523200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M500523200%26sid%3Dliteratum%253Aachs%26aulast%3DLloyd%26aufirst%3DD.%2BB.%26aulast%3DLira%26aufirst%3DM.%2BE.%26aulast%3DWood%26aufirst%3DL.%2BS.%26aulast%3DDurham%26aufirst%3DL.%2BK.%26aulast%3DFreeman%26aufirst%3DT.%2BB.%26aulast%3DPreston%26aufirst%3DG.%2BM.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DSugarman%26aufirst%3DE.%26aulast%3DBonnette%26aufirst%3DP.%26aulast%3DLanzetti%26aufirst%3DA.%26aulast%3DMilos%26aufirst%3DP.%2BM.%26aulast%3DThompson%26aufirst%3DJ.%2BF.%26atitle%3DCholesteryl%2520ester%2520transfer%2520protein%2520variants%2520have%2520differential%2520stability%2520but%2520uniform%2520inhibition%2520by%2520torcetrapib%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D14918%26epage%3D14922%26doi%3D10.1074%2Fjbc.M500523200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="note"><p class="first last">A survey of the literature reports from 1950 to 2004 on BP studies in different animal species showed that rats were the most widely used animal species for preclinical BP study. It is believed that common mechanisms might affect BP in rats and humans and it might be predictive for BP effects in human. In our in-house telemeterized mice studies, BP and HR effects of various known clinical agents were reproduced in telemetry rats at clinically relevant doses/exposures; sensitivity to detect â¥5â10% changes.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i28"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01363">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_76880"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01363">10.1021/acs.jmedchem.5b01363</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Analytical and spectral characterization data and/or experimental procedures of all the key intermediates and final compounds <b>7a</b>â<b>c</b>, <b>8a</b>,<b>d</b>,<b>e</b>, <b>9a</b>,<b>b</b>,<b>e</b>â<b>j</b>, <b>10a</b>,<b>c</b>,<b>e</b>,<b>f</b>,<b>h</b>â<b>j</b>; table of solvent and addictive effects on Grignard addition of (<i>R</i>s)-<b>16</b>, and in vitro assays (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_001.pdf">jm5b01363_si_001.pdf (348.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01363/suppl_file/jm5b01363_si_002.csv">jm5b01363_si_002.csv (2.63 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01363&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-22%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01363%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01363" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799a2878d651975","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
